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Abstract 
 
Broad-Spectrum Chemokine Inhibitors (BSCIs) are a novel type of anti-
inflammatory drug, discovered by Fox and colleagues. We have shown that the 
syntheses of C-substituted γ-thialactams are possible via a modular approach 
starting from the simple amino acid cystine. These compounds are a new class of 
GPCR ligand, showing BSCI activity comparable to their non-sulfur counterparts. 
Initial migratory data suggests that these lactams are inhibitors of leukocyte 
migration and comparable to the analogous BSCI lactams at µM concentrations, 
with decreased activity at the nM scale. 
 
Efforts have been made to the synthesis of substituted piperidinones, as well as 
employing Jocic-Reeve-Corey-Link chemistry to the general synthesis of lactams, 
ultimately looking to the synthesis of C-substituted lactams. Attempting to utilise 
trichloromethyl carbinol chemistry for these purposes has led to the synthesis of 
stereochemically-pure heterocycles containing up to 3 stereocentres. α-
Trichloromethyl carbinols and asymmetric transfer hydrogenation chemistry are 
used from simple starting materials. Developments of this type of chemistry will 
undoubtedly lay the foundations to produce further non-racemic substituted 
heterocycles which will be important both synthetically and biologically.  
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Chapter 1 - Introduction 
1.1 Inflammation 
Inflammation is a biological and protective response of living tissue to harmful 
stimuli. A more precise definition from Stedman’s medical dictionary is “A 
fundamental pathologic process consisting of a dynamic complex of histologically 
apparent cytologic changes, cellular infiltration, and mediator release that occurs 
in the affected blood vessels and adjacent tissues in response to an injury or 
abnormal stimulation caused by a physical, chemical, or biologic agent, including 
the local reactions and resulting morphologic changes; the destruction or removal 
of the injurious material; and the responses that lead to repair and healing.”1 The 
classic signs and symptoms of acute inflammation are rubor (redness), calor (heat 
or warmth), tumor (swelling), dolor (pain) and functio laesa (inhibited or lost 
function).2-5 
 
Inflammation is vital in initiating the healing process - in its absence wounds and 
infections would never heal and progressive destruction of the tissue would 
compromise the survival of the organism. Although this process serves to protect 
its host, if kept uncontrolled inappropriate inflammatory response can contribute 
to a wide range of disorders and diseases including: autoimmune,6-9 
Alzheimer’s,10-12 cancer,13-15 arthritis16-17 and many others. 
 
1.1.1 Inflammation Mechanism 
The inflammation mechanism, although very complex, exhibits a certain order of 
events (Figure 1), beginning with tissue injury followed by the release of 
chemicals and leukocyte (white blood cell) migration.18-21 When tissue cells 
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become injured they release a number of chemicals (for example kinins, 
prostaglandins and histamine) that initiate the inflammatory response. These 
chemicals work together, causing dilation of blood vessels and permeability of the 
capillaries which in turn increases the blood flow to the injured site. These 
substances also act as chemical messengers that attract some of the body's natural 
defence cells, a mechanism known as chemotaxis. Chemotaxis leads to the 
migration of leukocytes. During an inflammatory response, two types of 
leukocytes are predominant - macrophages and neutrophils. Macrophages, the 
largest of the leukocytes, aid the healing process by engulfing bacteria and dead 
cells and ingesting them so that the area is clear for new cells to grow. Neutrophils 
are first to the injured site and function by neutralising harmful bacteria. Their 
activity and death in large numbers usually results in the formation of pus. 
Angiogenesis, the formation of new blood vessels, occurs once sufficient 
cleansing of the area has been achieved, followed by a proliferation and 
remodeling phase.22-24 
 
Figure 1. Common inflammatory and immune processes. Bacteria and other pathogens enter the 
wound and platelets release blood clotting proteins to the site. Vasodilation is activated by mast 
cells delivering blood, plasma and cells to the injured site. Neutrophils and macrophages kill and 
degrade pathogens, while macrophages release cytokines that attract immune system cells to the 
injured site for repair. Inflammation ceases when the pathogen is eliminated and the wound 
repaired. (Reproduced and altered from Molecular biology in medicinal chemistry)24 
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1.1.2 Treatment of Inflammation  
There are a number of ways to treat inflammation. Ice and cold water have long 
been associated with the treatment of inflammation, although it probably helped to 
suppress the pain of the inflammation rather than to treat the problem directly.25 It 
has been recognised that lifestyle and environment play an important role in 
inflammatory responses - a recent study has found that certain dietary components 
can play an important role in the treatment of inflammation.26 Other natural anti-
inflammatory agents have been used and are available in many forms such as 
topical applications (like creams and lotions), supplements, herbal extracts and 
natural oils.27 Suffice to say, the most widely used treatment of inflammatory 
diseases and disorders in use today are anti-inflammatory agents which are 
classified into three groups: steroidal, non-steroidal and immune-selective. Four 
of the top ten pharmaceutical products in 2011 were anti-inflammatory agents, 
with global sales figures exceeding £18 billion.28 
1.1.2.1 Steroid Anti-Inflammatory Drugs - Glucocorticoids 
For more than 50 years the beneficial effects of glucocorticoids in the treatment of 
inflammatory diseases have been appreciated.29 Unfortunately, they have been 
fraught with serious complications which have imposed limitations on the clinical 
use of this class of drugs.30 Nevertheless, these steroids, often referred to as 
corticosteroids, have been used in the treatment of diseases such as asthma, 
rheumatoid arthritis, inflammatory bowel disease and autoimmune disorders. 
2,10,12,16,31-33 They are a group of naturally occurring steroids produced in the 
adrenal cortex and work by down-regulating the gene expression of inflammatory 
mediators.34-35 Arguably the best known and most important natural 
glucocorticoid Cortisol (1.1), or hydrocortisone, is essential for life. A 
considerable research effort has been devoted to the structural modifications of 
glucocorticoids, with the hope of increasing their potencies while minimising their 
propensity to elicit systemic adverse effects. For instance, introduction of a ∆1-2 
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double bond and modifications to the -6,-9, -16 and -17 positions of the rings have 
all given positive results (Figure 2).30,36-46 
1
6
9
16
17
2
1-2
S
S
R
 
Figure 2. The glucocorticoids motif (left) and related drugs from certain modifications as shown 
in the table (right).  (Note: ∆1-2 are either unsaturated (U) or saturated (S)) 
 Seretide (Figure 3), the 3rd best selling drug globally with sales of £5.5 billion in 
2011,28 is used in the management of asthma and chronic obstructive pulmonary 
disease (COPD) and contains fluticasone (1.8), a corticosteroid.47 This anti-
inflammatory component is combined with salmeterol (1.9) to clear the lungs, 
airways and relieve the symptoms of coughing, wheezing and shortness of breath. 
 
Figure 3. The drug Seretide which contains fluticasone (1.8) and salmeterol (1.9). 
1.1.2.2 Non-Steroid Anti-Inflammatory Drugs (NSAIDs) 
The main therapeutic actions of salicylic acid (1.10)48 and its derivatives, such as 
aspirin (1.11), have long been recognised.49-51 With the passing of time, several 
other drugs were discovered that shared some or all of their antipyretic, anti-
inflammatory, and analgesic effects. These include phenazone (1.12), paracetamol 
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(1.13), phenacetin (1.14), ibuprofen (1.15), phenylbutazone (1.16), and, more 
recently, the fenamates (derived from fenamic acid (1.17)).52-54  
 
Despite the diversity of their chemical structures, these drugs all share the same 
therapeutic properties and were thus regarded as the aspirin-like drugs. Today the 
term ‘nonsteroidal anti-inflammatory drugs’ (NSAIDs) is more generally used, as 
they are quite clearly distinct from the steroidal structures of the glucocorticoids 
(vide supra) but produce similar anti-inflammatory effects. Unfortunately, these 
types of drugs also have their drawbacks. All of the NSAIDs are approximately 
equivalent in terms of anti-inflammatory efficacy but can also cause untoward 
side effects (e.g. gastrointestinal and renal adverse drug reactions) in a significant 
fraction of treated patients, which has frequently limited their use in therapy. 
 
Most NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase 
(COX).17 This enzyme is involved in the biosynthesis of prostaglandins (PGs) and 
thromboxane A2 (TXA2) from arachidonic acid (Figure 4), agents which are 
responsible for the body’s response to pain and inflammation.22b Inhibiting the 
enzyme lowers prostaglandin levels and alleviates these symptoms.35,55-57  
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Figure 4. Biosynthesis of prostaglandins from arachidonic acid via COX enzymes. 
1.1.2.3 Immune Selective Anti-Inflammatory Derivative (ImSAIDs) 
ImSAIDs are a new category of anti-inflammatory drug which are unrelated 
to steroids or NSAIDs. They are a class of peptides, or amino acid complexes, that 
aid in reducing over-activation of leukocytes and thus help support anti-
inflammatory activity, a function which is not performed by conventional 
NSAIDs and glucocorticoids.58-59 
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The current lead ImSAID contains the three amino acid sequence FEG (1.18). 
This has become the foundation for this category of drug, along with its D-
enantiomeric form feG (1.19).60 It is now well accepted that the immune, nervous 
and endocrine systems communicate and interact to control and modulate 
inflammation and tissue repair.61 
 
1.2 Chemokines 
During leukocyte extravasations, the movement of leukocytes out of the 
circulatory system towards the site of tissue damage or infection, resident 
macrophages in the affected tissue release cytokines (vide infra) such as IL-1, 
TNF-α and chemokines. Targeting leukocyte recruitment to abolish inappropriate 
inflammation is therefore an attractive therapeutic strategy, and has recently 
become an important focus for anti-inflammatory drug design.62-66 One of the best 
studied examples is the chemokine system, with chemokine inhibitiors proving to 
be novel anti-inflammatory drugs, although care has to be taken to balance the 
inhibition as chemokines also have a beneficial role on the immune system. 
 
1.2.1 Chemokine Classification 
Chemokines are a family of structurally related small proteins secreted by the cell 
that exhibit very specific cysteine motifs in their amino acid sequence. The 
approximately 50 chemokines and 19 receptors identified to date are classified 
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into four families on the basis of the pattern of the first two of four cysteine 
residues of the ligand, given the preferred names CXC, CC, C, and CX3C. Less 
commonly, these groups are referred to by the Greek letters α, β, γ and δ 
respectively.67 
 
CXC, CC, and CX3C chemokines all have four conserved cysteines, whereas C 
chemokines have only two, corresponding to the second and fourth cysteines in 
the other classes. The CXC family is characterised by the presence of a single 
amino acid residue between the first two cysteines, whereas the large CC 
chemokine family consists of chemokines with the first two cysteine residues 
adjacent to each other (it should be noted that there is a small subgroup of CC 
chemokines which have six cysteine residues). Analogously, the CX3C 
chemokines contain three amino acid residues between the first two cysteines 
(Figure 5).67-69 
 
Figure 5. Classification of each chemokine family. C indicates the cysteine residue; X, an amino 
acid other than cysteine; ---, other amino acids; and ~, gaps in the alignment. The number of 
members in each class is listed on the right. Spacing between cysteines is similar with the N and C 
terminus varying in length. 
Both the CC and CXC groups have many known members, with examples 
including macrophage inflammatory protein (MIP-1α or CCL3), monocyte 
chemotactic protein (MCP-1 or CCL2) and Interleukin-8 (IL-8 or CXL8). Human 
lymphotactin α and β, and fractalkine and their equivalents in other species are the 
only known examples of C and CX3C chemokines respectively.  
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1.2.2 Chemokine Receptors 
To the best of our knowledge there are now 19 chemokine receptors (summarised 
in Table 1).68-70 These chemokines signal through type 1 G-protein coupled 
receptors (GPCRs) to regulate a range of immune functions: wound healing, 
lymphoid trafficking, lymphoid organ development, inflammation, cell 
recruitment, metastasis, angiogenesis/angiostasis and Thr1/Thr2 development, 
with particular focus on regulating leukocyte trafficking.66,71-73  
 
Chemokine  
Receptor 
Human Chemokine 
Ligand/s 
Chemokine 
Receptor 
Human Chemokine 
Ligand/s 
CXCR1 CXCL1, 6 & 8* CCR3 CCL2, 5, 7, 8, 11*, 13, 
15, 24*, 26* & 28. 
CXCR2 CXCL1-8 CCR4 CCL17 & 22 
CXCR3 CXCL9-11 CCR5 CCL3-5, 8, 11, 14 & 
16 
CXCR4 CXCL12# CCR6 CCL20 
CXCR5 CXCL13 CCR7 CCL19 & 21 
CXCR6 CXCL16 CCR8 CCL1*, 4, 16 & 17 
CXCR7 CXCL11 & 12~ CCR9 CCL25 
CCR1 CCL3, 5, 7, 8, 13, 14, 
15*, 16 & 23* 
CCR10 CCL27 & 28 
CCR2 CCL2*, 7, 8, 11, 13, 
16 
XCR1 XCL1 & 2 
  CX3CR1 CX3CL1 
Table 1. Summary of the known chemokine receptors and their human ligands. * Indicates the 
principal endogenous agonist/s. #Specfically; SDF-1α & SDF-1β, the active isomers of CXCL12. 
~Specifically; SDF-1α. 
Chemokine receptors are based on and named after the chemokine class that bind 
to them, with ten human chemokine receptors being highly selective (Kd ~ 1 nM)  
for one main endogenous chemokine ligand (monogamous receptors): CXCR1, 
CXCR4, CXCR5, CXCR6, CCR6, CCR8, CCR9, CCR10, XCR1 and CX3CR1. 
The other nine chemokine receptors are undiscriminating. It has become clearer 
that chemokines and their receptors can be usefully sub-classified into 
homeostatic leukocyte homing molecules (CXCR4, CXCR5, CCR7, CCR9) 
versus inflammatory/inducible molecules (CXCR1, CXCR2, CXCR3, CCR1-6, 
CX3CR1).74-76 
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1.2.3 GPCRs 
GPCRs, also known as 7-transmembrane (7TM) receptors, are part of a very large 
group of receptors which share a common protein structure. They interact with G-
proteins and control signal transduction pathways in different ways which are 
involved in signalling a broad spectrum of biological processes such as peptide 
hormones, neurotransmitters, neuropeptides and odorants. They play an important 
role in physiological regulation and their malfunction can result in many diseases, 
so it comes as no surprise that they are a major class of drug target and are 
incredibly important to the pharmaceutical industry. Indeed, it is thought that 
GPCRs are targets for more than 50% of the current therapeutic agents, and their 
importance cannot be emphasised more than the awarding of the 2012 Nobel Prize 
in Chemistry “for studies of G-protein-coupled receptors”.77 
 
GPCRs can exist as either an active or inactive form. The GPCR is activated by an 
external signal in the form of a ligand or other signal mediator interacting with a 
cavity of the transmembrane domain at the N-terminus, whilst the C-terminus is 
bound to G-proteins within the cell. Upon activation of GPCRs, GPCRs associate 
with distinct classes of heterotrimeric G-proteins composed of three subunits: the 
α-subunit that has the guanine-nucleotide binding site and GTPase activity, and 
the β- and γ-subunits that form a tightly bound dimer.78-81 Activated GPCRs 
promote the release of guanosine diphosphate (GDP) from the inactive α-subunits 
of G proteins and the binding of guanosine triphosphate (GTP), which then leads 
to the formation of free α-GTP and βγ-subunits that are able to interact with a 
diverse array of effector enzymes and ion channels (Figure 6). This change in 
activity is thought to be due to the terminal phosphate group which, in the GTP-
bound form, stabilises the Gα protein. 
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Figure 6. GPCR activation and mechanism through ligand binding. A ligand binds to GPCR 
inducing a conformational change which exchanges GDP with GTP at G-α. Free α-GTP and βγ 
subunits can then influence enzymes and cells. 
Due to the success of small molecule inhibitors of GPCRs in the treatment of 
many diseases,23,82 and the fact that chemokine receptors are GPCR expressed, 
small molecule inhibitors of chemokine receptors become an attractive therapeutic 
target, and one which is extensively researched with great interest to the 
pharmaceutical industry.  
 
1.2.4 Chemokines as Pharmaceutical Targets 
One problem in investigating the roles of chemokines and their possible role in 
the pathogenesis of a disease is the fact that chemokine receptors can bind to 
several different chemokines, and each chemokine can bind to several different 
receptors.83 Each receptor-chemokine combination may direct a different 
inflammatory response and this response can be tailored by the body based on the 
type of injury or threat. There are two approaches for pharmaceutical targets: 
chemokine receptor antagonists, which target single chemokine/chemokine 
receptor combinations and chemokine inhibitors, which target a range of 
chemokine/chemokine receptor combinations. For the former, with the exception 
of selective CCR5 antagonists for HIV,84 such as Celsentri (1.20)85 and Fuzeon,86 
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the promise of obtaining new therapeutics related to chemokine receptors has not 
yet been realised.87-88 Grainger et al. took the first step towards designing small 
molecule inhibitors of monocyte chemoattractant protein-1 (MCP-1), now known 
as CCL2, and testing these in vitro.89-91 Importantly, once these inhibitors were 
identified in vitro, progress for anti-inflammatory activity in vivo leading to the 
controlling of the inflammatory response during many diseases could be realised. 
Recently published CXCR3 agonists include tetrahydroisoquinolines (1.21) and 
fused piperidinyl diazepanones (1.22),92-93 but unfortunately of all the antagonists 
to date, none have been approved for the treatment of inflammatory and/or 
autoimmune diseases.94 
 
For the later class of inhibitors, Fox and colleagues have developed a novel form 
of anti-inflammatory chemokine inhibitor, broad-spectrum chemokine-inhibitors 
(BSCIs). 
 
1.3 Broad Spectrum Chemokine Inhibitors (BSCIs) 
1.3.1 Peptide 3 – The First BSCI 
The first chemokine inhibitor, was derived from the human MCP-1, or CCL2, 
sequence (vide supra).89 It is a 12-amino acid linear peptide corresponding to 
amino acids 51 to 62 of CCL2, with the sequence EICADPKQKWVQ (Figure 7).  
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Figure 7. Amino acid sequence of the first broad spectrum chemokine inhibitor derived from 
CCL2, Peptide 3. 
It was found that this amino acid sequence, termed Peptide 3, was a highly 
effective inhibitor for a wide range of chemokines in vitro in response to CC or 
CXC chemokine induced mononuclear-cell migration, with its ED50 being 
between 8 and 14 μM. It was also found that THP-1 cell migration, a leukemia 
cell line, was also inhibited, but the peptide has no effect on leukocyte migration 
induced by a range of other pro-inflammatory signals, thus it was dubbed the first 
example of a BSCI.90-91 Subsequently, a number of studies on Peptide 3 were 
carried out, in order to increase its potency and its inhibition in vivo. 
 
1.3.2 NR58-3.14.3 
A range of strategies have been used in the past to convert peptides with 
biological activity in vitro into agents with activity in vivo, including the design 
and synthesis of retro-inverse peptides in which L-amino acids are substituted 
with D-amino acids in the reverse sequence.95 By utilising these strategies the first 
two amino acids of Peptide 3 were removed and the amino acid sequence was 
reversed and replaced with D-amino acids. Cyclisation by adding a cysteine 
residue and oxidiation to give a di-sulfide bridge produced NR58-3.14.3 (Figure 
8) which was a thousand fold more active than Peptide 3 and a potent inhibitor in 
vivo. 
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Interestingly, NR58-3.14.3 inhibited inflammation in a number of disease models, 
such as atherosclerosis, ischemia, lung disease, surgical adhesions, endometriosis 
and pulmonary graft-versus-host disease, and is therefore a powerful anti-
inflammatory agent in vivo, suppressing pro-inflammatory cytokine production 
and leucocyte recruitment while retaining the broad spectrum inhibitory activity 
of the parent peptide.91 
 
 
Figure 8. NR58-3.14.3, the reverse cyclised D-amino version of Peptide 3, with increased 
chemokine inhibition and in vitro activity. 
Unfortunately there are limitations on the use of oligopeptides, both 
experimentally and therapeutically in vivo, and Peptide 3 and NR58-3.14.3 are not 
exempt from these, with both oligopeptides having poor oral bioavailability and 
short plasma half-lives.  
 
 
 
15 
 
1.3.3 SAR - The Critical Motif and Non-Peptide Analogues 
In order to design a non-peptide BSCI mimetic that retained the broad specificity 
of the original peptides a structure-activity relationship (SAR) analysis was 
performed to identify the critical motifs required.  
 
After much investigation it was found that a tryptophan (W), glutamine (Q) motif, 
WχQ, with a suitable spacer (dubbed χ here) was needed for BSCI activity 
(Figure 9). Results suggested a molecule with the presence of an aromatic group, 
or at least a bulky hydrophobic group, at an appropriate distance from a glutamine 
like primary amide was needed. 
 
 
Figure 9. The critical motif in order to retain BSCI activity from oligopeptides Peptide 3 and 
NR58-3.14.3 was found to be tryptophan-spacer-glutamine. 
With the critical motif of tryptophan-spacer-glutamine now established, the design 
and synthesis of non-peptide BSCIs could be realised and experiments were 
carried out using four glutamine mimetics; N-acylated products, bis-primary 
amides, benzylamides and acylaminoglutarimides. Combinations with three large 
hydrophobic groups gave twelve compounds for testing (Scheme 1). They were 
all synthesised using standard peptide coupling reagents and conditions.96-97 
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Scheme 1. Design and synthesis of non-peptide analogues of oligopeptides Peptide 3 and NR58-
3.14.3. (a) BOP, NEt3, DMF, NH3. (b) BOP, NEt3, DMF, PhCH2NH2. (c) DCC, NHS, DMF, ∆. R 
= (CH2)8CH=CH2 (1.23, 26, 29, 32). R = Ph (1.24, 27, 30, 33). R = tBuO (1.25, 28, 31, 34). 
The best of this series of compounds was the (S)-N-undec-10-enoyl-3-
aminogluarimide (1.32), dubbed NR58,4 with an ED50 of 5 nM, even more potent 
than previously reported BSCIs.71 At high dosages an anaesthetic effect was 
observed, with no toxic effects at high or low dosage. The cheaper synthesis of 
NR58,4 meant it was a basis for further investigation into this class of drug in 
vivo. 
NR58,4  
Surprisingly, although 1.32 is an effective anti-inflammatory agent in models of 
acute inflammation, it was apparent that it is much less effective than the parent 
oligomers, Peptide 3 and NR58-3.14.3, in models of chronic inflammation. 
Pharmacokinetic studies were carried out to determine the fate of these molecules 
in vivo and it was found that imides of this type undergo rapid degradation in vivo 
as a result of enzymatic ring opening, producing isoglutamine (1.36), Nα-acyl-
glutamine (1.37) and N-acyl glutamic acid (1.38) metabolites (Scheme 2).97 
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Scheme 2. Possible degradation pathways of BSCIs in vivo. 
1.3.3.1 Lactam BSCIs 
In order to prevent this degradation but retain the BSCI activity, a series of 5 (-γ), 
6 (-δ) and 7 (-ε) membered lactams (Figure 10) were synthesised and, although 
each lactam had a lower efficacy than its parent imide, the caprolactam (1.43) 
looked promising. 
 
Figure 10. Lactams synthesised in order to resist degredation in vivo. The ED50’s are shown for 
comparison. 
Naturally, this led to an extensive investigation of the side chain of the 
caprolactam by altering the acyl side chain using simple acylation chemistry 
(Scheme 3) on (S)-3-aminoazepan-2-one (1.45), with interesting results.98 The 
presence of a quaternary carbon at the α-position of the side chain dramatically 
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increased the potency of the BSCIs while shortening the long lipophilic side-chain 
increased their oral potency by over 1000-fold. It was also shown that, like the 
aminoglutarimides, the (S)-enantiomers of the lactams were more potent than the 
(R)-enantiomers.  
 
Scheme 3. Caprolactam side chain investigation. Acylation chemistry used to identify the best side 
chain for BSCI activity. 
One of the most potent and successful BSCIs synthesised by the Fox group, (S)-3-
(2',2'-dimethyl-propionyl)amino-caprolactam (1.47), contains a caprolactam and a 
hydrophobic tertiary butyl group, with an ED50 of 40 pM (or 0.04 nM). Its ease of 
synthesis combined with its outstanding potency means that similar types of 
molecules are attractive targets for the pharmaceutical industry. Indeed, a 
compound similar to this, FX125L, is currently undergoing clinical trials as a 
powerful anti-inflammatory drug, and has passed phase I of clinical trials.99-100 
 
Despite being small and simple, obviously these types of molecules display 
complex pharmacology with further information regarding their mode of action in 
vivo needed. The original peptide BSCIs were designed to be chemokine receptor 
ligands, but it seemed more likely that BSCIs targeted a component of the 
chemokine signalling pathway associated with the migratory response.90 Indeed it 
has since been found, through screening a large number of receptors, that it is in 
fact through the human type 2 somatostatin receptor (SSTR2), or one which is 
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closely related, where the inhibition of chemokine-induced leukocyte migration 
occurs.101-103 
 
1.4 Somatostatin 
Somatostatin (SST, (1.48)), originally identified by Krulich and co workers,104 is a 
peptide hormone with multiple physiological functions including inhibition of 
secretion of growth hormone (GH), glucagon, insulin, gastrin, and other hormones 
secreted by the pituitary and gastrointestinal tract. In humans SST, also known as 
a growth hormone-inhibiting hormone (GHIH) or somatotropin release-inhibiting 
factor (SRIF), is distributed throughout the endocrine system and was first located 
in the hypothalamus by Pelletier and co-workers.105 It has also been implicated in 
affecting neurotransmission in the central nervous system as well as cell 
proliferation and is therefore regarded as a multi-functional peptide hormone.106-
109 
 
The structure of SST, first deduced by the nobel laureate Roger Guillemin110 and 
co-workers,  is a cyclic tetradecapeptide having the primary structure NH2-Ala-
Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH with a disulphide 
bond between the cysteine residues, confirmed by using solid-phase peptide 
synthesis.  
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SST is synthesised as two active forms: the predominant, but functionally less 
active SST molecule consisting of 14 amino acids known as SST-14 (1.48) with a 
disulfide bond linking the cysteine residues at positions 3 and 14, and a larger 
more potent molecular form, SST-28 (1.49), which is a congener of SST-14 
extended at the amino terminal. 
 
 
1.4.1 Somatostatin Receptors and SSTR2 
There are 5 known receptors of somatostatin, SSTR1 through to 5, with 6 separate 
receptor subtypes (SSTR2 being split into types A and B), and like chemokine 
receptors they too are all GPCRs.106,111  They are expressed throughout the body 
in several different tissues and cell types, in varying numbers and combinations. 
SSTRs interact with several types of Gα, β and γ proteins and have also been 
shown to interact directly with structural cell proteins through their C-terminal 
domains. 
 
SSTR2 is responsible for the inhibition of glucagon and GH, and it is now 
apparent that BSCIs act through the somatostatin type 2, or a closely related, 
receptor. A group at Merck synthesised the first potent non-peptide agonist which 
selectively bound to the SSTR2 receptor.108 An integrated approach of 
combinatorial chemistry and high-throughput receptor-binding techniques was 
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used to rapidly identify subtype selective compounds, with compound L-779,976 
(1.50) giving the best results. The first small molecule SSTR2 antagonists (1.51) 
were synthesised by Pfizer in the hope of up-regulating GH in farm animals.112-113 
        
 
1.4.2 Somatostatin, BSCIs and Inflammation 
The current mechanistic thought process is that agonism by somatostatin inhibits 
growth hormone and not chemokine inhibitiors, but agonism by the BSCI class of 
molecules results in inhibition of cell migration, or chemotaxis. The mechanism is 
thought to be similar to that shown in Figure 11.102 
 
 
Figure 11. Diagramatic representation of the current proposed mechanism of sstr2 ligands and 
BSCIs. 1 - Classical agonist lacking BSCI activity, 2 - Powerful agonists which exert a degree of 
BSCI activity, 3 - BSCIs acting through SSTR2, or a closely related receptor, 4 - BSCIs acting by 
other mechanisms at somatostatin receptors. 
 
1.5 Research Hypothesis 
A number of benzothiazepinone GPCR ligands are already known in literature, 
most notably compounds 1.52 and 1.53.114-116 
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With the knowledge of GPCR ligands and our experience in the field of BSCIs, 
hopefully we can exploit the known therapeutic pathway both in acute and chronic 
inflammation and build new GPCR ligands with increased functionality and 
structural diversity. In the process we can investigate further the true biological 
mechanism, devise new specialised libraries and aid in drug discovery. 
Importantly the new compounds synthesised will differ from known GPCR 
ligands because they will not have the benzene moiety a carbamide moiety or any 
substitution at the N-4 position. The chemistry used to synthesise these new 
ligands could simultaneously be exploited to synthesise further novel lactams or 
heterocycles which may have important medicinal properties. 
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Chapter 2 – γ-Thialactams 
2.1 Introduction 
Caprolactam (2.1), a derivative of azepine, is without doubt one of the most useful 
and important lactams.117 It has been used extensively as a precursor in the 
manufacture of nylon 6, with quantities in excess of 2 billion kilograms being 
produced annually.118-122 Simple C-substitiuted caprolactams possess significant 
central nervous system (CNS) activity123 while other derivatives have useful 
analgesic effects124 and have found use as antitussives, mydriatics, antispasmodics 
and oral hypoglycaemics.125,126 Noteworthy are the broad spectrum inhibitors of 
chemokines, previously discussed, with structures similar to 2.2. The synthesis of 
C- substituted caprolactams such as compound 2.3 would give valuable insights 
into the mechanistic and pharmacological outcome of this class of drug. The 
synthesis of these molecules might prove difficult as only a small number of 
general methods exist for the stereoselective preparation of such systems. 
 
 
2.1.1 Routes to C-Substituted Lactams 
The Beckmann rearrangement (Scheme 4), first reported by Beckmann in 1886, is 
the acid mediated isomerisation of oximes (2.4) to amides (2.5).127,128 Lactams are 
obtained from the rearrangement of alicyclic oximes (2.6) and are unproblematic 
for simple substrates and for cases where n = 1, 2 and 3. The Beckmann 
rearrangement is a highly efficient and versatile process in the synthesis of 
lactams. 
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Scheme 4. The Beckmann rearrangement of oximes to amides (left) and alicyclic oximes to 
lactams (right). 
Unfortunately problems arise in cases of unsymmetrical oximes (2.8) where 
usually a mixture of products is obtained via two possible pathways (Scheme 
5).129 Although anti-rearrangement is favoured with the most substituted carbon 
migrating, both pathways can occur. 
 
Scheme 5 The two possible pathways of the Beckmann rearrangement with the anti-rearrangment 
(red arrow) being favoured. 
Similarly the Schmidt reaction130,131 of alicyclic ketones (2.11) is an efficient way 
of synthesising lactams (Scheme 6) but again has the problem of giving a mixture 
of products with unsymmetrical ketones. 
 
Scheme 6. The Schmidt reaction (or rearrangement) 
The limited selectivity and lack of flexibility in the ring expansion has created the 
need for a more flexible process. A general route to caprolactams is the 
intramolecular cyclisation of ε-aminohexanoic acids,132 but yields for 2.1 are low. 
Thermal or photochemical induced ring expansions of oxaziridines to azepan-2-
ones are possible,133,126 for example flash pyrolysis of oxaziridine (2.14) affords 
the corresponding caprolactam (Scheme 7). 
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Scheme 7. Caprolactam via flash pyrolysis 
 Surprisingly, only a few general methods are known for the preparation of C-
substituted azepan-2-ones.125 These include: 
 Photochemical rearrangement of oxaziridines (such as 2.15 and 2.18) 
developed by Aubé134-137 after pioneering work by Lattes138 and co-workers. 
Scheme 8. Rearrangement of oxaziridines to form lactams. 
 Photoinduced ring expansion of azidocyclohexenone (2.21) described by 
Sato.139 
 
Scheme 9. Ring expansion to form lactams. 
 Cyclisation of a novel sila-Pummerer rearrangement of ω-amidosulfoxides 
(2.23) by Kita and co-workers.140,141 
30 
 
 
Scheme 10. Cyclisation of sulfoxides to form lactams. 
 Cobalt-mediated carbonylation of 2-vinylazetidines (2.25) developed by 
Alper.142 
 
Scheme 11. Carbonylation to form lactams. 
 α-Alkylation of chiral N-dialkylamino derivatives (2.27) developed by 
Enders.143 
 
Scheme 12. Alkylation of lithium derivatives to form lactams. 
 Photoinduced Schmidt rearrangement from (triisopropylsilyl)-azidohydrin 
derivatives (2.29) reported by Evans.144 
 
Scheme 13. Schmidt rearrangement of azidohydrin derivatives to form lactams.  
Although the synthesis of C-substituted azepan-2-ones (2.3) would be desirable to 
further our research for drug design by optimising the target interactions of our 
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lead compound, the inherent difficulty in their synthesis, lack of efficiency and 
versatility in their preparation call for an alternative. We envisaged the 1,4-
thiazepan-5-one derivatives (2.32) as a good alternative, not merely because of 
their relative ease of synthesis and robustness, but also because this moiety has 
been seen and synthesised within a number of medicinally important compounds. 
It is also known that the inclusion of a sulfur atom within certain lactam rings has 
little impact on the biological effect of the related lactam. 
 
 
2.1.2 1,4-Thiazepan-5-one Moiety 
The 1,4-thiazepan-5-one moiety (2.33) has been the subject of intense interest 
within chemical and pharmacological research since the discovery that some 
members of the group were angiotensin converting enzyme (ACE) inhibitors.145 It 
can be seen in the drug diltiazem (2.34),146-147 used for angina and heart problems, 
and a potent calcitonin gene-related peptide (CGRP) receptor antagonist (2.35),148 
as well as in numerous ACE (2.36) and interleukin-1 converting enzyme (ICE) 
inhibitors (2.37).145,149-150 
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The 1,4-thiazepan-5-one moiety is contained within the benzothiazepinone moiety 
which has frequently been employed as a scaffold for the development of 
peptidomimetics with their preparation generally being more straightforward.151 
The benzothiazepinone derivatives also possess various biological activities. 
Although we are not interested in the synthesis of benzothiazepinones it is 
apparent that the chemistry used in their syntheses might be applicable to the 
synthesis of our lactams. 
2.1.2.1 Synthesis of Thiazepan-5-one Moiety 
Synthetically, these structures have been made in a number of different ways. 
These include: 
 Aromatic nucleophilic substitution of o-fluoronitrobenzene (2.38) with a 
protected cysteine derivative (2.39) followed by reduction of the nitro 
compound and ring closure.152-154 
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Scheme 14. Thiazepan-5-one moiety via aromatic nucleophilic substitution. 
 Utilising bromo compounds derived from Baylis–Hillman adducts (2.43) 
involving selective S-alkylation followed by lactam formation.155-157 
2 t
p
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Scheme 15. Thiazepan-5-one moiety via S-alkylation and ring closure. 
  CuI catalysed coupling.150  
Scheme 16. Thiazepan-5-one moiety via CuI catalysed coupling. 
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 Condensation of an amino alcohol (2.51) or halo-ethylamine (2.55) with a 
suitably protected cysteine residue ((2.52) or (2.54)).149,158-160  
 
 
Scheme 17. Thiazepan-5-one moiety via condensation of a protected cysteine residue. 
 Michael addition of a β-nitro olefin (2.58) with a suitably protected cysteine 
residue.145,161 
 
Scheme 18. Thiazepan-5-one moiety via Michael addition reactions. 
 Intramolecular Ugi condensations.162-163 
 
Scheme 19. Thiazepan-5-one moiety via Ugi condensations. 
Many of these synthetic approaches to the thiazepan-5-one moiety are clearly 
related to the structures which we wish to synthesise. In all cases, the synthetic 
method is either limited in scope or versatility for our purposes, has substitution at 
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the N-4 position of the lactam, requires severe reaction conditions, is multistep or 
utilises chemistry which takes advantage of a benzene group, giving the undesired 
benzothiazepinone moeity. 
 
2.1.3 Synthetic Strategy 
The synthetic strategy usually employed in synthesising the 1,4-thiazepan-5-one 
moiety within the literature is the coupling of a protected cysteine derivative with 
a suitable amine derivative and cyclisation to form the lactam. Therefore for our 
purposes we proposed substituted amine derivatives that contains a β-leaving 
group (2.65), derived from a β-hydroxyamine (2.66), and a suitably protected 
substituted thiol derivative containing a leaving group (2.64), derived from 
cysteine (2.67) as shown in Scheme 20.  
 
 
Scheme 20. Synthetic strategy to the thialactams 
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In order to test the viability of this strategy, and the project, firstly the simple 1,4-
thiazepan-5-one would be synthesised ((2.63):R, R’, R’’ = H) for comparison with 
the analogus non-sulfur containing caprolactam (2.3) previously synthesised. If 
inserting sulfur into the ring has little to no effect on the molecules’ properties or 
mode of action then the same synthesis could be used, depending on its 
robustness, and a library of substituted 1,4-thiazepan-5-ones realised. This could 
then in turn be used to build a structure activity relationship and discover which 
parts of the molecule are important for biological activity and whether C-
substitiution helps the lead compound (2.3). 
 
2.2 Lindley/Ahmed Methods 
As eluded to, our original thought process into the synthesis of 1,4-thiazepan-5-
ones was the coupling of cysteine with a suitably protected amine, acylation and 
ring closure. Lindley had previously published a paper164 in 1959 on the synthesis 
of S-benzyloxycarbonylaminoethyl-L-cysteine (2.73) so our first attempt was to 
repeat this procedure and attempt a continuation to the thialactam (Scheme 21).   
 
Unfortunately this original strategy posed a number of problems. Protection of 2-
bromoethylamine hydrobromide (2.68) with benzyloxycarbonyl chloride (CbzCl, 
2.69) to produce the desired protected bromoethylamine (2.70) is straightforward, 
as is the Finkelstein reaction to the corresponding iodo-compound (2.71). The 
coupling of this iodo-compound to L-cysteine is where problems arose, with all 
attempts at the coupling failing. In every case a white solid was recovered from 
the coupling reactions but identification, purification and characterisation of such 
compounds proved difficult due to their extreme lack of solubility in any solvent. 
To try and resolve this problem slightly basic deuterated water was employed but 
even then the compounds were hard to characterise. Acylations on the 
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uncharactarisable compound, as well as attempting an N-tert-butoxycarbonyl 
(Boc) protection (Scheme 22), did not furnish the desired products, 2.74 and 2.77 
respectively. 
 
3
3
3
2
2
2
2
Scheme 21. First attempted synthesis of thialactam derivative via Lindley method. *Compound 
not purified and used directly. 
 
 
Scheme 22. Attempted Boc protections on thialysine derivative. 
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 Attempts were also made to Boc-protect the cysteine before coupling (Scheme 
23), which proved more difficult than first thought. Again characterising these 
proved difficult and it was unclear whether or not the reaction proceeded in the 
first instance.  
 
Scheme 23. Attempted Coupling of a Boc-protected cysteine residue with protected ethylamine 
derivative. 
Coupling reactions of the cysteine hydrochloride (2.72) directly with the protected 
bromo-ethylamine (2.70) to form the S-benzyloxycarbonylaminoethyl-L-cysteine 
(2.73), instead of performing the Finklestein and coupling, were carried out and 
again gave inconclusive results. At this early stage in the project it was decided a 
different strategy was needed for the synthesis of the thiazepan moiety. Firstly the 
synthesis of the simplest thiazepan-5-one (2.56) was attempted using a strategy 
published by Ahmed (Scheme 24) in 1984.160 
Scheme 24. Attempted Ahmed synthesis of thialactam 
Unfortunately we could not reproduce the same results as the original paper; the 
reaction simply did not work for us. These first attempts were deemed 
unacceptable and an alternative strategy was needed. 
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2. 3 Modular Approach to Thialactams 
Due to the lack of success via the Lindley and Ahmed methods, and a wealth of 
literature on lanthionine building blocks,165-170 a modular approach to the 
synthesis of 1,4-thiazepin-5-one derivatives was the next logical step (Scheme 
25). This approach involved five key elements: the protection of cystine (2.81) 
(the dimer of cysteine), its reduction, coupling with a suitable protected amine, 
ring closure to form the caprolactam (2.87) and finally deprotection and acylation 
of the head group. The similarity of this method to that of the Lindley and Ahmed 
methods are clear, with the exception that all reactive functional groups are now 
protected. Importantly, using the correct protecting group and leaving group 
chemistry was key to the synthesis of the final product, and also for important 
intermediates that could be used for further chemistry. For instance, the thialysine 
building block (2.86) could easily be utilised to synthesise somatostatin ligands. 
Scheme 25. Modular approach to the synthesis of the thialactams 
With this in mind, we realised that the amine protecting group on the cysteine 
derivative (PG2) would have to withstand amine and carboxylic acid deprotection 
conditions in order to generate the desired cyclised product (2.87) but also have 
the capability of being selectively labile itself for the useful thialysine building 
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block (2.86). With the wealth of literature and our experience in using 
carbobenzyloxy (Cbz), tert-butyloxycarbonyl (Boc) and 9-
fluorenylmethyloxycarbonyl (Fmoc) protecting groups, we decided a combination 
of these would allow us to generate a robust thialysine derivative. The Boc 
protecting group is unreactive to most bases and nucleophiles, allowing for 
orthogonal Fmoc or Cbz protection, ideal for our scenario. We therefore 
envisaged the cystine (2.81) to be Fmoc or Cbz protected with the nucleophilic 
coupling of a Boc protected amine derivative (2.85). tert-Butyl (tBu) ester, a 
protecting group for carboxylic acids which is acid labile, would also allow the 
possibility of a double deprotection during the Boc deprotection reaction. 
Importantly the Fmoc or Cbz protecting groups could be deprotected selectively at 
either the thialysine (2.86) or lactam (2.87) stages. 
 
2.3.1 Cystine Protection 
The initial reaction was the ester formation (or acid protection) of cystine 
derivative (2.81) which was achieved in quantitative yield using tert-butyl acetate 
and perchloric acid (Scheme 26) according to the method of Amaral.171 This 
reaction was very straightforward with scales of 10 g of cystine easily converted 
to the product (2.88), although great care must be employed when using the 
extremely corrosive and explosive perchloric acid.  
Scheme 26. Acid protection of cystine using tBuOAc & HClO4. 
Amine protection was achieved by using either fluorenylmethyloxycarbonyl 
chloride (FmocCl) or CbzCl (Scheme 27).172-173 A bi-phasic reaction with 
aqueous NaHCO3 and chloroform was the preferred method, giving higher and 
reproducible yields as originally the Fmoc protecting group was added using N-
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methylmorpholine (NMM) in THF. Purification of a large quantity of the Fmoc 
material (2.90) posed problems as it was found that it decomposed during column 
chromatography. Recrystallisation from CH2Cl2:Methanol (1:5) afforded the 
product, but the yield was significantly reduced to 43%. After further 
investigation and continuation of the synthesis, Cbz was used exclusively as the 
amine protecting group. 
Scheme 27. Amine protection of protected cystine, the complete protection of cystine. 
 
2.3.2 Reduction of Protected L-Cystine – The Use of Phosphines 
The reduction of suitably protected L-cystine using phosphines was achieved via 
two methods, either using triphenylphosphine (PPh3) or tributylphosphine (PBu3), 
(Scheme 28). 
 
R Additives Solvent PG Yield (%) 
2.91 PPh3, ME THF:H2O (1:1) Cbz  71 
 PBu3 THF:H2O (10:1) Cbz  99 
2.92 PPh3, ME  THF:H2O (1:1) Fmoc 53   PBu3 THF:H2O (10:1) Fmoc < 10 
Scheme 28. Formation of protected cysteine; the reduction of protected cystine. 
PPh3 and 2-mercaptoethanol (ME) were used in THF and water, while PBu3 was 
used in only THF and a little water. Reduction of Cbz protected cystine (2.89) was 
achieved in good and comparable yields for both PPh3 and PBu3, but surprisingly 
when the Fmoc protecting group was used (2.90), only the PPh3 method produced 
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the desired result, while the PBu3 caused deprotection of the Fmoc protecting 
group. The deprotection mechanism of Cbz (Scheme 29) and Fmoc (Scheme 30) 
protected amines differ significantly and play an important role in our findings. 
 
 
Scheme 29. Deprotection of Cbz protected amine. 
 
Scheme 30. Deprotection of Fmoc protected amine. 
The deprotection of Cbz requires a strong acid such as HBr or hydrogenation, 
whereas the Fmoc is stable to these conditions because neither SN1 nor SN2 can 
occur at the CH2 carbon. PPh3 has a pKaH of 2.73 while PBu3 has a pKaH of 8.43. 
Fmoc cleavage is usually achieved with a number of bases, including most 
notably piperidine which has a pKa of 11.24 and ethanolamine which has a pKa of 
9.50. Surprisingly the PBu3 must be acting as a strong enough base in the 
reduction reaction to cause the Fmoc group to be removed (Scheme 31). PPh3 on 
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the other hand is not basic enough to cause deprotection of the Fmoc group and 
hence the reduction of the cystine will proceed. 
 
Scheme 31. Reaction of Fmoc with PPh3 and PBu3. 
As eluded to earlier, due to this finding and the fact that the Fmoc compound 
(2.90) decomposed on the column and had to be recrystallised giving lower yields, 
the Cbz protecting group was preferred. All subsequent reactions were carried out 
using Cbz as the preferred protecting group. Although, it should be noted that it is 
possible to reduce the Fmoc protected cystine using PPh3 and mercaptoethanol to 
form the desired Fmoc protected cysteine (2.92), albeit with a lower and less 
reliable yield. 
 
2.3.3 Protected Bromoethylamine 
The synthesis of N-Boc-2-bromoethylamine (2.95) was first carried out by Boc 
protecting ethanolamine (2.93) using triethylamine in THF and water (Scheme 
32). The Boc protected ethanolamine was then subjected to a substitution reaction 
using N-bromosuccinimide and PPh3, furnishing the desired organic halide (2.95). 
It should be noted that mesylation of alcohol 2.94 was carried out, but coupling in 
the next stage of the synthesis was unsuccessful and therefore abandoned. The 
synthesis of organic bromides and coupling was our preferred method. 
Scheme 32. Synthesis of Boc-protected bromoethylamine. 
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The synthesis of N-Boc-2-bromoethylamine by the above method gave mixed 
results and yields of final product (2.95), especially in the Boc protection of 
ethanolamine to form the Boc-protected species 2.94. Starting from the 
commercially available tert-butyl-N-(hydroxyethyl)carbamate (2.94) and carrying 
out the bromination step simplified our synthesis, giving greater yields of 
protected bromoethylamine. The synthesis from commercially available Boc-
protected ethanolamine derivatives was therefore preferred, although the complete 
synthesis from simple ethanolamine derivatives, and the one shown in Scheme 
32, is much more general and is the preferred synthesis when substituted Boc 
protected amines are not commercially available. 
 
2.3.4 Coupling Reaction - Thialysine Derivative 
Following the synthesis of N-Boc-2-bromoethylamine (2.95) and with the suitably 
protected Cbz cysteine (2.91) in hand, the coupling of these reagents was now 
possible. This was achieved in reasonable yields using a bi-phasic reaction with 
tetra-N-butylammonium bromide (TBAB) as the phase-transfer catalyst in EtOAc 
and aqueous NaHCO3, furnishing the desired thialysine derivative (2.96). 
 
Scheme 33. Formation of the thialysine derivative via coupling. 
 
2.3.5 Deprotection and Ring Closure 
The thialysine derivative (2.96) could now be de-protected selectively and 
cyclised to produce the desired Cbz-protected caprolactam (2.97, Scheme 34). 
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Removal of the protecting groups was achieved using trifluoroacetic acid (TFA) 
followed by intramolecular condensation using diphenyl phosphorazidate 
((PhO)2P(O)N3). 
 
Scheme 34. Deprotection and ring-closure to form the Cbz-protected thialactam 
The reaction mechanism for the deprotection and ring closure using TFA and 
(PhO)2P(O)N3 are shown below in Scheme 35 and Scheme 36.174-175  
 
Scheme 35. Boc-deprotection of thialysine derivative with TFA. 
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Scheme 36. Ring closure of thialysine derivative with (PhO)2P(O)N3. 
During the first step both tBu ester and Boc groups would be displaced from our 
thialysine derivative (2.96) forming the intermediate (2.98) (which was not 
purified). In the second step the carboxylic acid oxygen would attack the 
phosphorus atom in (PhO)2P(O)N3 to give two possible acyl phosphates, 2.99 and 
2.100. The acyl azide (2.101) would be formed by a SN2 type reaction of (2.99) 
with the azide anion or SN1 type rearrangement of (2.100). Intramolecular reaction 
of the amine with the acyl phosphates as well as the acyl azide would form the 
lactam (2.102). All routes are likely to occur, although the predominant route is 
most likely the acyl phosphate (2.100) reacting with the amine (as shown in the 
dotted box in Scheme 36) as studies via the Young racemization test have 
suggested a concerted transition state.175 This amide bond formation is the N-
acylation of the amine as a nucleophile. If there is no nucleophile, the reaction 
will stop at the stage of the acyl azide (2.101), which will thermally undergo the 
Curtius rearrangement to furnish the isocyanate. 
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2.3.6 Deprotection and Acylation 
Lactam 2.97 was easily deprotected with HBr to produce the hydro-bromide salt 
(2.103). A number of acylations were carried out directly on the salt to produce 
the desired 1,4-thiazepin-5-one derivatives (Scheme 37). 
Scheme 37. Deprotection and acylation. The final steps in the synthesis of thialactams. 
 
 
 
The acylation step was carried out with 3 side chains: tBu, adamantane and 2,2-
dimethylundecane (Table 2). These were selected because in previous 
experiments with analogous structures, tBu gave the best biological results, 
adamantane gives a crystalline product, and similarly good biological results, and 
the long chain was selected because it is known to inhibit the chemotaxis of THP-
1 cells and human polymorphonuclear cells induced by other CC and CXC 
chemokines in biological testing.90,96-98 All of these can then be compared with 
their analogous non-sulfur containing compounds which have previously been 
synthesised to see the effect (if any) of replacing one CH2 in the ring with a sulfur 
atom. 
 
 
Entry Rʹ Yield (%) 
(2.104) tBu*  50 
(2.105) Adamantane*  92 
(2.106) CH3(CH2)9C(CH3)2*  57 
Table 2. Acylation of 2.103. *Synthon of acid chloride. 
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2.4 Summarised Approach to Asymmetric γ-Thialactams 
The complete synthesis of the thialactams is shown below in Scheme 38. 
 
Scheme 38. Summarised approach to thialactams. 
This modular approach was repeated successfully and was therefore the chosen 
synthetic route for the synthesis of the thiazepan-5-ones. 
 
2.5 Expanding the library 
With the simple caprolactams (2.104-2.106) synthesised and the synthetic route 
realised (Scheme 38) the library of compounds could then be extended. The same 
approach as the simple caprolactam was employed with the protected cysteine 
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(2.91) being coupled together with suitably substituted bromoethylamine 
derivatives instead of N-Boc-2-bromoethylamine (2.95).  
 
2.5.1 3-Substituted Thialactam Derivatives 
The synthesis of the 3-methyl-thiazepin-5-one family and 3S-benzyl-thiazepin-5-
ones are shown in Scheme 39 and Scheme 40 respectively. The methyl 
substituted bromine compounds (2.107) were easily prepared by the bromination 
of commercially available (R)-N-Boc-alaninol and (S)-N-Boc-alaninol, as 
described for the synthesis of protected bromoethylamine (Scheme 32) 
previously. Similarly, the benzyl derivative, (S)-2.112, was synthesised from the 
available L-phenylalaninol, although the synthesis of its enantiomer (and hence 
the diastereoisomers of (3S,6R)-2.116-2.118) was more of a challenge. The 
NMRs of all isolated compounds contained only one diastereoisomer. 
 
3 2
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Scheme 39. Synthesis of the 3-methyl-thiazepin-5-one derivatives. 
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(X) R Yield (%) 
(3S,6R)-2.116 tBu  74 
(3S,6R)-2.117 1-Adamantane  33 
(3S,6R)-2.118 CH3(CH2)9C(CH3)2  65 
Scheme 40. Synthesis of the 3-benzyl-thiazepin-5-one derivatives. 
 
2.5.2 Diastereoisomer of Benzyl-Thialactam 
Attempts to synthesise the enantiomer of (S)-2.112 via an alternative method, the 
Boc protection of D-phenylalanine (2.119) and subsequent transformations 
(Scheme 41), failed. It was thought that the Boc protected anhydride of D-
phenylalanine (2.121) could be reduced and brominated to the desired 
bromoethylamine derivative (R)-2.112, but problems occurred during the 
reduction of the anhydride. Any attempt to reduce the anhydride with sodium 
borohydride failed and an alternative method was sought. 
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Scheme 41. Original attempt in the synthesis of (R,R)-benzyl-thialactams. 
The alternative route to the bromethylamine agent (R)-2.112 utilised a 
modification of the Abiko method (Scheme 42).176 This involved reduction of D-
phenylalanine to the corresponding alcohol (2.123) with the in situ generation of 
borane (BH3) followed by the addition of aqueous sodium hydroxide. With the 
synthesis of this alcohol, bromo-compound (R)-2.112 could easily be synthesised 
via Boc protecting and brominating (vide supra). Finally, the (R,R)-benzyl-
thialactam was synthesised by coupling the suitably protected cysteine residue 
(2.91) by the same procedure as its diastereoisomer. 
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Scheme 42. Synthesis of (R,R)-benzyl-thiazepin-5-one derivative via a modified Abiko method. 
 
2.5.3. Proposed route to 2, 4 & 7-Substituted Thialactam Derivatives  
The synthesis of 2, 4 and 7 substituted thiazepan-5-ones (2.119) could be 
envisaged in a similar manner via the same modular approach as previous 
thialactams. The synthesis of 2 substituted thialactams would require for instance 
a bromethylamine agent such as 2.121 derived from its corresponding alcohol 
(2.120) as shown in Scheme 43. The two SN2 reactions would mean that the 
original stereochemistry of the alcohol starting material would be retained in the 
final synthesis of the lactam ring. 
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The synthesis of the N-4 substituted derivatives of the thiazepan-5-one can be 
realised by beginning the synthesis with a suitable bromoethylamine agent (such 
as (2.123)) and coupling with the cysteine residue (2.91), which I have shown to 
be successful for N-methyl. Continuing the synthesis as before (vide supra) would 
generate the desired lactams (2.125). Alternatively, N-4 substituted derivatives 
could be realised by the direct conversion of the unsubstituted thiazpean-5-one 
(2.76) via N-alkylation, for which there is literature precedent.149,177  
 
Scheme 43. Proposed route to 2-substituted thialactams. 
 
3 M
4
4 4
Scheme 44. Synthetic route to 4-substituted thialactams. 
7-Substituted lactams could again be synthesised in a similar manner by 
beginning with substituted cysteine derivatives (2.127) and applying the same 
methodology. Indeed, I have shown that methyl protected penicillamine can be 
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used together with N-Boc-2-bromoethylamine (2.95) to generate 2.130. 
Deprotection and ring closure should furnish the 7-substituted lactams.   
 
Scheme 45. Synthetic route to 7-substituted thialactams can be realised from substituted cysteine 
derivatives (top) proven possible by the synthesis of 2.130 (bottom). Subsequent steps were not 
carried out. 
 
2.6 Long Chain Investigation 
As previously explained the synthesis of long chain compounds ((2.106) and 
(3S,6R)-(2.118)) were carried out because we knew that the 2’,2’-
dimethyldodecane side chain attached to lactams is key to the inhibition of the 
chemotaxis of THP-1 cells and human polymorphonuclear cells induced by other 
CC and CXC chemokines.96-98 For consistency and comparison, these long chain 
dimethyl compounds were synthesised with the thiazpin-5-one derivatives. We 
know from previously published research by the Fox group that 2’,2’-
dimethylated compounds are very potent, but there were gaps in our literature 
which needed investigating.96-98 Fox had synthesised 2’,2’-dimethylated 
compounds of type 2.132 and 2.133 where n is equal to 9, 2, 1 and 0, but a 
systematic approach was never employed to see what size chain gave the best 
biological results. 
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It was therefore necessary to synthesise the full set of side chains filling the gaps 
in the literature, thus optimising the side chain length. The 2’,2’-
dimethyldodecanoylamino thiazepan derivatives (2.106) and (3S,6R)-(2.118) were 
first synthesised and with the preferred synthetic scheme established the whole set 
of long chains could be synthesised. The 2-pyridone head group (2.162) instead of 
the caprolactam (2.103) was used as a large quantity of the 2-pyridone was easily 
synthesised.  
 
2.6.1. 2',2'-Dimethyldodecanoylamino Thialactam Derivatives 
The synthetic route to the 2’2’-dimethyldodecanoyl derivatives is shown below in 
Scheme 46. Alkylation of decyl iodide with the lithium enolate of methyl 
isobutyrate (2.134) and base hydrolysis of the methyl ester were carried out with 
only simple work up procedures (vide infra). Purification of the long chain acid 
(2.137) to give clean product was carried out before the acid chloride was reacted 
with the appropriate thiazepin salt. The acid chloride was once isolated on a small 
scale for analysis, otherwise it was reacted immediately to give the final product. 
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Scheme 46. Synthetic route to the 2’2’-dimethyldodecanoyl thialactam derivatives. 
2.6.2 Purification Process to the Synthesis of 2’2’Dimethyldodecanoic Acid 
During the synthesis of the 2’2’-dimethyldodecanoic acid (2.137) from the 
synthetic approach above it would not be unreasonable to expect impurities from 
the alkylation or the hydrolysis steps. An excess of methyl isobutyrate (2.134) 
ensures that all of the iodo-species is consumed (confirmed by NMR). Therefore, 
during the hydrolysis step, the only other impurity would be another acid. A 
simple work up procedure to eliminate any acid impurities and avoid the need for 
chromatography or distillation was adopted and is discussed herein. 
 
Using the Henderson-Hasselbalch equation (Equation 1) and re-writing it using 
the power laws we can then think about the partition coefficient of our substance 
during the work up procedure to come up with an equation which will help us in 
the purification. 
݌ܪ = ݌ܭ௔  −  log ൬[ܽܿ݅݀][ܾܽݏ݁]൰ ≡ [ܽܿ݅݀][ܾܽݏ݁]  = 10௣௄ೌି ௣ு  
Equation 1. Henderson-Hasselbalch equation rearranged. 
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The partition coefficient, or distribution coefficient, is defined as the ratio of 
concentrations of a compound in the two phases of a mixture of two immiscible 
solvents at equilibrium (Equation 2). 
ܲ =  [ܽܿ݅݀]݅݊ ݋ݎ݃ܽ݊݅ܿ ݌ℎܽݏ݁[ܾܽݏ݁]݅݊ ݋ݎ݃ܽ݊݅ܿ ݌ℎܽݏ݁ 
Equation 2. Partition coefficient of a species P. 
Considering our bi-phasic mixture, we know that the percentage of acid in the 
organic layer during the work up procedure will be the amount of acid in the 
organic layer divided by the total amount as shown in Figure 12. 
   % ܽܿ݅݀ ݅݊ ݋ݎ݃ܽ݊݅ܿ ݌ℎܽݏ݁ =  [ோ஼ைమு(೚ೝ೒)][ோ஼ைమு(೚ೝ೒)]ା [ோ஼ைమ(ೌ೜)ష ]ା[ோ஼ைమு(ೌ೜)]  × 100 
Figure 12. Equation showing the percentage of acid in the organic phase. By considering a bi-
phasic work up (top) we can calculate the percentage of acid in the organic layer by considering 
the amount of acid in the organic layer divided by the whole (bottom). 
Substituting our partition coefficient equation and our re-arranged Henderson-
Hasselbalch equation into the above equation we can calculate the percentage of 
acid in the organic layer if we know the pKa, pH and partition coefficient of our 
substance with this new equation (Equation 3).  
ݕ =  ܲ ×  10(௣௄ೌି ௣ு)1 + 10(௣௄ೌି ௣ு) + ܲ × 10(௣௄ೌି ௣ு)  
Equation 3. % of acid in an organic phase during a work up. 
The isobutyrate impurities and our long chain 2’2’dimethyldodecanoic acid will 
probably have a similar pKa (~5), therefore when the pKa and pH of our 
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substances are the same the percentage of acid in the organic phase will be equal 
to 50% (because the Henderson-Hasselbalch equation will be reduced to 1). In 
reality the partition coefficient for our long chain will be far different from the 
partition coefficient of the isobutyrate impurity. Our long chain will be very 
hydrophobic and therefore its partition coefficient will be very high, much greater 
than the shorter isobutyrate. If we assume that our partition coefficient for the 
2’2’dimethyldodecanoic acid is approximately 10000 and our partition coefficient 
for our impurity is roughly 5 (which is a reasonable estimate for both) then we can 
plot a graph from our equations (Figure 13). 
 
Figure 13. A plot of the percentage of acid in the organic phase during a separation for our 2’2’-
dimethyl substances. The red line is representative of the long chain 2’2’dimethyldodecanoic acid. 
The green line is representative of the methyl isobytyric acid. 
From the 2 plotted lines in Figure 13 we can see that the “apparent” pKa (ʹpKa) 
has shifted. When the partition coefficient is very high, like in this case, we can 
think of the apparent pKa of our substance being similar to that of Equation 4. 
′݌ܭ௔ = ݌ܭ௔ + log(ܲ − 1) 
Equation 4. The apparent pKa of a compound. 
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12 14
%
 o
f a
ci
d 
(in
 o
rg
an
ic
 p
ha
se
)
pH
P=10000
P=5
59 
 
The apparent pKa of our isobutyrate has increased slightly, but not as much as the 
2’2’dimethyldodecanoic acid. It is not hard to see that if we keep the pH to 8 or 
above we can get the maximum amount of 2’2’dimethyldodecanoic acid with no 
isobutyrate impurities. This technique of keeping the pH to ~8.0 was carried out 
and the procedure worked extremely well. The 1H NMR spectra of the crude ester 
(2.136) and final 2’2’dimethyldodecanoic acid (2.137) are shown below in Figure 
14 and Figure 15 respectively.  
 
Figure 14. 1H NMR of crude (2.136). It is possible to see the isobutyrate impurity in the 1H NMR 
as there are two ester peaks (peak 1 and 2). There are also two peaks for the methyl groups 
(labelled peak 3) corresponding to desired product and impurities. 
 
 
Figure 15. 1H NMR of (2.137). Keeping the pH to 8 after the hydrolysis gives clean product with 
no ester or isobutyrate impurities (as seen by the single peak at peak 1 and the disappearance of the 
ester peaks). 
In the crude ester 1H NMR (Figure 14) isobutyrate impurities are apparent while 
the final acid 1H NMR there are no significant impurities (Figure 15). 
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2.6.3 δ-Lactam Side Chain Investigation 
Adopting the same techniques that were used for the 2’2’-dimethyldodecanoic 
acid thiazepan derivatives, the full set of 2’2’-dimethyl side chains, with a δ-
lactam (or piperidin-2-one) as the head group, were synthesised (Scheme 47). The 
synthesis with the piperidin-2-one (2.162) was used because it was quick, facile 
and available in large quantities, as well as their having been a wide range of 
piperidinone compounds already tested (vide supra).  
 
(X) n Yield (%) (X) n Yield (%) 
2.139 8 >99 2.155 7 >99 
2.140 7 >99 2.156 6 97 
2.141 6 >99 2.157 5 >99 
2.142 5 >99 2.158 4 >99 
2.143 4 99 2.159 3 98 
2.144 3 63 2.160 2 99 
2.145 2 78 2.161 1 96 
2.146 8 84 2.163 8 16 
2.147 7 81 2.164 7 31 
2.148 6 69 2.165 6 17 
2.149 5 94 2.166 5 14 
2.150 4 47 2.167 4 41 
2.151 3 8 2.168 3 34 
2.152 2 3 2.169 2 7 
2.153 1 NA 2.170 1 0.6 
2.154 8 98    
Scheme 47. δ-lactam long chain synthesis. Investigation into the chain length requirement. 
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2.7 Biological Assays 
Compounds were subjected to two different biological assays, an SSTR2 binding 
assay and a leukocyte migration assay. SSTR2 binding data was obtained by Tilly 
Sharp at Total Scientific (Babraham Research Campus, Cambridge) using a 
technique called fluorescence polarisation (FP). Leukocyte migration data was 
determined by Dr Jill Reckless of the Department of Medicine at the University of 
Cambridge, using a multi-well filter migration assay system protocol. 
 
2.7.1 Fluorescence Polarisation (FP) 
FP is a technique used to study molecular interactions. Experiments are done in 
solution allowing true equilibrium analysis and measurements do not degrade the 
sample, so they can be treated and re-analysed. FP also allows real time 
measurements to generate kinetic assays, is insensitive to variations in 
concentration and is an optimal technique for homogeneous assay formats.178 
 
When fluorescent molecules in solution are excited with plane-polarised light, 
they emit light back into the same plane if the molecules remain stationary during 
the excitation of the fluorophore. This observation by Perrin is the basis of the 
theory of FP.179-183 In reality, molecules rotate and tumble and the planes into 
which the light is emitted can be very different from the plane used for initial 
excitation. If the polarised light used for excitation is vertical then the emitted 
light in the horizontal and vertical planes can be monitored. If the molecule is 
very large then little movement will take place during excitation and the polarised 
light emitted will remain highly polarised. However, if the molecule is small then 
the rotation of the molecule is faster and the polarised light emitted will be less 
than in the excitation plane (the light becomes depolarised). The FP of 
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fluorophore labelled somatostatin bound to SSTR2 can be compared to that which 
has been displaced by a test compound (Figure 16). 
 
Figure 16. Principles of the fluorescence polarisation assay.  
If a test compound displaces somatostatin, the non-bound somatostatin will cause 
the emission of depolarised light. Conversely, if the compound does not displace 
somatostatin, the emitted light will remain polarised.  
 
2.7.2 FP Results 
2.7.2.1 Long Chain Investigation Results 
The long chain compounds, 2.163-2.170, were tested using FP techniques for their 
SSTR2 binding activity at a concentration of 100 μM. The FP assay was run 
following a standard protocol with the polarisation calculated from the emitted 
light measured in the vertical and horizontal planes. The data is given as a 
percentage inhibition of SS-14 FITC from SSTR2, as summarised in Table 3. 
 
The results clearly show that competitive binding occurs when the chain length is 
eleven carbons long, with almost 50% inhibition. Full inhibition occurs when the 
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chain length is twelve carbons long. Aside from the 2’,2’-dimethyldodecane side 
chain, none of the other compounds show any displacement of somatostatin. 
 
(X) n Inhibition (%) Corrected Inhibition (%) 
2.171* 9 N/A 99 
2.163 8 39 46 
2.164 7 -21 -20 
2.165 6 -5 -2 
2.166 5 -5 -16 
2.167 4 -7 -6 
2.168 3 -5 -5 
2.169 2 -70 -72 
2.170 1 -7 -7 
2.172* 0 N/A 10 
Table 3. FP results of long chain piperidinones. *Compound previously synthesised by D.J.Fox 
and shown here for comparison. 
2.7.2.2 Thialactam FP Results 
The thialactams synthesised were also tested for their SSTR2 binding activity via 
the same protocol as the long chain piperidinones, the results of which are shown 
in Table 4. For comparison the results found for analogous non-sulfur containing 
lactams are shown in Table 5, as previously determined by the Fox group. 
 
(X) Rʹ R Inhibition (%) 
Corrected 
Inhibition (%) 
2.104 tBu H -3 -2 
2.105 Adamantane H -8 -10 
2.106 CH3(CH2)9C(CH3)2 H 108 114 
(3R,6R)-2.111 tBu Me -11 -10 
(3S,6R)-2.111 tBu Me -23 -16 
(3S,6R)-2.116 tBu Bn -21 -19 
(3S, 6R)-2.117 Adamantane Bn -15 -6 
(3S,6R)-2.118 CH3(CH2)9C(CH3)2 Bn 94 107 
Table 4. FP results of thilactams synthesised. 
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(X) Rʹ Corrected Inhibition (%) 
Leukocyte Migration 
Inhibition ED50 (nM) 
2.2 tBu 6 0.04 
2.173 Adamantane 21 0.09 
2.174 CH3(CH2)9C(CH3)2 107 0.09 
Table 5. FP and leukocyte migration results of caprolactams previously synthesised by D.J.Fox. 
It can be seen from the results that the long chain dimethyl compounds 2.106 and 
(3S,6R)-2.118 are unaffected by the inclusion of the sulfur atom or a benzyl side 
chain attached to the ring, with similar inhibition of somatostatin for the 
thialactams as the analogous caprolactam (2.174). Including sulfur decreases the 
inhibition for smaller side chains, with the adamantane side group being affected 
the most. The inclusion of a side group on the thialactam also decreases its 
inhibition ability, with the general trend of a bulkier side group (H>Me>Bn) 
giving a progressively worse result. 
 
2.7.3 Leukocyte Migration 
A multi-well filter migration assay system (Figure 17) was used to determine 
leukocyte migration.62 Each upper chamber in the migration assay contained 
leukocyte and inhibitor (motile cells), while the test substance containing fluid (or 
chemoattractant) was placed in the lower chamber. The upper and lower chambers 
were separated by a suitably porous filter allowing cell migration in the direction 
of the concentration gradient (from the upper chamber to the lower chamber).  
 
Figure 17. Illustration of a multi-well filter migration assay. 
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The migrated cells were quantified using the yellow dye 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT, 2.175). In the presence of reductases 
MTT is reduced to a purple formazan (2.176). The concentration of reductases is 
related to the number of living cells, so measuring the amount of formazan is a 
way of determining the number of living cells. Leukocyte migration data was 
determined by Dr Jill Reckless of The Department of Medicine at The University 
of Cambridge in this way, and determined as percentage inhibition of neutrophil 
migration at a given concentration. 
            
2.7.3.1 Leukocyte Migration Results 
Results for the thialactams 2.104-2.106 and (3S,6R)-2.116-2.118 are shown below 
in Graph 1. It can be seen from the results that the simple thialactams 2.104-
2.106 show very strong inhibition at M concentrations, and are comparable to 
the analogous caprolactam 2.2. At nano molar concentrations the compounds do 
not have the same effect as caprolactam 2.2. As for the substituted thialactams 
(3S,6R)-2.116-2.118, inhibition occurs but not as potent as their unsubstituted 
counterpart. Data for these compounds at nM concentrations give inconsistent 
results. 
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Graph 1. Leukocyte migration results of compounds 2.106-2.108 and (3S,6R)-2.118-2.120. 
 
We can therefore conclude that the inclusion of a sulfur atom into the lactam ring 
has little effect on the molecules biological properties. Any substitution at the 3 
position of the lactam ring decreases the potency of the molecule. 
 
It should be noted that a large quantity of the salts of the lactams, the penultimate 
compound of type 2.103, of each family subset have been kept and therefore a 
larger library of compounds (by the simple acylation reaction) is easily possible 
than that which has been made. A structure activity relationship could therefore be 
generated for these thialactam compounds. 
 
2.8 Conclusions and Future Work 
We have shown that the syntheses of C-substituted γ-thialactams are possible via 
a modular approach starting from the simple amino acid cystine. These 
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compounds are a new class of GPCR ligand, showing BSCI activity comparable 
to their non-sulfur counterparts. Initial migratory data suggests that these lactams 
are inhibitors of leukocyte migration and comparable to the analogous BSCI 
lactams at µM concentrations, with decreased activity at the nM scale. The 
inclusion of sulfur into this class of lactam has little effect on its biological ability. 
Initial findings suggest that C-substitution at the 3-position of the 1,4-thiazepan-5-
one class of lactam decreases their biological activity, and are less potent anti-
inflammatory agents, with the exception of 2.118. Further biological studies are 
needed in order to fully appreciate the effects of C-substitution on this class of 
compound. We envisage the synthesis of more C-substituted lactams via this 
modular approach and further biological studies in order to build a structure 
activity relationship for these classes of molecules. 
 
The SSTR2 binding data shows that a chain length of at least eleven carbons is 
needed for inhibition of the binding of somatostatin at SSTR2 at 100 µM. Apart 
from the long chain dimethyl compounds, 2.106 and (3S,6R)-2.118, the sulfur 
containing lactams show no displacement of somatostatin, though they do show 
leukocyte migratory inhibition, confirming it is not necessary for the compounds 
to occupy the somatostatin binding site to act as a potent BSCI. 
 
The thialysine derivative and its analogues (2.177) prepared during the synthesis 
of these C-substituted γ-thialactams could be utilised by making new SSTR2 
ligands (Scheme 48) by introducing this motif into SSTR2 ligands identified by 
Merck (see Section 1.4.1). Measuring the effect of these structural changes on the 
SSTR2 mediated activity of these compounds could then be calculated.  
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Scheme 48. Incorporating the thialysine derivatives to make new SSTR2 ligands. (see Section 
1.4.1) 
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Chapter 3 – Asymmetric Lactams via Jocic-Reeve- 
Corey-Link Reactions 
3.1 Introduction 
In continuation of our interest with previous BSCIs of type 3.1-3.3 with our aim 
of synthesising C-substituted lactams such as 3.4-3.6, our attention turned to the 
synthesis of C-substituted δ-valerolactams, or piperidinones (3.7). 
                    
The simple 3-aminopiperidine-2-ones 3.8 and 3.9 are now commercially available 
and used as heterocyclic building blocks for the synthesis of a wide range of 
biologically important compounds, from conformationally constrained 
peptidomimetics, such as Freidinger lactams, to antileishmanials.184-191 
       
Although 3-aminopiperidine-2-ones are known, surprisingly and to the best of our 
knowledge only a few syntheses have been reported for C-substituted 3-
aminopiperidine-2-ones (3.10).189,192-205  
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We have been interested in developing a short asymmetric synthesis of this type 
of lactam based on the following reasoning; 
1. We know that 3-aminopiperidin-2-ones of type 3.7 inhibit leukocyte 
chemotaxis in vitro due to a range of chemokines and act as anti-inflammatory 
agents in vivo.90,96-98 
2. The incorporation of substituents at the C-4,5 and 6 positions would not only 
introduce an additional point of diversity but also influence the conformation 
of the molecule. 
3. An alternative asymmetric synthesis of substituted lactams could be attempted 
which, if successful, could be beneficial to the chemical community while 
simultaneously furthering our knowledge of BSCIs. 
4. The chemistry used in synthesising this type of lactam could then be utilised 
in the synthesis of other substituted lactams or heterocycles, which may have 
important uses. 
We began our endeavours by concentrating our efforts towards the synthesis of 
the dimethylpiperidin-2-ones (3.11-13).  
           
Dimethyl derivatives of lactams were of interest because our previous research 
had shown that related molecules of this type exhibited good biological activity. 
We also knew that α,α-disubstituted α-amino acids belong to the group of 
nonproteinogenic peptide components, that 2-aminoisobutyric acid derivatives 
make up a high proportion of natural polypeptide antibiotics and peptaibols, and 
although not directly related have structural similarities with the type of 
compounds we wished to synthesise.206-209 The antibiotic penicillin210-213 (3.14) 
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also has a gem-dimethyl structure with similarities to the compounds we wished 
to synthesise, further strengthening our reason for their synthesis.   
 
We initially envisaged the dimethylpiperidin-2-one lactams (3.15) being formed 
by ring closure of a suitable enantiopure α-amino acid (3.16), which would be 
synthesised asymmetrically from the α-azido-acid (3.17) and the corresponding α-
trichloromethyl carbinol (3.18), all derived from a suitable aldehyde (3.19) as 
shown in Scheme 49. 
 
Scheme 49. Proposed retrosynthetic route to substituted 3-aminopiperidine-2-ones 
This process would involve a wide array of chemistry, some of which will briefly 
be discussed first. 
3.2 α-Trichloromethyl Carbinol Chemistry 
Throughout this and subsequent experiments our aim was to utilisie α-
trichloromethyl carbinol derivatives (3.19), and their chemistry, in the synthesis of 
asymmetric lactams. 
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3.2.1 General Synthesis of α-Trichloromethyl Carbinols 
The condensation of chloroform with aryl aldehydes and ketones under basic 
conditions are the earliest and most standard methods for the preparation of α-
trichloromethyl carbinols.214-219 Many different methods for their synthesis exist 
as summarised in Scheme 50. Chloral (3.20) is often used in the presence of a 
Lewis acid or arylmagnesium bromide with aromatic hydrocarbons to produce the 
desired α-trichloromethyl carbinol.220-225 Of particular interest (vide infra) are the 
reactions of aldehydes with chloroform under basic conditions in the presence of 
phase transfer catalysts (PTCs) such as quaternary ammonium salts.226-230 α-
Trichloromethyl carbinols can also be synthesised by the reaction of electrophilic 
aldehydes with a trichloromethyl anion (3.21) generated via electrochemical 
reduction (3.22), or the reaction of trimethylsilyltrichloroacetate (3.23) or 
(trichloromethyl) trimethylsilane (3.24) with catalytic fluoride ion.231-236 
 
Scheme 50. Synthetic routes to α-trichloromethyl carbinols. 
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All these methods to generate α-trichloromethyl carbinols have now been 
superseded by two main protocols, the Corey-Link and Wyvratt methods (Scheme 
51).215,237-239  
 
Scheme 51. Corey-Link and Wyvratt methods to the synthesis of α-trichloromethyl carbinols. 
For our purposes, the preferred method for the synthesis of α-trichloromethyl 
carbinols is most certainly the Corey-Link method, as it provides rapid access to 
α-trichloromethyl carbinols from all classes of aldehydes without aldehyde 
enolisation. Although the Wyvratt method affords α-trichloromethyl carbinols 
with improved efficiency compared to the Corey-Link method, the basic nature of 
the method means that aliphatic aldehydes generate aldol products during the 
reaction, making it undesirable for our synthesis.237 
 
3.2.2 Jocic Reaction 
The Jocic reaction (Scheme 52), a reaction without precedent, was first reported 
by Jocic in 1897 and is the generation of α-chlorophenylacetic acid (3.26) from 
phenyltrichloromethylcarbinol (3.25) with ice cold aqueous potassium 
hydroxide.240  
 
Scheme 52. Jocic Reaction. 
With little to no subsequent work on this area until almost a century later, Reeves’ 
seminal contribution both mechanistically and synthetically revived the reaction 
which subsequently gave rise to the reaction being named the Jocic-Reeve 
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reaction.241-244 Notably, Reeve found that the Jocic reaction is general for 
secondary trichloromethyl carbinols and trichloroethanol, and that tertiary 
trichloromethyl carbinols form ketones with the loss of carbon monoxide. 
 
3.2.3 Jocic-Reeve Reaction Mechanism 
Jocic reported that his reaction proceeds through a gem-dichloroepoxide 
intermediate (3.28),240 with later work by McElvain and Stevens,245 and 
Weizmann246 also claiming a reaction mechanism involving a gem-
dichloroepoxide intermediate from α-trichloromethyl carbinols. The gem-
dichloroepoxide intermediate was later verified by Reeve. 
  
Scheme 53. The Jocic-Reeve reaction mechanism. 
There has though been much speculation regarding the true mechanism of the 
Jocic reaction. Reeve performed detailed mechanistic investigations241,243-244 and 
proposed four possible mechanisms including, a carbonium ion mechanism, a 
carbene mechanism, a hypochlorite mechanism and a chlorooxirene 
mechanism.69-70,74 None of these truly accounted for all of the experimental 
observations, with the carbene mechanism the closer match. Reeve concluded that 
whilst the true mechanism of the Jocic reaction was uncertain the SN2 mechanism 
represents a minor pathway while the major pathway involves either carbonium 
ion, carbene, hypochlorite or chlorooxirene intermediates. 
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3.2.4 Jocic-Reeve Reaction Uses 
Since its re-emergence and popularisation the Jocic-Reeve reaction has been 
utilised in a number of synthetic applications (Scheme 54) with particular interest 
on the reactivity of α-trichloromethyl carbinols with a range of nucleophiles. As 
mentioned, α-chloroacids (3.31)241 can be synthesised under the original 
conditions while MeOH acting as the nucleophilic source and an excess of KOH 
furnishes α-methoxyesters (3.32).247 The reaction can be stopped at the α-
methoxyacid stage if there is no excess hydroxide.218,246,248 Other possible 
nucleophilic sources include fluoride from TBAF to generate α-fluoroacids 
(3.33),249 sodium azide250 and the subsequent reduction of the α-azidoacid to 
generate α-aminoacids (3.34)251 and a variety of sulfur containing compounds 
such as thioureas, thiobenzhydrazide, o-aminothiophenol and thiosemicarbazide 
to generate a range of sulfur compounds,242,252-257 such as thiazolidinones (3.35). 
More recently the Snowden group have extended the scope of the Jocic-Reeve 
reaction by investigating the regioselective substitution of gem-dichloroepoxides 
involving alkenyl trichlorocarbinols to give either γ-substituted enoic acids (3.36) 
or α-substituted acids, depending on the nature of the nucleophile in protic 
solvent.258 They have also exploited the Jocic-Reeve reaction in the development 
of one-carbon homologation-functionalisation reactions, converting α-
methyltrichlorocarbinols to their homologated carboxylic acids by treatment with 
either NaBH4 in alkaline tert-butyl alcohol (3.38) or with sodium 
phenylseleno(triethyl)borate complex, prepared in situ, in ethanol.259-260 Of 
significant importance to our studies, Oliver and Schmidt showed that the Jocic-
Reeve reaction could be utilised to synthesise heterocycles when the substrate was 
tethered with an appropriately located nucleophile for intramolecular ring 
formation.261 Indeed they reported that a vicinal hydroxyl group afforded 
stereospecific formation of chiral cis- and trans-epoxides (3.37) from the 
corresponding α-(trichloromethyl)glycols. Surprisingly, there are only a small 
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number of nucleophiles known (N3-, ArO-, F-) that give a stereoselective 
intermolecular Jocic-Reeve reaction. 
 
Scheme 54. Reactions of α-trichloromethyl carbinols. 
 
3.3 Corey-Link Chemistry 
Arguably the most popular and recognisable utilisation of the Jocic-Reeve 
reaction, and one which certainly renewed interest in the area, is the Corey-Link 
reaction (Scheme 55).237-238,262 It is a specific example of the much broader and 
more general Jocic-Reeve reaction but has somehow gained “named reaction” 
status through its popularity and third party classification.260,263  
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Scheme 55. Corey-Link reaction. 
The Corey-Link reaction utilises asymmetric α-trichloromethyl carbinols (3.43) in 
the synthesis of non-proteogenic α-amino acids (3.45). Asymmetric α-
trichloromethyl carbinols were prepared by the oxidation of achiral α-
trichloromethyl carbinols (3.19) into trichloromethyl ketones (3.40) with 
chromium and the subsequent enantioselective reduction with the Corey-Bakshi-
Shibata (CBS)264  reduction catalyst (3.42). The trichloromethyl ketones were 
reduced either to the (S)- or the (R)-forms with greater than 96:4 
enantioselectivity. A Jocic-Reeve reaction of the enantiopure α-trichloromethyl 
carbinols with sodium azide under basic conditions in a solution of 
dimethoxyethane (DME) and water gave enantiopure α-azidoacids (3.44) which 
were reduced with palladium catalysed hydrogenation to their respective α-amino 
acids in high yields and purity.262 
 
3.3.1 Corey-Link Reaction Mechanism 
The Corey-Link reaction is said to proceed via a gem-dichloroepoxide 
intermediate (3.46) followed by SN2 attack of the azide nucleophile (Scheme 
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56).262 The inversion of the stereochemistry is in agreement with earlier findings 
by Reeve, who incidentally was the first person to show that α-trichloromethyl 
carbinols could be transformed into α-amino acids,251 albeit racemically, and 
indicative of the gem-dichloroepoxide intermediate.  
Scheme 56. Corey-Link reaction mechanism. 
It is evident from the high yields and purity of the α-azidoacids, together with the 
complete inversion of stereochemistry, that the Corey-Link mechanism is a 
collapse of the Jocic-Reeve reaction mechanism to a major SN2 type pathway due 
to the inclusion of the azide nucleophile. The Corey-Link synthesis shows that α-
trichloromethyl carbinols are convenient precursors for the preparation of 
substituted carboxylic acids, esters, and other synthetically useful 
compounds.260,265-267 
3.4 Dimethyl Lactam Derivatives via α-Trichloromethyl Carbinol Chemistry 
As eluded to, we envisaged the dimethylpiperidin-2-one lactams (3.15) being 
formed by ring closure of a suitably substituted enantiopure α-amino acid (3.16) 
synthesised using the α-trichloromethyl carbinol chemistry described earlier. 
 
3.4.1 Towards the Synthesis of Asymmetric 3-Amino-6,6-dimethylpiperidin-2-ones 
We envisaged the synthesis of the 3-amino-6,6-dimethylpiperidin-2-ones (3.11) 
via the δ-nitro-α-trichloromethylcarbinol (3.48). 
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Scheme 57. Retrosynthetic approach to 3-amino-6,6-dimethylpiperidin-2-ones. 
We hoped that conversion of this carbinol to the corresponding α-azidoacid 
(3.53), reduction and ring closure would furnish the desired product (Scheme 58). 
Scheme 58. Proposed route to 3-amino-6,6-dimethylpiperidin-2-ones. 
 
If the syntheses of the racemic piperidinones (3.11) were possible then Corey-
Link chemistry would be used to synthesise the enantiopure piperidinones (3.11) 
by oxidising the δ-nitro-α-trichloromethylcarbinol substrate to its corresponding 
trichloromethyl ketone (3.57) and reducing using the CBS reduction, as in the 
Corey-Link reaction (Scheme 59).  
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Scheme 59. Proposed route to asymmetric piperidinones. 
3.4.1.1 δ-Nitro-α-trichloromethylcarbinol Route 
Synthesis of the δ-nitro-α-trichloromethylcarbinol was accomplished easily in 
high yield and purity over two steps. The Michael addition of 2-nitropropane 
(3.49) and acrolein (3.50) furnished the 4-methyl-4-nitropentanal (3.51) in 
quantitative yield.268-274 The aldehyde then underwent the Corey-Link method for 
generating α-trichloromethylcarbinols using trichloroacetic acid and sodium 
trichloroacetate in DMF to give the desired racemic δ-nitro-α-
trichloromethylcarbinol (3.52). 
 
Scheme 60. Synthesis of δ-nitro-α-trichloromethylcarbinol. 
DMF was preferred over DMSO215,275 as the solvent as it gave better yields and 
reproducibility. Monitoring the reaction using NMR experiments in DMSO-d6 
gave inconsistent results. It is worth noting that the acrolein in the Michael 
addition needed to be distilled in order for the reaction to proceed. 
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With the successful synthesis of the δ-nitro-α-trichloromethylcarbinol the 
proposed reaction scheme looked promising. Indeed, the Corey-Link reaction of 
the carbinol gave the desired 2-azido-5-methyl-5-nitrohexanoic acid (3.53) in high 
yields, but unfortunately the hydrogenation step to form the diamine (3.54), which 
would seem straight forward, could not be accomplished (Scheme 61).  
 
Scheme 61. Corey-Link chemistry and attempted synthesis of the diamine derivative. 
Many reducing agents were attempted (Scheme 62). Both Pd/C (the original 
Corey-Link method of preparing α-aminoacids) and PtO2 catalysts with hydrogen 
were attempted, with little success. Even Raney nickel failed to reduce the 
carbinol to the α-aminoacid. It seemed logical to think that these reductions were 
failing because the diamine formed would be highly insoluble in the methanol 
solvent system employed in our hydrogenations, therefore a MeOH:H2O (1:1) 
mixture was attempted again with little luck. The same train of thought led to the 
attempted Boc protection in situ of the product by using an excess of di-tert-butyl 
dicarbonate (3.58), this also failed. The α-azidoacid was methylated (3.59) using 
acetyl chloride-methanol as a final attempt at hydrogenating the resulting ester to 
a useful diamine as we wanted to eliminate the possibility of the acid affecting the 
reduction. Again I could not isolate the desired product from the reaction. 
Unfortunately I found that it is much more difficult to perform a hydrogenation on 
a compound that contains acid, azide and nitro functionalities than originally 
anticipated, and I was unable to synthesise or isolate a useful diamine derivative. 
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Scheme 62. Reduction attempts on the nitro-azido-acid (3.53). 
3.4.1.2 Reduction Test  
Due to the problems with the hydrogenation, and to check that it wasn’t our 
method that was affecting our results, I decided to quickly investigate a similar 
type chain acid-azide to see if we could produce the desired α-aminoacid (Scheme 
63). The Fox lab had plenty of butyraldehyde (3.61) and the Corey-Link 
chemistry carried out on that aldehyde indeed furnished the desired α-aminoacid 
(3.64). I at least felt assured that the method of performing hydrogenations was 
adequate and that my concerns that a compound containing acid, azide and nitro 
functionalities was difficult to reduce confirmed. 
Scheme 63. Testing of Corey-Link chemistry with butyraldehyde (3.61). 
3.4.1.3 δ-Amino-α-trichloromethylcarbinol Route 
The unsuccessful route to the gem-dimethyl lactams via the δ-nitro-α-
trichloromethylcarbinol was a disappointing result and it became apparent that if I 
wanted to continue our syntheses of the lactams via Jocic-Reeve-Corey-Link 
chemistries we needed to synthesise an α-trichloromethylcarbinol substrate which 
contained a protected δ-amino group (Scheme 64). I set out to synthesise our new 
carbinol substrate (3.65) by performing the necessary chemistry on our previously 
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synthesized 4-methyl-4-nitropentanal (3.51) and attempting to reduce the nitro 
functional group of this substrate first before undergoing the Jocic-Reeve type 
reaction. 
 
Scheme 64. Alternative substrate for the synthesis of the desired piperidinones. 
Reduction of the nitro group was attempted from various analogues of the nitro 
aldehyde (3.51). Direct reduction of the nitro group with H2 and Pd/C to generate 
the reduced amino aldehyde seemed unlikely, and indeed did not work. Reduction 
of the aldehyde with sodium borohydride in ethanol furnished the nitro alcohol 
(3.66) in quantitative yields on small and large scale. The reduction of the nitro 
group from this compound via H2 and Pd/C was  again unsuccessful, but a method 
used by Jim Andersons group in reducing tertiary nitro compounds using zinc and 
6M HCl gave the corresponding amino alcohol (3.67, Scheme 65).276-280  
 
Scheme 65. Reduction of 4-methyl-4-nitropentanal. 
Although the reduction of the nitro compound (3.66) succeeded using zinc, 
isolating the reduced product (3.67) gave unreliable and poor yields, typically 
between 8-14% (with the exception of 99% on one ocassion). Protection of the 
amine group from this isolated product is possible but also unreliable. It was 
found that protecting the amine directly after taking up the reaction in base 
(Scheme 66) produced the desired protected amino alcohol derivative (3.68) 
reliably in overall yields of between 12-34%. We also generated the Boc protected 
version of the protected amino alcohol (3.67-Boc) in yields of up to 55%. 
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Scheme 66. Generating the protected amino alcohol 3.68. 
With the successful synthesis of the protected amino alcohol we could now 
oxidize this compound and perform the required Jocic-Reeve-Corey-Link 
chemistry. Oxidation of 3.68 was achieved in high yields if Dess-Martin 
periodinane (DMP)281-284 was used, while the Swern oxidation285-287 gave poor 
results (Scheme 67). The Corey-Link method of synthesising α-trichloromethyl 
carbinols was utilised to synthesise the desired carbinol (3.70) from its aldehyde 
(3.69). 
Scheme 67. Synthesis of the amine-protected trichlorocarbinol. 
Several interesting points should be noted. We could not understand why the 
Swern oxidation gave poor results, and when we initially used DMP for the 
oxidation we were generating a compound which gave experimental data that was 
inconsistent with the expected structure of 3.69. We later found that the aldehyde 
is most likely in equilibrium with, or converted to, its pyrrolidine form (Scheme 
68). As we would later find, aldehydes of this type, even though Cbz-protected, 
could form cyclic compounds, or react to produce undesirable products. 
 
Scheme 68. Compound 3.69 in equilibrium with 3.71. 
In either case, when the Corey-Link method was applied to isolated product 3.69 
the desired α-trichloromethyl carbinol was generated. With the synthesis of the 
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protected δ-amino-α-trichloromethyl carbinol (3.70), we envisioned conversion to 
the desired 3-amino-6,6-dimethylpiperidin-2-ones (3.11) by performing the 
required Corey-Link chemistry (Scheme 69). 
 
Scheme 69. Synthesis of 3-amino-6,6-dimethylpiperidin-2-ones. 
While several substrates have been utilised in the Corey-Link process (vide 
supra), amine-containing substrates have rarely been studied. Treatment of the 
trichloromethyl carbinol (3.70) was expected to provide α-dichloroepoxide 
intermediate (3.73) as previously proposed for this process which, upon epoxide 
cleavage by azide with inversion, would provide acid chloride (3.74) which would 
then furnish the azido-acid (3.72) upon work-up (Scheme 70). However, despite 
extensive experimentation, this strategy was unsuccessful. It is thought that the 
amine plays a role in an unexpected capture of the presumed dichloroepoxide 
intermediate (3.73) which generates an undesired pyrrolidine product (3.76), but 
this was never isolated from the crude reaction mixture. 
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Scheme 70. Attempted Corey-Link chemistry on the protected δ-amino α-trichloromethyl carbinol 
(3.70). 
We initially foresaw the use of chromium for the oxidation of carbinols to the 
trichloroketones and CBS catalyst for the asymmetric reductions (i.e. Corey-Link 
reaction in Scheme 71)  but simultaneous work carried out on the use of CCl3 as a 
directing group for asymmetric transfer hydrogenation meant the CBS catalyst 
was abandoned in favour of ruthenium-based catalysts. In any case, we were 
unable to oxidise the α-methyl trichlorocarbinol (3.70) to its trichloroketone 
(3.77) counterpart using DMP, IBX, chromium or Swern oxidations. Combined 
with the failure of the Corey-Link procedure to form the azido-acid (3.72) the 
syntheses of these types of compounds were abandoned. 
Scheme 71. Asymmetric synthesis of piperidinones. 
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3.4.1.4 Asymmetric Transfer Hydrogenation of Trichloroketones 
Investigations into asymmetric transfer hydrogenations288-290 of chloroketones and 
subsequently trichloroketones (3.78) were being carried out within our group by 
Michael Perryman. He found that ruthenium could be used for the asymmetric 
transfer hydrogenation of chloroketones (Figure 18). 
 
R Conversion (%) ee (%) 
CH
3 
 > 99  95  
CH
2
Cl  > 99  79  
CHCl
2 
 > 99  71  
CCl3 > 99 35 
Figure 18. Asymmetric transfer hydrogenation of chloroketones using ruthenium catalyst. 
Results for aromatic trichloroketones, producing the corresponding asymmetric 
trichlorocarbinol, did not look promising, giving low enantiomeric excesses. 
Undeterred, Perryman investigated the use of ruthenium as a catalyst for a range 
of aliphatic trichloroketones. These trichloroketones (3.80), synthesised from their 
respective aldehydes, were subjected to asymmetric transfer hydrogenations to 
give asymmetric α-trichloromethyl carbinols (3.81) in high yields and 
enantiomeric excesses. The best results obtained, some of which are shown in 
Figure 19, used TsDPEN and [Ru(p-cymene)Cl2] dimer to generate the transfer 
catalyst TsDPENRu(p-cymene)Cl.  
 
Preliminary results, again by Perryman, show that alkyl side chains of 
trichloroketones can be reduced to their respective α-trichloromethyl carbinols in 
high yields and enantiopurity using ruthenium catalysts, therefore allowing us to 
use this chemistry for the generation of asymmetric lactams within our synthesis. 
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R Conversion (%) Yield (%) ee (%) 
Me > 95  50 99  
nPr > 95 37 95 
(CH2)9CH3 > 95 95 95 
(CH2)2Ph > 95  90 97  
CH(CH3)(CH2)2CH3 > 95 68 91:89 (4:3) 
Figure 19. Selected results for the asymmetric transfer hydrogenation of aliphatic 
trichloroketones. 
3.5 Towards a General Synthesis of Asymmetric Lactams 
During the unsuccessful attempts at synthesising the dimethylpiperidinones I was 
also attempting to perform the general synthesis of 3-amino-lactams from simple 
amino-alcohols (Scheme 72). Again I would utilise the Jocic-Reeve-Corey-Link 
reaction for the synthesis of racemic lactams and, if successful, the asymmetric 
transfer hydrogenations using ruthenium chemistry to generate the asymmetric 
lactams. This would allow the synthesis of C-substituted lactams from substituted 
amino-alcohols.  
Scheme 72. Proposed general synthetic route to lactams. 
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To begin with I used benzyl chloroformate as the protecting group (much like the 
piperidinone strategy) as I was hoping that the amino lactams would be formed by 
simultaneously deprotecting, reducing and cyclising the azido acid (3.86) formed 
from the Corey-Link reaction. Unfortunately a number of problems arose when 
attempting the synthesis of these lactams with the Cbz protecting group. When 
ethanolamine was used (n=1), the acetate (3.85a-i) or oxazolidinone (3.85a-ii) of 
the methyltrichlorocarbinol was formed during the Corey-Link method. The 
synthesis from propanolamine (n=2) works up to the α-methyl trichlorocarbinol, 
albeit with very low yields (16%), but the azido acid could not be generated. For 
the pentanolamine derivative (n=4) a cyclised product of unknown structure is 
formed. The difficulty and unreliability in synthesising the Cbz-protected 
methyltrichlorocarbinols was apparent. Despite the amine group being protected, 
it still plays a role in disrupting our chemistry. This finding simultaneously 
became apparent during the synthesis of these and our piperidinones (vide supra) 
and so the use of phthalidimides was rationalised in order to generate the 
trichlorocarbinols without the interference of the amine during the reactions. If the 
synthesis of lactams using phthalimides was realised at least the piperidinones 
could again be attempted. Indeed it is easily possible to synthesise the full set of 
phthalimide protected trichlorocarbinols (3.85a-h) in good yields (Figure 20). 
 
Complications became apparent when attempting the Corey-Link reaction with 
NaOH and NaN3 on the phthalimide protected trichlorocarbinol substrates (3.85e-
h). The basic nature of the Corey-Link reaction was not compatible with the 
phthalimide protecting group. Indeed there are a number of possible reaction 
pathways that can occur during these reactions. A modification of the Corey-Link 
procedure where DBU was used instead of hydroxide in MeOH seems an 
attractive alternative,263 but it has been shown that this procedure is only 
successful with tertiary trichloromethyl alcohols. The reason for the poor 
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performance of secondary trichloromethyl carbinols under these conditions is 
unknown. Although our scheme looks attractive for the general synthesis of 
lactams, we have not yet been successful in synthesising compatible protected 
amino trichloromethyl carbinols with the Jocic-Reeve-Corey-Link chemistries. 
  
 
 
 
 
 
 
 
 
 
 
Figure 20. Synthesis of alkylamine-protected trichloromethylcarbinols.#Product formed was the 
trichloroacetate (3.85a-i) or oxazolidinone (3.85a-ii) on separate occasions. *Unknown cyclised 
product formed from the reaction. NA = not attempted. 
3.6 Conclusions 
Efforts have been made to the synthesis of substituted piperidinones, as well as 
employing Jocic-Reeve-Corey-Link chemistry to the general synthesis of lactams, 
ultimately looking to the synthesis of C-substituted lactams. Protected amino 
trichloromethyl carbinols are much harder to work with than previously 
PG = Cbz PG = Phth 
(X) n Yield (%) (X) n Yield (%) 
3.83a 1 53 3.83e 1 48 
3.83b 2 99 3.83f 2 35 
3.83c 3 82 3.83g 3 NA 
3.83d 4 71 3.83h 4 68 
3.84a 1 45 3.84e 1 66 
3.84b 2 10 3.84f 2 65 
3.84c 3 94 3.84g 3 NA 
3.84d 4 78 3.84h 4 77 
3.85a 1 NA# 3.85e 1 43 
3.85b  2 16 3.85f 2 76 
3.85c 3 NA 3.85g 3 NA 
3.85d 4 NA* 3.85h 4 44 
93 
 
anticipated. The use of a phthalimide protecting group may provide the answer for 
utilising trichloromethyl carbinol chemistry in the presence of an amine group, if 
a successful modified Corey-Link procedure is found. A method for asymmetric 
transfer hydrogenation of trichloroketones has been established and can be utilised 
in the synthesis of asymmetric lactams if/when a route has been established.  
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CHAPTER 4 – Asymmetric Substituted β-Hetero-
δ-Lactams via Hybrid-Bargellini Reactions 
 
4.1 Introduction 
Continuing our interest in the field of substituted lactams, trichloromethyl 
carbinol reactions and using the chemistries we had developed within the group, 
our attention turned to substituted enatiomerically enriched heterocycles, more 
specifically substituted β-hetero-δ-lactams. 
 
4.2 Bargellini Reaction 
The Bargellini Reaction is a multicomponent coupling reaction which also 
involves gem-dichloroepoxides.291 First reported in 1906, it involves the in situ-
generation of trichloromethide anion from chloroform in the presence of NaOH 
and its reaction with phenol and acetone to generate α-phenoxyisobutyric acid 
(Scheme 73).292 
 
Scheme 73. The Bargellini Reaction. 
Since its initial report, the Bargellini reaction has been extensively investigated 
with many advances coming from research groups within the pharmaceutical 
industry. Variants of both nucleophile and ketone have been investigated; Korger 
reported the use of substituted phenols as nucleophiles to prepare griseofulvin 
analogues;293 Youseff used phenols as nucleophiles and cyclopentanone as the 
ketone;294 Lai used hindered amines as nucleophiles to create a series of hindered 
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morpholinones and piperazinones,295-298 and more recently activated arenes as 
nucleophiles to give hindered phenols;299 Butcher300 used aromatic amines as 
nucleophiles; Grella investigated a wide range of cyclic ketones;301 while Yu used 
Bargellini reactions to generate α-hydroxy acids,302 as summarised below in 
Scheme 74.  
 
Scheme 74. Bargellini reactions using variants of both nucleophile and ketone. 
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Of importance to our research was the work carried out with binucleophiles in the 
Bargellini reaction, in particular the synthesis of hindered morpholinones or 
piperazinones (4.4) from ketones (such as acetone) and 2-amino-2-methyl-1-
propanol or 1,2-diaminopropanes (4.3), Scheme 75. Work performed by Lai (vide 
supra) of the BF Goodrich Corporation, who has been active in this area of 
chemistry over the past three decades, is of particular interest. 
 
Scheme 75. Heterocycles via the Bargellini reaction. 
 
4.2.1 Mechanism of Bargellini Reaction 
During the Bargellini reaction the product is formed by regioselective addition to 
an intermediate gem-dichloroepoxide (4.6). Typically the intermediate is formed 
by base deprotonation of chloroform with the in-situ-generated trichloromethide 
anion (4.5) coupling to a sterically accessible ketone (Scheme 76). The reaction of 
a nucleophile with the gem-dichloroepoxide then follows, in the same manner as 
the Jocic-Reeve-Corey-Link reactions (vide supra). If the nucleophile is a tethered 
binucleophile (as in Scheme 76) then the acyl chloride generated can be captured 
by the tethered nucleophile to form a heterocyclic compound. 
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Scheme 76. Mechanism of the Bargellini reaction. 
 
Worth noting are the statements by Snowden, who is an expert in the field of 
Jocic-Reeve-Corey-Link-Bargellini reactions, who has said regarding the 
Bargellini reaction “in general, alkyl aldehydes are not compatible with the 
reaction primarily due to competing aldol condensation and the relatively slow 
rate of dichloroepoxide formation from any formed secondary trichloromethyl 
alkoxide”.260 
 
4.3 Heterocycles via Hybrid-Bargellini Reactions 
As a continuation of our work towards substituted chiral lactams, we hoped to 
utilise some of the α-trichloromethyl carbinols we had previously synthesised in a 
hybrid-Bargellini type reaction. 
 
4.3.1 Utilising Previous Compounds 
Our first attempted synthesis of a heterocycle was via the δ-nitro-α-
trichloromethylcarbinol (3.52) previously synthesised. We hoped that the carbinol 
would form the gem-dichloroepoxide intermediate (4.9) with the use of NaOH, 
followed by the reaction of our binucleophile, ethanolamine, with this 
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intermediate with ring closure occuring by trapping of the acid chloride (Scheme 
77). The same conditions were used as those for the Bargellini reaction in Lai’s 
work, but unfortunately we were unable to isolate the desired product. Although 
we were confident that cyclisation did occur during these reactions (due to the 
appearance of multiple stereocentre peaks in the NMR), we were less confident 
about the suitability of the nitro carbinol for these reactions. 
 
Scheme 77. First attempt at a hybrid-Bargellini reaction utilising 3.52.  
Other previously synthesised trichloromethyl carbinols (vide supra) were also 
attempted giving inconclusive results. 
 
4.3.2 Checking the Chemistry – Modified Corey-Link Reaction 
At this juncture we were concerned with the selection of our substrate and 
whether or not we could use a binucleophile with alkyl trichloromethyl carbinols. 
We therefore focused our attention on checking the chemistry with the Corey-
Link reaction and to see whether or not we could trap the proposed 
dichloroepoxide intermediate during the reaction with two nucleophiles. 
 
We used hydrocinnamaldahyde (4.11) as our candidate molecule because it was 
structurally similar to the substrates we intended to use – it contains a bulky 
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quaternary carbon three carbon units away from the reactive site, separated by two 
CH2 units. Corey-Link chemistry on this substrate furnished the corresponding 
1,1,1-trichloro-4-phenylbutan-2-ol (4.12) and its azido-acid (4.13) in good to 
excellent yields (Scheme 78).  
 
Scheme 78. Corey-Link reaction using hydrocinnamaldehyde. 
When we introduce a second nucleophile into the Corey-Link reaction (in this 
case one equivalent of benzylamine) we were very pleased to discover that we 
could indeed trap the acid chloride intermediate to form the α-azido amide (4.14) 
in reasonable yields (Scheme 79).  
 
Scheme 79. Modified Corey-Link reaction using two nucleophilic sources. 
This is the first known example of utilising the Corey-Link reaction with two 
competing nucleophiles and generating an α-azido amide using an α-
trichloromethyl carbinol. This at least confirmed our belief that we could trap the 
acid chloride intermediate formed during the reaction of an alkyl trichlomethyl 
carbinol. 
 
In line with previous examples of this type of chemistry we propose the reaction 
mechanism in Scheme 80 and believe the mechanism to proceed via a gem-
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dichloroepoxide intermediate (4.15) with the competing benzylamine nucleophile 
trapping the α-azido acid chloride intermediate (4.16). 
Scheme 80. Proposed mechanism of our modified Corey-Link reaction with two competing 
nucleophiles. 
To confirm the structure of our α-azido amide and our findings we also 
synthesised 4.14 stepwise (Scheme 81) from the α-azido acid Corey-Link adduct 
(4.13) by converting this acid into the acid chloride (4.16) and coupling with 
benzylamine. We have no doubt that the compound we synthesised is indeed the 
α-azido amide (4.14) with all characterisation data supporting this structure. 
Scheme 81. Stepwise synthesis of α-azido amide 4.14 to confirm its structure. 
 
4.3.3 Lactams via Hybrid Bargellini Reactions  
With the modified Corey-Link reaction confirming the trapping of the proposed 
dichloroepoxide intermediate with two nucleophiles, we could now attempt our 
hybrid Bargellini reactions on alkyl substrates. We decided to begin with our test 
substrate, hydrocinnamaldehyde. Our first attempts using 1,1,1-trichloro-4-
phenylbutan-2-ol (4.12) by modifying Lai’s procedure (using a homogeneous 
reaction mixture without the use of CH2Cl2 or a phase transfer catalyst as in our 
modified Corey-Link reaction) gave a mixture of products which could not be 
separated. By deferring back to Lai’s biphasic procedure using CH2Cl2 and a 
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phase transfer catalyst we successfully synthesised racemic β-hetero-δ-lactams 
using both ethanolamine and ethylenediamine as the binucleophile (Scheme 82). 
 
 
Scheme 82. Lactams via a hybrid Bargellini reaction. 
We were extremely pleased with the outcome of these reactions, not only because 
we had synthesised the desired lactams but also because we performed a hybrid-
Bargellini reaction on an alkyl substrate, something that was previously thought to 
be unachievable. We wrongly assumed the structure of the heterocycle of the 
carbinol with the ethanolamine binucleophile would be the morpholine-2-one 
(4.18), not the lactam (4.19), with the more nucleophilic nitrogen attacking the 
gem-dichloroepoxide first, followed by ring formation via attack of the oxygen 
nucleophile (vide infra). 
  
4.3.4 N-Alkylation of Racemic β-Hetero-δ-lactams 
It has been well documented that piperazin-2-ones are good peptidomimetics303 
and have attracted much attention because of their biological and synthetic 
applications, as have morpholinones.304 N-Alkylated heterocycles of this type 
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similarly give significant properties to the molecules, therefore we performed N-
alkylations to build a library of products which would hopefully prove to have 
biological activity.  
 
R (X) Yield (%) 
Ms 4.20 31 
C(O)Me 4.21 88 
C(O)Et 4.22 82 
C(O)iPr 4.23 9 
C(O)tBu 4.24 89 
Figure 21. N-alkylation of the piperazin-2-one 4.17. 
The N-acylation of the piperazin-2-one (4.17) proved very straightforward and 
gave high yields for a range of compounds (Figure 21). On the other hand, the 
alkylation of the morpholinone (4.18/4.19) was not achieved using any acyl 
chloride. This was a very surprising result and prompted us to re-evaluate our 
thought that the ethanolamine would form the lactam preferentially and not the 
lactam during the hybrid-Bargellini reaction.  
 
4.3.5 Morpholinone (Lactam vs Lactone) 
It was important for us to confirm the structure that the hybrid-Bargellini reaction 
of ethanolamine with our trichlorocarbinol would produce, either the 
morpholinone (4.18) or the lactam (4.19). We believe the reaction proceeds 
through a gem-dichloroepoxide intermediate (4.15), formed from the basic 
deprotonation and epoxide formation of the α-trichloromethyl carbinol (4.12), 
which undergoes nucleophilic attack from the binucleophile ethanolamine (4.26)  
in Scheme 83. We assumed that as nitrogen is more nucleophilic in character than 
oxygen, it would ring open the gem-dichloroepoxide intermediate via the blue 
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pathway, a (Scheme 82), preferentially over ring opening from the less 
nucleophilic oxygen via the red pathway, b (Scheme 82). 
Scheme 83. Possible pathways during our modified Bargellini reaction with ethanolamine. 
We found a number of reasons, compounded by the fact that the product would 
not N-acylate (Scheme 84), which strongly suggested the lactam and the red 
pathway, pathway b, occurs and not the morpholin-2-one pathway, pathway a 
(Scheme 82).  
 
Scheme 84. Failed N-alkylation attempts of 4.12 imply the formation of the lactam (4.19). 
Firstly, the infrared spectrum of the compound in question has an amide peak at 
1650 cm-1 which strongly suggests we had synthesised the lactam (4.19). Indeed, 
this infrared shift is comparable to that of piperidin-2-one reported by Torra305, 
with a carbonyl band at 1660 cm-1. If we had synthesised the morpholin-2-one 
(4.18) then the carbonyl IR band would be in the region of 1730-1750 cm-1, much 
107 
 
like that reported by Nikishin306 for δ-valerolactone with a carbonyl band at 1730 
cm-1. This together with the characteristic 1H & 13C NMR peaks of our 
ethanolamine derivative in chloroform-d: 
 δH: 7.00 (1H, br s, CONH), 4.32 (1H, dd, J 9.0, 4.0, 
CHOCH2), 3.75 (2H, t, J 5.0, OCH2CH2NH), δC: 61.9 
(CHOCH2); and in d6-DMSO; δH: 8.28 (1H, t, J 5.5, 
CONHCH2),  
compared with the characteristic 1H & 13C NMR peaks of the 3-
phenethylpiperazin-2-one (4.17) product in chloroform-d: 
 δH 6.55 (1H, br s, CONH), 3.46-3.36 (2H, m, 
CHCONHCHH), 3.13 (1H, dtd, J 13.0, 4.0, 0.5, 
CHNHCHH), 2.96 (1H, dddd, J 13.0, 9.5, 4.0, 2.0, 
CHNHCHH), 1.90 (1H, br s, CHNH), δC: 41.4  
 (CHNHCH2). 
highlights a number of interesting points; 
1) The stereocentre, highlighted in green, is a distinct dd coupling to only 2 other 
hydrogens. This suggests the lactam is formed, as there is no splitting by an NH 
group. If it was a morpholin-2-one then we would expect the stereocentre to be a 
ddd, as we have seen with all other compounds of this nature (despite the 
potentially labile nature of amine protons in deuterated solvents), or a multiplet as 
in our comparison with (4.17). 
2) The CH2's within the heterocycle closest to the stereocentre, highlighted in 
orange, have a distinct triplet. These chemical shifts are further upfield than 
expected if a morpholinone had been synthesised, as the COOCH2 would be a 
triplet at a higher chemical shift of around 4 ppm. 
O
C
NH
O
H H
H
HN
C
NH
O
H
H H
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3) The carbon spectra show a CH2 peak at 62 ppm, highlighted in blue, which 
would correspond to a CHOCH2 and not a CHNHCH2 carbon, like we have seen 
in our other heterocycles at 42 ppm.  
4) There's only one NH, shown in red, and it appears at 7 ppm. This most likely 
corresponds to a CONH and not a CHNHCH2, which would be at around 2 ppm, 
as we have seen in many of our other heterocycles. However, NH’s are known to 
move about, so this evidence alone is not conclusive. 
5) To add to points 3) and 4), when the spectra are recorded in DMSO-d6, an NH 
peak at 8.28 ppm and a triplet corresponding to a CONH with an adjacent CH2 is 
visible, which would correspond to the lactam. There is also only one stereocentre 
peak, at 58.3 ppm, in the carbon spectrum. 
With this information, the lack of acylation and the IR spectra, we believe there to 
be enough evidence to assign the compound as the morpholin-3-one. To 
strengthen our argument a number of manipulations were attempted on the 
product. If the structure was indeed the lactam (4.19), as we now thought, then 
reduction of the amide to its amine and acylation of the then free amine (to give 
compounds like 4.29) should be possible (Scheme 84). Unfortunately 
complications arose during these reactions, we produced a linear compound of 
unknown structure.  
 
Scheme 85. Using N-alkylations to prove the structure of our ethanolamine derivative. 
 
4.3.6 Racemisation Test 
To see whether or not racemisation could occur during these hybrid-Bargellini 
reactions we subjected the α-trichloromethyl carbinol to the original conditions 
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using deuterated water. We used ethylenediamine as our binucleophile and found 
no incorporation of deuterium during the reaction (Scheme 86). Therefore we are 
confident that no racemisation occurs during these reactions. 
 
Scheme 86. Racemisation test during our hybrid-Bargellini reactions. 
4.4 Enantiomerically Enriched Piperazin-2-ones 
Herein we describe the novel synthesis of enantiomerically enriched piperazin-2-
ones using transfer hydrogenation and a hybrid-Bargellini reaction. (S)-3-
phenylethylpiperazin-2-one ((S)-4.17) and (R)-3-phenethylpiperazin-2-one ((R)-
4.17) were synthesised (Scheme 86) from the corresponding trichloroketone 
(4.30), realised by refluxing the racemic α-trichloromethyl carbinol (4.12) with 
IBX in ethyl acetate, followed by asymmetric reduction. 
Scheme 87. Asymmetric synthesis of piperzinones using transfer hydrogenation and a hybrid-
Bargellini reaction. 
Catalytic asymmetric transfer hydrogenation307-312 of the ketone with the in situ 
generation of either (R,R)-TsDPENRu(p-cymene)Cl or (S,S)-TsDPENRu(p-
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cymene)Cl gives the corresponding enantiomerically enriched (R) and (S) α-
trichloromethyl carbinols, (R)-4.12 and (S)-4.12 respectively. We believe the 
reaction proceeds via the CCl3 of the carbinol acting as the directing group 
through a favoured electrostatic interaction with the catalyst (4.37) during the 
hydrogenation cycle (Scheme 88). 
2
3
 
Scheme 88. Catalytic cycle during the transfer hydrogenation reactions (top) with the proposed 
electrostatic interaction with trichloroketones (bottom). 
We propose the formation of the heterocycle, and the hybrid-Bargellini reactions, 
proceeds through a gem-dichloroepoxide intermediate with complete inversion of 
stereochemistry (Scheme 89) giving e.e’s greater than 95%. All reactions proceed 
in high yields in only 4 steps from the corresponding aldehyde. 
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Scheme 89. Proposed hybrid-Bargellini mechanism. 
The synthesis of multiple stereocentres within a heterocycle is also of great 
importance, both synthetically and medicinally.313-314 With our successful 
asymmetric synthesis of the α-substituted-β-hetero-δ-lactams we wished to utilise 
the chemistry to see if we could introduce 2 new stereocentres within the 
molecule using an enantiopure binucleophile, which would furnish an asymmetric 
α,γ,δ-substituted-β-hetero-δ-lactam.  
 
We first wanted to check that the reaction of the racemic α-trichloromethyl 
carbinol would proceed with a chiral binucleophile. With the availability of (1R, 
2R)-1,2-diphenylethane-1,2-diamine ((R,R)-DPEN) and (1S, 2S)-1,2-
diphenylethane-1,2-diamine ((S,S)-DPEN) we proceeded with our hybrid-
Bargellini reaction using racemic α-trichloromethyl carbinol (4.12). Indeed, the 
reaction of the enantiopure diamine under our conditions proceeded to give a 
mixture of the two possible diastereoisomers (Scheme 90) which were separable 
by column chromatography.  
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Scheme 90. Hybrid-Bargellini reaction using enantiopure diamine and racemic alkyl α-
trichloromethyl carbinol. 
This was extemely encouraging, and so we proceeded to perform the hybrid-
Bargellini reaction using a chiral diamine on an enantiopure α-trichloromethyl 
carbinol. The reaction of a stereochemically pure α-trichloromethyl carbinol ((S)-
4.12) with either (R,R)-DPEN or (S,S)-DPEN furnishes the asymmetric α,γ,δ-
substituted-β-hetero-δ-lactams 4.41 and 4.42 respectively (Scheme 91) in 
excellent yields. 
Scheme 91. Synthesis of a three stereocentered lactam using our hybrid-Bargellini reaction with 
enantio-enriched α-trichloromethyl carbinol and chiral binucleophile (diamine) source. 
 
4.5 Conclusions and Future Work 
We have shown that it is possible to synthesise stereochemically pure 
heterocycles containing up to 3 stereocentres using α-trichloromethyl carbinols 
and asymmetric transfer hydrogenation chemistry from simple starting materials. 
Developments of this type of chemistry will undoubtedly lay the foundations to 
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produce further non-racemic substituted heterocycles which will be important 
both synthetically and biologically.  
 
Future work should include an investigation into the scope of the reaction using a 
range of α-trichloromethyl carbinols and binucleophiles, which will undoubtedly 
enhance the applicability of this chemistry. We envisage the synthesis of a wide 
range of asymmetric heterocycles using this type of chemistry (Scheme 92). 
 
Scheme 92. Future work: expanding the scope of the reaction. 
Also, with the recent publication by Snowden of a convenient one-pot synthesis of 
trichloromethyl carbinols from primary alcohols with complete stereochemical 
fidelity (Scheme 93),315 the range of heterocycles available from our method, 
using simple starting materials, is potentially vast. 
 
Scheme 93. Future work: starting from primary alcohols. 
Also of interest is the kinetic resolution of the racemic carbinol using chiral, 
stereochemically pure nucleophiles. This could afford substituted heterocycles 
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successively eliminating the need for an oxidation and hydrogenation step 
(Scheme 94), a very exciting thought. 
1
2
3
 
Scheme 94. Potential for kinetic resolution of heterocycles. 
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Chapter 5 – Experimental 
 
5.1 General Experimental 
All the reagents used were purchased from the Sigma-Aldrich, Alfa-Aesar or 
Fluorochem Chemical Company and unless stated otherwise were used as 
received. 
1H- and 13C-NMR spectra were recorded on a Bruker Avance DPX-400 Fourier 
transform spectrometer using an internal clock with a QNP probe, X-Win NMR 
software package, and Icon NMR interface, unless stated otherwise. Chemical 
shifts are quoted in parts per million (ppm) downfield from tetramethylsilane.  
Solvents were used as an internal standard when assigning NMR spectra (δH: 
CDCl3 7.26 ppm, CD3OD 3.31 ppm, d6-DMSO 2.50 ppm, D2O 4.79 ppm; δC: 
CDCl3 77.1 ppm, CD3OD 49.0 ppm, d6-DMSO 39.5 ppm). Coupling constants 
(J) are quoted in Hertz (Hz), rounded to the nearest 0.5 Hz, and characterised 
with either Bruker biospin Topspin Version 2.1 or MestRe-C V 4.5.6.  
Abbreviations used in the descriptions of spectra are as follows; s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad, i = ipso, o = ortho, m = 
meta, p = para, ax. = axial and eq. = equatorial. 13C-NMR spectra were recorded 
with broadband proton decoupling and spectra were assigned on the basis of 
COSY, PENDANT and HMQC spectra. 
Infrared spectra were recorded on a Nicolet Avatar 320 FT-IR spectrophotometer 
using EZ OMNIC software package 1, and are quoted in wavenumber (cm-1). 
Optical rotations were recorded on an Optical Activity Ltd. AA-1000 millidegree 
auto-ranging polarimeter (using the sodium D line; 589 nm) and [α]Ds are given 
in units of 10-1 deg cm2 g-1. The samples were made using spectroscopic grade 
MeOH or chloroform.  
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Mass spectra were obtained via ESI on a Bruker Esquire 2000 with Hyphenation 
Star Version 3.0 Interface and Bruker Daltonics Esquire Version 5.2 software. 
Accurate mass spectra were obtained using a Bruker micro-TOF ESI attached to 
a time of flight (TOF) analyser. 
Melting points for solid crystalline products were determined on a Stuart 
Scientific SMP10 Digital Melting Point Apparatus, with 3 runs of each 
compound, and a range given in oC rounded to the nearest degree. CHN 
elemental analyses were carried out by Warwick Analytical Services. 
Thin Layer Chromatography (TLC) was performed using silica (0.25 mm) coated 
alumina plates. 
 
5.2 Chapter 2 Experimental 
5.2.1 Thialactam derivatives 
N-Benzyloxycarbonyl-2-bromoethylamine (2.70) 
 
Sodium bicarbonate (4.2 g, 50.0 mmol) was added portion wise to a stirred 
mixture of 2-bromoethylamine hydrobromide (10.0 g, 48.8 mmol) in H2O (100 
mL) and the mixture was cooled in an ice bath. Benzylchloroformate (9 mL, 63.9 
mmol) was added dropwise to the mixture followed by 1 M NaOH (50 mL) with 
vigorous stirring over a period of 2 h.  The precipitate formed was collected and 
dissolved in EtOAc (50 mL), dried over sodium sulfate, filtered, concentrated in 
vacuo and recrystallised from Petroleum ether 40-60 to give a white crystalline 
solid (12.5 g, 48.4 mmol, 99%); m.p.: 46-47 oC; υmax (cm-1): 3305 (NH), 1680 
(CO), 1537 (COO), 1263 (CH2) 746, 709 (Ph); δH (400 MHz, CDCl3) 7.32-7.38 
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(5H, m, Ph), 5.28-5.13 (1H, br, NH), 5.12 (2H, s, CH2Ph), 3.61 (2H, q, J 6.0, 
CH2NH) and 3.47 (2H, t, J 6.0, BrCH2); δC (100 MHz, CDCl3) 156.8 (CO), 136.2 
(i-Ph), 128.6 (Ph), 128.2 (Ph), 128.0 (Ph), 67.8 (CH2Ph), 42.8 (CH2NH) and 31.4 
(BrCH2); m/z 258.1 (M + H+) & 280.1 (M + Na+). This data is consistent with 
that previously reported.164 
 
N-Benzyloxycarbonyl-2-iodoethylamine (2.71) 
 
N-Benzyloxycarbonyl-2-bromoethylamine (2.3 g, 8.9 mmol) was refluxed for 1.5 
h in acetone (30 mL) with potassium iodide (1.5 g, 8.9). After cooling the 
solution was diluted with diethyl ether and quickly filtered to remove potassium 
bromide. The mother liquor was washed with H2O and concentrated in vacuo and 
used without further purification. 
 
2-Amino-3-(2-benzyloxycarbonylamino-ethylsulfanyl)-propionic acid (2.73) 
 
To a stirred solution L-cysteine hydrochloride (0.1 g, 0.7 mmol) in H2O (5 mL) 
was added 2.71 (0.2 g, 0.7 mmol) in ethanol (10 mL). The pH of the solution was 
adjusted to 10 by dropwise addition of 5 M NaOH and the mixture left stirring 
for 2 h. The solution was acidified to pH 4 using 1 M HCl and the precipitated 
product was filtered and dried in vacuo to give a white crystalline solid (0.2 g, 
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0.5 mmol, 82%); υmax (cm-1): 3335 (CONH), 3030 (NCH2), 1688 (C=O), 1594, 
1546 (Ph), 1269 (OH), 1143 (CO), 736 (Ph); δH (400 MHz, D2O/NaOH) 
Unsuitable for characterisation, peaks at 7.42, 5.11, 3.36, 3.34, 2.81, 2.77, 2.67; 
δC
 (100 MHz, D2O/NaOH) Unsuitable for characterisation. 
 
General Method A: Synthesis of Cbz-L-Cys-OtBu 
L-Cystine-OtBu (2.88) 
 
tert-Butyl acetate (100 mL) was added to a stirred solution of L-cystine (10.0 g, 
41.6 mmol) in 70% v/v perchloric acid (16.6 mL) at ambient temperature behind 
a blast shield. After 30 min, the solution became clear, and after 3 h a white solid 
appeared. Stirring was continued for another 18 h and the reaction mixture was 
cooled on ice for 15 minutes. H2O (100 mL) was added followed by EtOAc (100 
mL) until the entire solid was dissolved, and the pH was adjusted from 1 to 9 
using 10 M NaOH. The organic layer was separated and the aqueous layer was 
extracted further with EtOAc (2 x 70 mL). The organic layers were combined 
and dried over sodium sulfate, filtered and concentrated in vacuo to give a light 
yellow oil (14.6 g, 41.4 mmol, 99%); [ߙ]஽ଵହ (c = 1, MeOH) − 7.1; υmax (cm-1): 
2975 (COC(CH3)3), 1719 (OCOC), 1394, 1396 (C(CH3)3); δH (400 MHz, CDCl3) 
3.66 (2H, dd, J 8.0, 4.5, 2 × CHNH2), 3.12 (2H, dd, J 13.5, 4.5, 2 × CH2S-), 2.86 
(2H, dd, J 13.5, 8.0, 2 × CH2S-), 1.72 (4H, br s, 2 × NH2) and 1.47 (18H, s, 2 × 
C(CH3)3); δC (100 MHz, CDCl3) 172.9 (CO) 81.8 (OC(CH3)3), 54.3 (CHNH2), 
44.05 (CH2S) and 28.04 (C(CH3)3); m/z (C14H29N2O4S2 (M + H+) requires 
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353.1563) found 353.1563, (C14H28N2NaO4S2 (M + Na+) requires 353.1383) 
found 353.1382. This data is consistent with that previously reported.173 
 
Cbz-L-Cystine-OtBu (2.89) 
 
To 2.88 (14.7 g, 41.6 mmol) partitioned between sat. aq. NaHCO3 (125 mL) and 
chloroform (125 mL) at 0 oC was added benzylchloroformate (17.5 mL, 124.8 
mmol) and allowed to stir for 2 h at room temperature. After this time the 
aqueous layer was separated and discarded. Pyridine (4.1 mL) was added 
dropwise to the remaining chloroform layer at 0 oC causing effervescence. After 
complete addition of the pyridine with no more effervescence the solution was 
successively washed with 1 M H2SO4, distilled H2O and diluted aq. NaHCO3. 
After drying over sodium sulfate, and concentrating in vacuo the residue was 
purified by silica column chromatography (eluent; EtOAc to EtOAc:MeOH 
(9:1)) to give an off white crystalline solid (23.5 g, 37.8 mmol, 91%); m.p. 73-74 
ºC; [ߙ]஽ଵ଺ (c = 1, MeOH) -58.5; [ߙ]஽ଶସ (c = 1, MeOH) -66.8; υmax (cm-1): 3369 
(NH), 2977 (COC(CH3)3), 1707 (OCON, CO), 1516 (CH), 1153 (CO);  δH (400 
MHz, CDCl3) 7.38-7.27 (10H, m, 2 × Ph), 5.68 (2H, br d, J 7.5, 2 × NHCH) 5.10 
(4H, s, 2 × CH2OCO), 4.56-4.50 (2H, m, 2 × NHCH), 3.18-3.09 (4H, m, 2 × 
CH2S) and 1.46 (18H, s, 2 × C(CH3)3); δC (100 MHz, CDCl3) 169.3 
(CHCOOC(CH3)3), 155.7 (OCONHCH), 135.2 (i-Ph), 128.4 (Ph), 127.5 (Ph), 
126.9 (Ph), 82.9 (OC(CH3)3), 67.0 (CH2OCO), 54.2 (CONHCHCO), 41.5 
(CH2SS), 27.9 (C(CH3)3); m/z (C30H40N2NaO8S2 (M + Na+) requires 643.2118) 
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found 643.2134.  This compound is known but has previously only been reported 
with m.p and 1H NMR data (90 MHz), which is consistent with that reported 
here.172 
 
Fmoc-L-Cystine-OtBu (2.90) 
 
2.88 (7.0 g, 20 mmol) and fluorenylmethoxycarbonyl chloride (10.2 g, 40 mmol) 
were dissolved in THF (50 mL) under nitrogen. The reaction was cooled in an 
ice bath and NMM (4.5 mL, 40 mmol) was slowly added to the solution. The 
resulting mixture was stirred for 16 h. Ethyl acetate (200 mL) was added to the 
mixture, which was then washed with 5% aq. potassium hydrogen sulfate (4 x 50 
mL) and water (3 x 50 mL). The organic layer was separated, dried over sodium 
sulfate, and concentrating in vacuo yielding a crude yellow liquid which was 
purified by silica column chromatography (eluent; EtOAc to EtOAc:MeOH 
(9:1)) to give an off white solid (14.2 g, 18 mmol, 90%); m.p. 150-151 ºC; [ߙ]஽ଵ଺ 
(c = 1, MeOH) -30.2; υmax (cm-1): 3335 (NH), 2977 (COC(CH3)3), 1720 (OCON, 
CO), 1516 (CH), 1151 (CO);  δH (400 MHz, CDCl3) 7.76 (4H, d, J 7.5, 2 × 
CH(C)(C)CH), 7.62 (4H, d, J 7.5, 2 × CH(C)CH(C)CH), 7.41 (4H, t, J 7.0, 2 × 
CHCH(C)(C)CHCH), 7.33 (4H, t, J 7.5, 2 × CHCH(C)CH(C)CHCH), 5.71 (2H, 
d, J 7.0, 2 × NHCH), 4.57 (2H, dd, J 13.0, 5.5, 2 × CHNH), 4.41-4.33 (4H, m, 2 
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× OCH2), 4.23 (2H, t, J 7.0, 2 × OCH2CH), 3.28-3.19 (4H, m, 2 × CH2S) and 
1.51 (18H, s, 2 × CO2C(CH3)3); δC (100 MHz, CDCl3) 169.1 (CHCOOC(CH3)3), 
155.7 (OCONHCH), 143.7 ((C)CH(C)), 141.4 ((C)(C)), 127.4 (Ph), 127.0 (Ph), 
126.2 (Ph), 119.9 (CH(C)CH(C)CH), 82.9 (OC(CH3)3), 67.0 (CH2OCO), 54.2 
(CONHCHCO), 41.7 (CH2SS), 27.9 (C(CH3)3); m/z (C44H48N2NaO8S2 (M + Na+) 
requires 819.2746) found 819.2746. This data is consistent with that previously 
reported.168 
 
Cbz-L-Cys-OtBu (2.91) 
 
Reduction of L-Cystine, Method I – Triphenylphosphine, mercaptoethanol 
To a stirred solution of 2.89 (6.2 g, 10.0 mmol) in 100 mL of THF was added 
Ph3P (2.6 g, 10.0 mmol), 2-mercaptoethanol (1.24 mL, 10.0 mmol), and water 
(100 mL), and the reaction mixture was stirred at 50 °C under nitrogen for 16 h 
before being concentrated in vacuo. The residue was purified by silica column 
chromatography (eluent; EtOAc:Hexane (1:9) to EtOAc) to give a colourless oil 
(4.4 g, 7.1 mmol, 71%). 
Reduction of L-Cystine, Method II – PBu3 Method 
To a stirred solution of 2.89 (11.7 g, 18.8 mmol) in THF (100 mL) under 
nitrogen was added PBu3 (7 mL, 28.1 mmol). After 60 minutes H2O (10 mL) was 
added and the mixture stirred at room temperature until the reaction was 
complete (17 h). The THF was removed in vacuo and the residue diluted with 
EtOAc (100 mL). The resulting mixture was washed successively with 10% 
citric acid, H2O and brine. The organic extracts were combined and dried over 
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sodium sulfate, filtered and concentrated in vacuo. The residue was purified by 
silica column chromatography (eluent; EtOAc:Hexane (1:9) to EtOAc) to give a 
colourless oil (11.7 g, 18.8 mmol, > 99%); [ߙ]஽ଶସ (c = 1, MeOH) -23.1; υmax (cm-
1): 3342 (NH), 2978 (COC(CH3)3), 2573 (SH), 1712 (OCON, CO), 1499 (CH), 
1150 (CO); δH (400 MHz, CDCl3) 7.31-7.40 (5H, m, Ph), 5.96 (1H, d, J 7.5, N-
HCH), 5.15 (2H, s, CH2Ph), 4.59 (1H, dt, J 7.5, 4.0, CHNH), 2.97 (2H, dd, J 9.0, 
4.0, CHCH2SH), 1.51 (s, 9H, C(CH3)3) and 1.37-1.41 (1H, m, SH); δC (100 MHz, 
CDCl3) 168.9 (CHCOOC(CH3)3), 155.7 (OCONHCH), 136.2 (i-Ph), 128.5 (Ph), 
128.2 (Ph), 128.1 (Ph), 82.9 (OC(CH3)3), 67.0 (CH2OCO), 55.5 (CONHCHCO), 
28.0 (C(CH3)3) and 27.44 (CH2SH); m/z (C15H21NNaO4S (M + Na+) requires 
334.1083) found 334.1086; 278.1. This compound is known but has previously 
been reported without any characterisation.316 
 
Fmoc-L-Cys-OtBu (2.92) 
 
Fmoc-L-Cys-OtBu (2.92) was synthesised according to cystine reduction method 
I or method II using 2.90 (8.0 g, 10 mmol). In each case the residue was purified 
by silica column chromatography (eluent; EtOAc:Hexane (1:9) to EtOAc) to give 
a colourless oil (method I: 4.2 g, 5.3 mmol, 53%; method II: 0.7 g, 0.9 mmol, 
9%); [ߙ]஽ଶସ (c = 1, MeOH) -30.4; υmax (cm-1): 3342 (NH), 2978 (COC(CH3)3), 
2570 (SH), 1722 (OCON, CO), 1501 (CH), 1150 (CO); δH (400 MHz, CDCl3) 
7.76 (2H, d, J 7.5, CH(C)(C)CH), 7.62 (2H, d, J 7.5, CH(C)CH(C)CH), 7.41 
(2H, t, J 7.0, CHCH(C)(C)CHCH), 7.33 (2H, t, J 7.5, CHCH(C)CH(C)CHCH), 
5.71 (1H, d, J 7.0, NHCH), 4.57 (1H, dd, J 13.0, 5.5, CHNH), 4.41-4.33 (2H, m, 
OCH2), 4.23 (1H, t, J 7.0, OCH2CH), 3.08-2.89 (2H, m, 2 × CH2S), 1.51 (9H, s, 
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CO2C(CH3)3) and 1.38 (1H, t, J 9.0, SH); δC (100 MHz, CDCl3) 169.0 
(CHCOOC(CH3)3), 155.7 (OCONHCH), 143.8 ((C)CH(C)), 141.3 ((C)(C)), 
127.6 (Ph), 127.0 (Ph), 125.8 (Ph), 119.9 (CH(C)CH(C)CH), 82.9 (OC(CH3)3), 
67.0 (CH2OCO), 55.2 (CONHCHCO), 47.1 (CHCH2O), 27.9 (C(CH3)3) and 27.4 
(CH2SH); m/z (C22H25NNaO4S (M + Na+) requires 422.1396) found 422.1398. 
This data is consistent with that previously reported.316 
 
N-(tert-Butoxycarbonylamino)ethanol (2.94) 
 
To a solution of ethanolamine (3 mL, 50 mmol) in a 1:1 mixture of THF/H2O 
(100 mL), triethylamine (8.4 mL, 60 mmol) and Boc2O (13 g, 60 mmol) were 
added consecutively at 0 °C. After 30 min, the solution was stirred overnight at 
room temperature. The turbid solution was extracted with Et2O (2 × 100 mL), the 
aqueous layer was acidified to ~pH 4 by careful addition of half sat. citric acid at 
0 °C and extracted with CH2Cl2 (3 × 200 mL). The combined organic extracts 
were dried over sodium sulfate and concentrated in vacuo. The residue was 
purified by silica column chromatography (eluent; EtOAc:Hexane (1:1) to 
EtOAc) to give a colourless oil (4.4 g, 27  mmol, 54%); υmax (cm-1): 3331 (NH), 
3253 (OH), 2978 (COC(CH3)3), 1714 (OCON, CO), 1499 (CH), 1153 (CO); δH 
(400 MHz, CDCl3) 4.92 (1H, s, NH), 3.78-3.65 (2H, s, CH2OH), 3.39-3.23 (2H, 
m, NHCH2), 2.33 (1H, s, OH) and 1.45 ((9H, s, C(CH3)3); δC (100 MHz, CDCl3) 
156.6 (NHCOOC(CH3)3), 79.6 (NHCOOC(CH3)3), 62.3 (CH2OH), 43.3 
(NHCH2), 28.3 (C(CH3)3); m/z (C7H15NO3 (M + H+) requires 162.1124) found 
162.1126. This data is consistent with that previously reported.317 
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N-(tert-Butoxycarbonyl)-2-bromoethylamine (2.95) 
 
A solution of di-tert-butyl dicarbonate (20.5 g, 94 mmol) in MeOH (60 ml) was 
added over a period of 30 minutes to a stirred solution of 2-bromoethylamine 
hydrobromide (12.3 g, 60.0 mmol) and NEt3 (13.91 ml, 100 mmol) in MeOH (60 
mL). After stirring at room temperature for 18 h, the reaction mixture was 
concentrated in vacuo. H2O (100 mL) was added to the residue and extracted 
with dichloromethane (3 × 30 mL). The combined extracts were dried over 
sodium sulfate and concentrated in vacuo. The residue was purified by silica 
column chromatography (eluent; EtOAc:Hexane (1:9) to EtOAc) to give a 
colourless oil (12.1 g, 54.4 mmol, 90%); υmax (cm-1): 3331 (NH), 2978 
(COC(CH3)3), 1712 (OCON, CO), 1499 (CH), 1150 (CO); δH (400 MHz, CDCl3) 
5.34-5.14 (1H, br s, NH), 3.49-3.34 (2H, m, CH2NH), 3.34-3.23 (2H, m, BrCH2) 
and 1.33 (9H, s, C(CH3)3); δC (100 MHz, CDCl3) 155.6 (NHCOOC(CH3)3), 79.5 
(NHCOOC(CH3)3), 42.3 (CH2NHCO), 32.3 (BrCH2CH2), 28.3 (C(CH3)3); m/z 
(C7H1479BrNNaO2 (M + Na+) requires 246.0100) found 246.0102. This data is 
consistent with that previously reported.317 
 
General Method B: Thiol 2.91 coupling with suitable alkyl halide 
5-[(tert-Butyloxycarbonyl)amino]-ethane-2-Benzyloxycarbonylamino-3-
mercapto-propionic acid tert-butyl ester (2.96) 
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2.91 (3.8 g, 12.3 mmol) and 2.95 (2.8 g, 12.3 mmol) were combined and stirred 
in EtOAc (55 mL) under nitrogen. A solution of tetra-N-butylammonium 
bromide (15.8 g, 49.1 mmol) in NaHCO3 (0.5 M, 55 mL) was added after stirring 
for 10 minutes, keeping the pH to 8.5. The mixture was stirred under nitrogen at 
room temperature for 16 h. The organic layer was separated, washed with H2O (3 
× 30 mL), dried over sodium sulfate and concentrated in vacuo. The residue was 
purified by silica column chromatography (eluent; EtOAc:Hexane (1:9) to 
EtOAc) to give a colourless oil (3.8 g, 8.4 mmol, 68%); [ߙ]஽ଶ଺ (c = 1, MeOH) -
22.9; υmax (cm-1): 3331 (NH), 2977, 2931 (COC(CH3)3), 1697 (OCON, CO), 
1508 (CH), 1392, 1366, 1343 (C(CH3)3), 1152 (CO); δH (400 MHz, CDCl3) 7.40-
7.27 (5H, m, Ph), 5.77 (1H, d, J 6.0, CH2OCONH), 5.13 (2H, s, CH2Ph), 5.01-
5.11 (1H, br s, CH2NH) 4.48 (1H, dt, J 12.5, 5.5, CHNH), 3.38-3.16 (2H, m, 
CH2NH), 3.01 (1H, dd, J 14.0, 4.5, CHCHHS), 2.95 (1H, dd, J 13.5, 5.5, 
CHCHHS) 2.66 (2H, t, J 5.5, SCH2CH2NH), 1.49 (s, 9H, C(CH3)3) and 1.45 (s, 
9H, C(CH3)3); δC (100 MHz, CDCl3) 169.5 (CHCOOtBu), 155.8 (NHCO) 136.3 
(i-Ph), 128.5 (Ph), 128.18 (p-Ph), 128.15 (Ph), 82.8 (CHCOOC(CH3)3), 79.3 
(NHCOOC(CH3)3, 66.9 (CH2OCO), 54.4 (CONHCHCO), 39.6 (CH2NHCO), 
34.5 (CHCH2S), 33.1 (SCH2CH2NH) 28.4 and 27.9 (2 × CH3); m/z 
(C22H34N2NaO6S (M + Na+) requires 477.2030) found 477.2037. This compound 
has not previously been reported.  
 
 General Method C: Deprotection of Boc and tBu groups and ring closure 
(R)-6-(Carboxybenzylamino)-[1,4]-thiazepan-5-one (2.97) 
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To a solution of 2.97 (1.6 g, 3.6 mmol) in anisole (9.8 mL, 90.0 mmol) was 
added trifluoroacetic acid (14.7 mL, 197.9 mmol) in three portions and allowed 
to stand for 2 h and concentrated in vacuo. Diethyl ether (3 × 25 mL) was added 
and the solvent removed by decantation to give a viscous white residue. DMF 
(15 mL) was added and the mixture was stirred for 1 h at 0 ºC. Diphenyl 
phosphorazidate (1.2 mL, 5.4 mmol) was added followed by N-
methylmorpholine (1.6 mL, 14.5 mmol) and stirred overnight. To this solution 
was added EtOAc (25 mL) and H2O (25 mL).  The organic layer was collected, 
washed with brine and aqueous sodium bicarbonate (25 mL), dried over sodium 
sulfate, filtered and concentrated in vacuo. The residue was purified by silica 
column chromatography (eluent; EtOAc:Hexane (1:1) to EtOAc) to give a 
viscous liquid (0.7 g, 2.4 mmol, 66%); [ߙ]஽ଶ଺ (c = 1, MeOH) -15.8; υmax (cm-1): 
3220 (CONH), 3093, 2948 (CH2), 1716 (OCON), 1660 (CONH, lactam ring) 
1522 (CH2), 1241, 1225 (CO), 689 (SCH2); δH (400 MHz, CDCl3) 7.35-7.29 (5H, 
m, Ph), 7.17-7.00 (1H, br s, CHCONHCH2), 6.31 (1H, d, J 5.0, NHCH), 5.11 
(1H, d, J 12.5, CHHOCO), 5.08 (1H, d, J 12.5, CHHOCO), 4.75 (1H, ddd, J 9.0, 
6.0, 2.5, CHCONH) 3.68-3.55 (2H, m, NHCH2CH2S), 2.85-2.70 (2H, m, 
CHCH2S) and 2.68-49 (2H, m, NHCH2CH2S); δC (100 MHz, CDCl3) 174.7 
(CHCONHCH2), 155.3 (OCONH), 136.3 (i-Ph), 128.6 (Ph), 128.2 (Ph), 128.1 
(p-Ph), 66.9 (CH2OCO), 57.1 (CHCONH), 45.6 (NHCH2), 31.4 (CHCH2S) and 
30.5 (NHCH2CH2S); m/z (C13H16N2NaO3S (M + Na+) requires 303.0774) found 
303.0772. This compound is known but has previously been reported without 
any characterisation.318 
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General Method D: Cbz deprotection 
(R)-6-(Ammoniumbromide)-[1,4]-thiazepan-5-one (2.103) 
 
2.97 (0.7 g, 2.4 mmol) was dissolved in the minimum amount of acetic acid (~1 
mL). Hydrogen bromide (40% w/v in acetic acid, 4 mL) was added to this 
mixture and allowed to stand for 2 h. The solution was washed with diethyl ether 
and decanted to leave a light yellow precipitate which required no further 
purification (0.52 g, 2.3 mmol, 95%); m.p.: > 250 oC; υmax (cm-1): 3194 (CONH), 
3003, 2915, 2688, 1967 (CH2 & Br-NH3+), 1652 (CONH lactam), 1596, 1554, 
1471 (NH3+), 738 (CH2S); δH (400 MHz, D2O) 4.66 (1H, dd, J 10.0, 2.5, NHCH), 
3.71 (1H, ddd, J 16.0, 4.5, 3.0, NHCHH), 3.60 (1H, ddd, J 16.0, 9.0, 3.0, 
NHCHH), 3.03 (1H, dd, J 14.5, 10.0, CHCHHS) 2.82 (1H, ddd, J 14.5, 2.0, 0.5, 
CHCHHS) and 2.79-2.68 (2H, m, SCH2CH2NH); δC (100 MHz, D2O) 55.6 
(NH3+CHCO), 44.3 (CONHCH2), 29.4 (CHCH2SCH2) and 27.1 
(NH3+CHCH2SCH2); m/z (C5H11N2OS [(M – Br)+] requires 147.0587) found 
147.0590, (C5H8NOS [(M – NH3Br)+] requires 130.0321) found 130.0324. This 
compound has not previously been reported. 
 
General Method E: Acylation reaction of lactam salt with acid chloride 
(R)-6-(2',2'-Dimethylpropionylamino)-[1,4]-thiazepan-5-one (2.104) 
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To 2.103 (100 mg, 0.44 mmol) and sodium carbonate (140 mg, 1.32 mmol) in a 
round bottomed flask was added 5 drops of H2O. Trimethylacetylchloride (50 
μL, 0.44 mmol) in dichloromethane (5 mL) was added to the solution and stirred 
at room temperature for 2 h. The organic layer was separated and the aqueous 
layer wash washed with copious amounts of dichloromethane. The organics were 
combined, dried over sodium sulfate and concentrated in vacuo. The residue was 
purified by silica column chromatography (eluent; EtOAc:Hexane (1:1) to 
EtOAc (distilled solvents)) to give a white crystalline solid; (51 mg, 0.22 mmol, 
50%); m.p.: 156-158 oC; [ߙ]஽ଶ଴ (c = 0.5, CHCl3) -62.4; υmax (cm-1): 3389, 3282 
(CONH), 2969 (CH2 & CH3), 1740, 1670, 1634 (CONH solid state & CONH 
lactam), 1493, 1465 (CH2 & CH3); δH (400 MHz, CDCl3) 7.25-7.11 (2H, m, 2 × 
CONH), 4.85 (1H, ddd, J 8.5, 5.5, 2.5, CONHCH), 3.72-3.64 (2H, m, 
CONHCH2), 2.78-2.69 (2H, m, CHCH2S), 2.67 (1H, dd, J 10.0, 4.0, 
SCHHCH2NH), 2.60 (1H, dt, J 14.5, 3.5, SCHHCH2NH) and 1.27 (9H, s, 
C(CH3)3); δC (100 MHz, CDCl3) 177.9 (CHCONH), 175.1 (CONHCH), 55.6 
(CHCONH), 45.6 (CONHCH2), 38.7 (C(CH3)3) 30.9 (CHCH2SCH2), 30.6 
(CHCH2SCH2) and 27.4 (C(CH3)3); m/z (C10H18N2NaO2S (M + Na+) requires 
253.0981) found 253.0982. This compound has not previously been reported. 
 
General Method F: Acid chloride synthesis from its carboxylic acid 
1-Adamantanecarbonyl chloride (2.105 Synthon) 
 
To a solution of 1-adamantanecarboxylic acid (1.0 g, 5.5 mmol) in 
dichloromethane (5.5 mL) was added oxalyl chloride (0.48 mL, 5.5 mmol) at 0 
oC and a small drop of DMF. The solution was left stirring for 90 minutes, or 
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until completion following TLC, and concentrated in vacuo to give a white solid 
which was used immediately without further purification; (1.0 g, 5 mmol, 94%); 
m.p.: 51-52 oC; υmax (cm-1): 2905, 2852 (CH & CH2), 1787 (COCl), 1689 (CO), 
1452 (CH); δH (400 MHz, CDCl3) 2.14-2.02 (3H, m, 3 × CHCH2), 2.02-1.88 
(6H, m, 3 × CHCH2CH) and 1.80-1.65 (6H, m, 3 × CCH2); δC (100 MHz, 
CDCl3) 173.5 (COCl), 38.6 (3 × CH2 adamantane), 38.2 (CCO), 36.1 (3 × CH2 
adamantane), and 27.8 (3 × CH adamantane); m/z 221.1 (M + Na). This data is 
consistent with that previously reported.319 
  
(R)-6-(1'-Adamantanecarbonylamino)-[1,4]-thiazepan-5-one (2.105) 
 
Acylation was carried out according to General Method E using 2.103 (50 mg, 
0.22 mmol) and adamantane-1-carbonyl chloride (44 mg, 0.22 mmol). The 
residue was purified by silica column chromatography (eluent; EtOAc:Hexane 
(1:1) to EtOAc (distilled solvents)) to give a white crystalline solid; (62 mg, 20.1 
mmol, 92%); m.p.: 237-240 oC; [ߙ]஽ଶଵ (c = 1, CHCl3) -15.45; υmax (cm-1) 3245 
(CONH), 2905, 2848 (CH2 & CH), 1682, 1660, 1630 (CONH solid state & 
CONH lactam), 1497, 1434 (CH2); δH (400 MHz, CDCl3) 7.16 (1H, d, J 5.0, 
NHCH), 6.20 (1H, t, J 6.0, NHCH2), 4.88 (1H, ddd, J 9.5, 5.0, 2.0, NHCHCH2), 
3.77-3.76 (2H, m, NHCH2CH2) 2.77 (1H, d, J 14.5, SCHHCH2) 2.73-2.65 (2H, 
m, CHCH2S), 2.61 (1H, dd, J 14.5, 5.5, SCHHCH2), 2.04 (3H, m, 3 × CHCH2 
adamantane), 1.90 (6H, d, J 2.5, 3 × CCH2 adamantane) and 1.78-1.71 (6H, m, 3 
× CHCH2CH adamantane); δC (100 MHz, CDCl3) 177.2 (CHCONH), 175.0 
(CONHCH), 55.3 (CONHCH), 45.5 (CONHCH2), 40.5 (CCO), 39.9 (3 × CH2 
adamantane), 36.3 (3 × CH2 adamantane), 31.0 (CHCH2SCH2), 30.5 
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(CHCH2SCH2) and 27.9 (3 × CH adamantane); m/z (C16H24N2NaO2S (M + Na+) 
requires 331.1451) found 331.1444. This compound has not previously been 
reported. 
 
(R)-6-(2’,2’-Dimethyldodecanoylamino)-[1,4]-thiazepan-5-one (2.106) 
 
Acylation was carried out according to General Method E using 2.103 (50 mg, 
0.2 mmol) and 2.138 (54 mg, 0.22 mmol). The residue was purified by silica 
column chromatography with distilled solvents (eluent; Petroleum Ether 40-
60:EtOAc (1:1) to EtOAc) to give a clear viscous liquid (57 mg,  0.16 mmol, 
72%); [ߙ]஽ଶଽ (c = 0.1, MeOH) -5.0; υmax (cm-1) 3399, 3274 (CONH), 2921, 2852 
(CH2 & CH3), 1638 (CONH lactam), 1467 (NH), 1409 (CH3),  1354, 1321 
(C(CH3)2), 721 (CH2); δH (400 MHz, CDCl3) 7.16 (1H, d, J 5.5, CONHCH), 
6.73-6.58 (1H, m, CONHCH2), 4.87 (1H, ddd, J 9.0, 5.5, 1.5, CONHCH), 3.77-
3.60 (2H, m, NHCH2), 2.77 (1H, d, J 14.0 NHCHCHHS), 2.72-2.64 (2H, m, 
CHCHHS & SCHHCH2), 2.60 (1H, dd, J 14.5, 4.5, SCHHCH2), 1.54-1.43 (2H, 
m, CH2C(CH3)2), 1.25-1.22 (16H, m, CH3(CH2)8), 1.16 (3H, s,  C(CH3)2), 1.15 
(3H, s, C(CH3)2) and 0.86 (3H, t, J 7.0, CH3CH2); δC (100 MHz, CDCl3) 177.2 
(CO), 174.9 (CO), 55.6 (CONHCH), 45.7 (NHCH2), 42.1 (C(CH3)2), 41.3 
(CH2C(CH3)2), 31.8 (CH3CH2CH2), 31.0, 30.6 (NHCHCH2S & SCH2CH2), 30.1, 
29.6, 29.53, 29.48, 29.3 (CH3CH2CH2CH2CH2CH2CH2CH2), 25.23 (C(CH3)2), 
25.21 (C(CH3)2), 24.8 (CH2CH2C(CH3)2), 22.6 (CH3CH2) and 14.1 (CH3CH2); 
m/z (C19H36N2NaO2S (M + Na+) requires 379.2390) found 379.2390. This 
compound has not previously been reported. 
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(2S)-1-Bromo-2-N-tert-butoxycarbonylamino-propane ((S)-2.107) 
 
Bromination was carried out according to General Method G using N-(tert-
butoxycarbonylamino)-L-alaninol (1.8 g, 10.0 mmol). The residue was purified 
by silica column chromatography (eluent; EtOAc:Hexane (1:1) to EtOAc) to give 
a clear viscous liquid (1.2 g,  5.0 mmol, 50%); [ߙ]஽ଵଽ (c = 1, MeOH) -24.2; υmax 
(cm-1): 3317 (NH), 2975, 2933 (CH3 &CH2), 1685 (CO), 1499 (CH2) 1159 (CO); 
δH (400 MHz, CDCl3) 4.79-4.61 (1H, br s, NH), 3.95-3.79 (1H, m, CHCH3), 
3.53-3.33 (2H, m, BrCH2), 1.38 (s, 9H, C(CH3)3) and 1.17 (3H, d, J 6.5, 
CHCH3); δC (100 MHz, CDCl3) 154.8 (CO), 46.1 (CHCH3), 39.5 (BrCH2), 28.2 
(C(CH3)3) and 19.1 (CH3CH); m/z (C8H16BrNNaO2 (M + Na+) requires 260.0257 
and 262.0236) found 260.0261 and 262.0240. This compound is known but has 
previously been reported without any characterisation.321 
 
2-Benzyloxycarbonylamino-3-(2-tert-butoxycarbonylamino-propylsulfanyl)-
propionic acid tert-butyl ester ((2R,2S)-2.108) 
 
Coupling was carried out according to General Method B using 2.91 (1.2 g, 4.0 
mmol) and (S)-2.107 (1.0 g, 4.0 mmol). The crude product was purified by silica 
column chromatography (eluent; EtOAc:Hexane (1.5:8.5) to EtOAc) to give a 
colourless viscous liquid (0.6 g, 1.3 mmol, 33%); [ߙ]஽ଶ଺ (c = 0.5, MeOH) -18.6; 
υmax (cm-1) 3332 (CONH), 2975 & 2931 (CH Ph), 1702 (CONH), 1499 (NH), 
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1454 (CH2), 1392 (CH3), 1344 (C(CH3)3), 1240, 1152, 1044 (CO), 844 (CH2), 
775, 737 (para-Ph); δH (400 MHz, CDCl3) 7.37-7.27 (5H, m, Ph), 5.79-5.65 (1H, 
br s, PhCH2OCONHCH), 5.10 (2H, s, CH2OCO), 4.77-4.65 (1H, br s, NHBoc), 
4.49-4.40 (1H, m, CHCOOC(CH3)3), 3.89-3.68 (1H, m, CHCH3), 2.98 (2H, d, J 
5.0, CH(COOC(CH3)3)CH2S), 2.62 (2H, d, J 5.0, SCH2CHCH3), 1.45 (9H, s, 
C(CH3)3), 1.41 (9H, s, C(CH3)3) and 1.13 (3H, d, J 6.5, CH3CH); δC (100 MHz, 
CDCl3) 169.6 (CHCOOC(CH3)3), 155.8 (OCONH), 155.2 (OCONH), 136.4 (i-
Ph), 128.4 (Ph), 128.1 (Ph), 126.9 (p-Ph), 82.7 (CHCOOC(CH3)3), 79.3 
(NHCOOC(CH3)3, 66.9 (PhCH2O), 54.4 (CHCOOC(CH3)3), 46.1 (CHCH3), 40.0 
(SCH2CHCH3), 35.8 (OCOCHCH2S),  28.3 (C(CH3)3), 27.9 (C(CH3)3) and 19.9 
(CH3CH); ESI m/z (C23H36N2NaO6S (M + Na+) requires 491.2186) found 
491.2187, (C18H29N2O4S (M – Boc + H+) requires 369.1843) found 369.1843, 
(C14H21N2O4S (M – Boc – tBu + H+) requires 313.1217) found 313.1221. This 
compound has not previously been reported. 
 
(3S,6R)-6-(Carboxybenzylamino)-3-methyl-[1,4]-thiazepan-5-one  
((3S,6R)-2.109) 
 
Cyclisation was carried out according to General Method C using (2R,2S)-
2.108 (0.6 g, 1.2 mmol). The residue was purified by silica column 
chromatography (eluent; Petroleum Ether 40-60:EtOAc (9:1) to EtOAc) to give a 
white crystalline solid (0.2 g,  0.82 mmol, 64%); m.p.: 137-138 oC; [ߙ]஽ଶ଺ (c = 
0.5, MeOH) +22.8; υmax (cm-1) 3284 (CONH), 2936 (CH, CH2), 1702, 1655 
(CONH), 1491 (CH3), 1452 (CH2), 1350 (COCH2), 1214 (CO), 728, 696 (p-Ph); 
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δH (400 MHz, CDCl3) 7.37-7.26 (5H, m, Ph), 6.94 (1H, d, J 6.0, CONHCHCH3), 
6.32 (1H, d, J 5.5, CONHCHCONH), 5.09 (2H, s, PhCH2OCO), 4.65-4.53 (1H, 
m, CHCONH), 3.90-3.75 (1H, m, CHCH3), 2.94 (1H, d, J 14.0, pseudo-eq. 
CHCHHSCH2CHCH3), 2.76 (1H, d, J 14.5, pseudo-eq. CHCH2SCHHCHCH3), 
2.64-2.55 (2H, m, pseudo-ax. CHCHHSCHHCH) and 1.37 (3H, d, J 6.5, 
CHCH3); δC (100 MHz, CDCl3) 173.8 (CHCONHCH), 155.4 (OCONH), 136.2 
(i-Ph), 128.5 (Ph), 128.1 (Ph), 126.7 (p-Ph), 67.1 (PhCH2O), 57.3 
(CONHCHCONH), 49.4 (CHCH3), 36.8 (SCH2CHCH3), 30.5 
(CHCH2SCH2CHCH3) and 19.9 (CH3); m/z (C14H18N2NaO3S (M + Na+) requires 
317.0930) found 317.0938; This compound has not previously been reported. 
 
(3S,6R)-6-(ammonium bromide)-3-methyl-[1,4]-thiazepan-5-one ((3S,6R)-2.110) 
 
Deprotection was carried out according to General Method D using (3S,6R)-
2.109 (0.2 g, 0.7 mmol) to produce a viscous black liquid (0.2 g, 0.6 mmol, 
92%); δH (400 MHz, MeOD) 4.12 (1H, dd, J 9.0, 4.5 CHNH3+Br-), 3.58-3.50 
(1H, m, CHCH3), 2.74 (1H, dd, J 15.0, 3.0, pseudo-eq. SCHeqHCHCH3), 2.61-
3.53 (2H, m, CH2CHNH3+Br-) 2.44 (1H, dd, J 15.0, 5.5, pseudo-ax. 
SCHHaxCHCH3) and 1.14 (3H, d, J 7.0, CHCH3). δC (100 MHz, MeOD) 57.9 
(CHNH3+Br-), 49.3 (CHCH3), 37.2 (SCH2CHCH3), 29.5 (CH2CHNH3+Br-) and 
18.9 (CH3). m/z (C6H13N2OS+ (M – Br-) requires 161.0743) found 161.0746. This 
compound has not previously been reported. 
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Counter Ion Exchange (CIE) 
(3S,6R)-6-(ammonium chloride)-3-methyl-[1,4]-thiazepan-5-one  
((3S,6R)-2.110CIE) 
 
Compound (3S,6R)-2.110 was stirred in 2 M methanolic HCl  overnight. The 
resulting mixture was concentrated in vacuo to give the desired product as a 
white crystalline solid in quantitative yield; m.p. > 250 oC. Data was consistent 
with the above and the counter ion verified by mass spectrometry; m/z 
(C6H13ClN2NaOS (M + Na+) requires 219.0335) found 219.0334, (C6H13N2OS+ 
(M – Cl-) requires 161.0743) found 161.0745. This compound has not previously 
been reported. 
 
(3S,6R)-6-(1'-dimethylpropionylamino)-3-benzyl-[1,4]-thiazepan-5-one 
((3S,6R)-2.111) 
 
Acylation was carried out according to General Method E using (3S,6R)-
2.110CIE (82 mg, 0.4 mmol) and trimethylacetyl chloride (5 μL, 0.4 mmol). The 
residue was purified by silica column chromatography (eluent; Petroleum Ether 
40-60:EtOAc (1:1) to EtOAc) to give a white crystalline solid (52 mg, 0.2 mmol, 
51%); m.p.: 174-175 oC; [ߙ]஽ଶଽ (c = 0.05, MeOH) +36.2; υmax (cm-1) 3386 (NH), 
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3283 (CONH), 2968, 2930, 2871 (CH, CH2, CH3) 1632 (CONH), 1363 
(C(CH3)3), 1304, 1287 (CO); δH (400 MHz, CDCl3) 7.19 (1H, d, J 4.0, 
(CH3)3CCONHCH), 6.28 (1H, d, J 7.0, CONHCHCH3), 4.75 (1H, ddd, J 8.0, 
5.5, 4.0, NHCHCONH), 3.85-3.74 (1H, m, CHCH3), 2.94 (1H, dd, J 15.0, 2.5, 
pseudo-eq. CHCHHSCH2CHCH3), 2.92 (1H, ddd, J 14.0, 2.0, 1.0 pseudo-eq. 
CHCH2SCHHCHCH3), 2.66 (1H, ddd, J 15.0, 6.0, 1.0, pseudo-ax. 
CHCHHSCH2CHCH3), 2.57 (1H, dd, J 14.0, 10.0, pseudo-ax. 
CHCH2SCHHCHCH3), 1.50 (3H, d, J 7.0, CHCH3) and 1.22 (9H, s, C(CH3)3); 
δC (100 MHz, CDCl3) 173.9 ((CH3)3CCO), 170.5 (CONHCH), 56.1 
(CONHCHCONH), 49.5 (CHCH3), 38.8 (C(CH3)3) 36.7 (SCH2CHCH3), 30.8 
(CHCH2SCH2CHCH3), 27.5 (C(CH3)3) and 19.2 (CHCH3); m/z (C11H20N2NaO2S 
(M + Na+) requires 267.1138) found 267.1132; This compound has not 
previously been reported. 
 
(2R)-1-Bromo-2-N-tert-butoxycarbonylamino-propane ((R)-2.107) 
 
Bromination was carried out according to General Method G using N-tert-
butoxycarbonylamino-D-alaninol (0.5 g, 2.8 mmol). The residue was purified by 
silica column chromatography (eluent; EtOAc:Hexane (1:1) to EtOAc) to give an 
off white crystalline product (0.4 g, 1.7 mmol, 60%); m.p.: 86-88 oC; [ߙ]஽ଵଽ (c = 
1, MeOH) +22.8; υmax (cm-1): 3315 (NH), 2975, 2934 (CH3 & CH2), 1690 (CO), 
1159 (CO); δH (400 MHz, CDCl3) 4.87 (1H, d, J 8.0, NH), 3.91-3.72 (1H, m, 
CHCH3), 3.41-3.33 (2H, m, BrCH2), 1.33 (s, 9H, C(CH3)3) and 1.13 (3H, d, J 
6.5, CHCH3); δC (100 MHz, CDCl3) 154.6 (CO), 79.9 (C(CH3)3), 45.4 (CHCH3), 
39.4 (BrCH2), 28.2 (C(CH3)3) and 19.1 (CH3CH); HR ESI m/z (C8H16BrNNaO2 
(M + Na+) requires 260.0257 and 262.0236) found 260.0258 and 262.0238. This 
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compound is known but has previously only been reported with 1H NMR 
spectroscopic data, which is consistent with that reported here.322 
 
2-Benzyloxycarbonylamino-3-(2-tert-butoxycarbonylamino-propylsulfanyl)-
propionic acid tert-butyl ester ((2R,2R)-2.108) 
 
Coupling was carried out according to General Method B using 2.91 (0.53 g, 
1.7 mmol) and (R)-2.107 (0.4 g, 1.7 mmol). The crude product was purified by 
silica column chromatography (eluent; EtOAc:Hexane (1:9) to EtOAc) to give a 
viscous liquid (0.4 g, 0.9 mmol, 49%); [ߙ]஽ଶସ (c = 1, MeOH) -21.9; υmax (cm-1) 
3343 (CONH), 2976 & 2932 (CH Ph), 1697 (CONH), 1499 (NH), 1454 (CH2), 
1392 (CH3), 1344 (C(CH3)3), 1244, 1152 (CO), 843 (CH2), 774, 731 (p-Ph); δH 
(400 MHz, CDCl3) 7.36-7.24 (5H, m, Ph), 5.73 (1H, d, J 6.5, CH2OCONHCH), 
5.09 (2H, s, CH2OCO), 4.81-4.61 (1H, br s, NHCOOC(CH3)3), 4.45 (1H, dd, J 
13.0, 5.5, CHCOOC(CH3)3), 3.86-3.66 (1H, m, CHCH3), 3.00 (1H, dd, J 13.5, 
4.5, CHCHHSCH2CHCH3), 2.93 (1H, dd, J 13.5, 5.5, CHCHHSCH2CHCH3), 
2.68 (1H, dd, J 13.0, 5.5, SCHHCHCH3), 2.54 (1H, dd, J 13.0, 6.0, 
SCHHCHCH3), 1.45 (9H, s, C(CH3)3), 1.40 (9H, s, C(CH3)3) and 1.12 (3H, d, J 
6.5, CH3CH); δC (100 MHz, CDCl3) 169.5 (CHCOOC(CH3)3), 155.6 (OCONH), 
155.0 (OCONH), 136.2 (i-Ph), 128.33 (Ph), 128.32 (Ph), 127.9 (p-Ph), 82.5 
(C(CH3)3), 66.8 (PhCH2O), 54.3 (CHCO2tBu), 45.9 (CHCH3), 39.6 
(SCH2CHCH3), 35.4 (OCOCHCH2S),  28.3 (C(CH3)3), 27.8 (C(CH3)3) and 19.8 
(CH3CH); m/z (C23H36N2NaO6S (M + Na+) requires 491.2186) found 491.2176. 
This compound has not previously been reported. 
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(3R,6R)-6-(Carboxybenzylamino)-3-methyl-[1,4]-thiazepan-5-one  
((3R,6R)-2.109) 
 
Cyclisation was carried out according to General Method C using (2R,2’R)-
2.108 (0.4 g, 0.85 mmol). The residue was purified by silica column 
chromatography (eluent; Hexane:EtOAc (8:2) to EtOAc) to give a white 
crystalline solid (0.12 g,  0.42 mmol, 49 %); m.p.: 127-128 oC; [ߙ]஽ଶଽ (c = 0.5, 
MeOH) -45.5; υmax (cm-1) 3399, 3307 (CONH), 3060, 2965, 2901 (CH, CH2), 
1726, 1699 (CONH), 1655 (CO), 1489 (CH3), 1435 (CH2), 1344 (COCH2), 1233, 
1208 (CO), 754, 729, 695 (p-Ph); δH (400 MHz, CDCl3) 7.41-7.28 (5H, m, Ph), 
6.61 (1H, d, J 5.0, NHCHCH3), 6.30 (1H, d, J 5.5, PhCH2OCONH), 5.12 (1H, d, 
J 12.5, PhCHHOCO), 5.09 (1H, d, J 12.5, PhCHHOCO), 4.78-4.70 (1H, m, 
CHCONH), 3.94-3.85 (1H, m, CHCH3), 2.82 (1H, d, J 14.0, 
CHCHHSCH2CHCH3), 2.73 (1H, dd, J 14.0, 9.5, CHCHHSCH2CHCH3), 2.56 
(1H, dd, J 14.5, 9.0, CHCH2SCHHCHCH3), 2.46 (1H, dd, J 14.5, 
CHCH2SCHHCHCH3), and 1.30 (3H, d, J 6.5, CHCH3); δC (100 MHz, CDCl3) 
173.2 (CHCONHCH), 155.1 (OCONH), 136.2 (i-Ph), 128.4 (Ph), 128.1 (Ph), 
128.0 (Ph), 66.8 (PhCH2O), 57.0 (CONHCHCONH), 53.0 (CHCH3), 36.8 
(SCH2CHCH3), 31.0 (CHCH2SCH2CHCH3) and 22.0 (CH3); m/z 
(C14H18N2NaO3S (M + Na+) requires 317.0930) found 317.0932. This compound 
has not previously been reported. 
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(3R,6R)-6-(ammonium bromide)-3-methyl-[1,4]-thiazepan-5-one ((3R,6R)-
2.110) 
 
Deprotection was carried out according to General Method D using (3R,6R)-
2.109 (124 mg, 0.42 mmol) to give an off white solid (96 mg, 0.40 mmol, 95%); 
m.p.: >250 oC; [ߙ]஽ଶସ (c = 0.5, MeOH) -3.1; υmax (cm-1) 3205 (CONH), 2975, 
2903 (CH, CH2), 1649 (CONH), 1596 (NH3+), 1484 (CH3), 1450 (CH2); δH (400 
MHz, MeOD) 4.52 (1H, dd, J 9.0, 3.0 CHNH3+Br-), 3.91-3.82 (1H, m, CHCH3), 
2.85 (1H, dd, J 14.5, 9.0, pseudo-ax. SCHHCHNH3+Br-), 2.76 (1H, dd, J 14.5, 
3.0, pseudo-eq. SCHHCHNH3+Br-), 2.62 (1H, dd, J 14.5, 1.0, pseudo-eq. 
SCHHCHCH3), 2.54 (1H, dd, J 14.5, 9.0, pseudo-ax. SCHHCHCH3) and 1.27 
(3H, d, J 7.0, CHCH3); δC (100 MHz, MeOD) 171.3 (CO), 57.1 (CHNH3+Br-), 
49.4 (CHCH3), 37.7 (SCH2CHCH3), 28.5 (CH2CHNH3+Br-) and 21.4 (CH3); m/z 
(C6H13N2OS+ (M – Br-) requires 161.0743) found 161.0742. This compound has 
not previously been reported. 
 
(3R,6R)-6-(1'-Dimethylpropionylamino)-3-benzyl-[1,4]-thiazepan-5-one 
((3R,6R)-2.111) 
 
Acylation was carried out according to General Method E using (3R,6R)-2.110 
(24 mg, 0.1 mmol) and trimethylacetyl chloride (12 μL, 0.1 mmol, 1 eq). The 
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residue was purified by silica column chromatography (eluent; EtOAc:Petroleum 
Ether 40-60 (2:8) to EtOAc:Petroleum Ether 40-60 (1:1)) to give a white 
crystalline solid (21 mg, 0.1 mmol, 86%); m.p.: 138-139 oC; [ߙ]஽ଷ଴ (c = 0.072, 
MeOH) -41.9; υmax (cm-1) 3422 (NH), 3373, 3207 (CONH), 3085, 2959, 2904 
(CH, CH2, CH3) 1673, 1644 (CONH), 1490 (C(CH3)3); δH (400 MHz, CDCl3) 
7.19 (1H, d, J 4.5, (CH3)3CCONHCH), 5.90 (1H, d, J 5.0, CONHCHCH3), 4.85 
(1H, ddd, J 8.0, 5.5, 2.0, NHCHCONH), 4.01-3.90 (1H, m, CHCH3), 2.78 (1H, 
ddd, J 14.0, 2.0 1.0, pseudo-eq. CHCHHSCH2CHCH3), 2.66 (1H, dd, J 14.0, 9.5, 
pseudo-ax. CHCHHSCH2CHCH3), 2.59 (1H, dd, J 14.5, 9.0 pseudo-ax. 
CHCH2SCHHCHCH3), 2.50 (1H, dt, J 14.5, 1.0, pseudo-eq. 
CHCH2SCHHCHCH3), 1.33 (3H, d, J 7.0, CHCH3) and 1.20 (9H, s, C(CH3)3); 
δC (100 MHz, CDCl3) 177.8 ((CH3)3CCO), 173.7 (CONHCH), 55.8 
(CONHCHCONH), 53.1 (CHCH3), 38.7 (C(CH3)3) 37.1 (SCH2CHCH3), 30.8 
(CHCH2SCH2CHCH3), 27.4 (C(CH3)3) and 22.3 (CHCH3); m/z (C11H21N2O2S 
(M + H+) requires 245.1318) found 245.1317; This compound has not previously 
been reported. 
 
General Method G: Alcohol bromination using NBS 
2,2-Benzyl-(tert-butyloxycarbonyl)amino-1-bromoethane ((S)-2.112) 
 
N-Boc-L-phenylalaninol (5.0 g, 19.9 mmol) was dissolved in dry THF (75 mL) 
and triphenylphosphine (6.4 g, 24.5 mmol) was added in 3 portions with stirring. 
After complete addition, N-bromosuccinimide (4.3 g, 23.9 mmol) was added in 3 
portions and allowed to stir on ice under nitrogen for 1 h after which time the 
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mixture was brought to room temperature and stirred for 16 h. The solution was 
filtered through a thin pad of celite© using 100 mL of EtOAc:Petroleum ether 40-
60 (1:9) followed by 100 mL of EtOAc:Petroleum ether 40-60 (2:8) and 
concentrated in vacuo. The residue was purified by silica column 
chromatography (eluent; EtOAc:Hexane (1:9)  to EtOAc) to give a white 
crystalline solid (4.9 g, 15.8 mmol, 79%); m.p.: 100-102 oC; [ߙ]஽ଵଽ (c = 1, 
MeOH) -1.12; υmax (cm-1) 3353 (CONH), 2974 (CH2), 2929 (aryl  CH) 1690, 
1523 (CO), 1365, 1355 (C(CH3)3), 1266, 1251, 1163 (CO), 774, 703 
(monosubstituted Ph), 654 (CBr); δH (400 MHz, CDCl3) 7.35-7.20 (5H, m, Ph), 
4.80 (1H, d, J 7.5, NHCH), 4.13-3.95 (1H, m, CHCH2Br), 3.53 (1H, dd, J 10.0, 
4.0, BrCHH), 3.36 (1H, dd, J 10.0, 3.5, BrCHH), 2.94 (1H, dd, J 13.5, 6.0, 
PhCHH) and 2.85 (1H, dd, J 13.5, 8.5, PhCHH), 1.42 (9H, s, C(CH3)3);  δC (100 
MHz, CDCl3)  129.3 (Ph), 128.7 (Ph), 126.9 (Ph), 51.5 (CHCH2Br), 38.9 
(PhCH2), 37.4 (BrCH2) and 28.4 (CH3); m/z (C14H2079BrNNaO2 (M + Na+) 
requires 336.0570) found 336.0569. This compound is known but has previously 
only been reported with 1H & 13C NMR spectroscopic data, which is consistent 
with that reported here.320 
 
2-Benzyloxycarbonylamino-3-(2-tert-butoxycarbonylamino-3-phenyl-
propylsulfanyl)-propionic acid tert-butyl ester ((2R,2’S)-2.113) 
 
Coupling was carried out according to General Method B using 2.91 (0.6 g, 2.0 
mmol) and (S)-2.112 (0.6 g, 2.0 mmol). The residue was purified by silica 
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column chromatography (eluent; EtOAc:Hexane (1:9) to EtOAc) to give an off 
white crystalline solid (0.8 g, 1.5 mmol, 76%); m.p.: 82-83 oC; [ߙ]஽ଶଶ (c = 1, 
MeOH) -6.5; υmax (cm-1) 3372 (CONH), 2979 (CH’s, Ph), 1697, 1684 (CONH), 
1518 (Ph), 1348 (C(CH3)3), 1211, 1158 (CO), 853 (CH), 734, 696 (p-Ph); δH 
(400 MHz, CDCl3) 7.43-7.26 (5H, m, Ph), 7.26-7.16 (5H, m, Ph), 5.81 (1H, m, 
PhCH2OCONHCH), 5.14 (2H, s, CH2OCO), 4.90 (1H, m, NHCHCH2Ph), 4.55-
4.40 (1H, m, CHCOOC(CH3)3), 4.01-3.84 (1H, m, CHCH2Ph), 3.05-2.93 (2H, m, 
CHCH2SCH2CHCH2Ph), 2.92-2.76 (2H, m, SCH2CHCH2Ph), 2.74-2.56 (2H, m, 
SCH2CHCH2Ph), 1.48 (9H, s, C(CH3)3) and 1.43 (9H, s, C(CH3)3); δC (100 MHz, 
CDCl3) 169.6 (CHCOOC(CH3)3), 155.9 (OCONH), 155.3 (OCONH), 137.6 (i-
Ph), 136.4 (i-Ph), 129.4 (Ph), 128.5 (Ph), 128.1 (Ph), 126.6 (Ph), 82.7 
(CHCOOC(CH3)3), 79.4 (NHCOOC(CH3)3, 67.0 (CH2OCO), 54.4 
(CONHCHCO), 51.3 (CHCH2Ph), 39.4 (PhCH2CH), 37.3 (PhCH2CHCH2S),   
35.9 (OCOCHCH2S),  28.4 and 28.0 (2 × CH3); m/z (C29H40N2NaO6S (M + Na+) 
requires 567.2499) found 567.2507; anal. (CHN) (C29H40N2O6S requires C 
63.95, H 7.40, N 5.14) found C 63.94, H 7.39, N 4.97. This compound has not 
previously been reported. 
 
(3S,6R)-6-(Carboxybenzylamino)-3-benzyl-[1,4]-thiazepan-5-one ((3S,6R)-
2.114) 
 
Cyclisation was carried out according to General Method C using (2R,2’S)-
2.113 (1.7 g, 3 mmol). The residue was purified by silica column 
chromatography (eluent; EtOAc:Hexane (1:1) to EtOAc) to give a white 
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crystalline solid (0.7 g,  1.8 mmol, 60%); m.p.: 53-54 oC; [ߙ]஽ଵଽ (c = 1, MeOH) -
58.7; υmax (cm-1) 3279 (CONH), 3031, 2922 (CH’s, Ph), 1709, 1655 (CONH), 
1494, 1452 (Ph), 1351 (COCH2), 1213, 1050 (CO), 738, 696 (p-Ph); δH (400 
MHz, CDCl3) 7.46-7.35 (5H, m, Ph), 7.33-7.16 (5H, m, Ph), 6.28 (1H, d, J 5.0, 
CONHCHCONH), 6.14 (1H, d, J 6.5, CONHCH2Ph), 5.16 (1H, d, J 13.5, 
PhCHHOCO), 5.13 (1H, d, J 13.5, PhCHHOCO), 4.79-4.69 (1H, m, CHCONH), 
3.85-3.74 (1H, m, CHCH2Ph), 3.28 (1H, dd, J 13.5, 8.5, CHCHHPh), 3.11 (1H, 
dd, J 13.5, 7.0, CHCHHPh), 3.03 (1H, d, J 13.5, pseudo-eq. 
CHCHHSCH2CHCH2Ph), 2.88 (1H, d, J 14.5, pseudo-eq. 
CHCH2SCHHCHCH2Ph) and 2.69-2.61 (2H, m, pseudo-ax. 
CHCHHSCHHCHCH2Ph); δC (100 MHz, CDCl3) 173.8 (CHCONHCH), 155.4 
(OCONH), 137.6 (i-Ph), 136.4 (i-Ph), 129.5 (Ph), 129.3 (Ph), 128.8 (Ph), 128.7 
(Ph), 128.3 (Ph), 127.7 (Ph), 127.0 (Ph), 67.0 (PhCH2OCO), 57.7 
(CONHCHCONH), 55.3 (PhCH2CHNH), 38.9 (CHCH2Ph), 34.0 
(SCH2CHCH2Ph) and 31.0 (CHCH2SCH2CHCH2Ph); m/z (C20H22N2NaO3S (M + 
Na+) requires 393.1243) found 393.1243. This compound has not previously 
been reported. 
 
(3S,6R)-6-(ammonium bromide)-3-benzyl-[1,4]-thiazepan-5-one ((3S,6R)-
2.115)) 
 
Deprotection was carried out according to General Method D using (3S,6R)-
2.114 (0.3 g, 0.7 mmol) to produce an orange solid (0.2 g, 0.5 mmol, 72%); m.p.: 
> 250 oC; υmax (cm-1) 3191 (CONH), 3095, 3004, 2919 (CH2 & br, Br-NH3+), 
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1656 (CONH lactam), 1594, 1553, 1500 (NH3+), 745 (Ph), 727 (CH2S), 703 (Ph); 
δH (400 MHz, CD3OD) 7.33-7.17 (5H, m, Ph), 4.55 (1H, dd, J 11.0, 2.0, 
+NH3CHCH2S), 3.84 (1H, tdd, J 8.0, 5.0, 3.0, NHCHCH2Ph), 3.21 (2H, d, J 8.0, 
NHCHCH2Ph), 3.03 (1H, dd, J 15.0, 3.0, pseudo-eq. CHCH2SCHHCHCH2Ph), 
2.92 (1H, dd, J 14.0, 11.0, pseudo-ax. CHCHHSCH2CHCH2Ph), 2.86-2.78 (1H, 
m, pseudo-eq. CHCHHSCH2CHCH2Ph) and 2.74 (1H, ddd, J 15.0, 5.0, 0.5 
pseudo-ax. CHCH2SCHHCHCH2Ph); δC (100 MHz, CD3OD) 136.6 (i-Ph) 130.4 
(Ph), 129.8 (Ph), 127.9 (p-Ph),  58.3 (NH3CHCONH), 55.8 (PhCH2CHNH), 39.2 
(CHCH2Ph), 35.3 (SCH2CHCH2Ph) and 29.6 (CHCH2SCH2CHCH2Ph); m/z 
(C12H17N2OS ([M – Br]+) requires 237.1056) found 237.1054, (C12H14NOS ([M 
– NH3Br]+) requires 220.0791) found 220.0791, (C24H32N4NaO2S2 (2 × (M – 
HBr) + Na+) requires 495.1864) found 495.1866. This compound has not 
previously been reported. 
 
(3S,6R)-6-(2',2'-Dimethylpropionylamino)-3-benzyl-[1,4]-thiazepan-5-one 
((3S,6R)-2.116)) 
 
Acylation was carried out according to General Method E using (3S,6R)-2.115 
(25 mg, 0.08 mmol). The residue was purified by silica column chromatography 
with distilled solvents (eluent; EtOAc:Petroleum Ether 40-60 (1:1) to EtOAc) to 
give a white crystalline solid (19 mg,  0.06 mmol, 74%); m.p.: 122-123 oC; υmax 
(cm-1) 3379, 3358, 3248 (CONH), 2958 (CH2), 1666 (CONH lactam), 1632 
(CO), 1480 (NH), 1362 (C(CH3)3),  1293, 1271, 1227 (CO), 770 (Ph), 738 
(CH2S), 701 (Ph); δH (400 MHz, CDCl3) 7.36-7.17 (6H, m, 5 × Ph & 
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CONHCHCONH) 6.43 (1H, d, J 7.5, NHCHCH2Ph), 4.86 (1H, ddd, J 10.0, 5.5, 
2.5, (CH3)3CCONHCH), 3.84-3.73 (1H, m, NHCHCH2Ph), 3.37 (1H, dd, J 13.5, 
8.5, NHCHCHHPh), 3.13 (1H, dd, J 13.5, 7.0, NHCHCHHPh),  2.99 (1H, d, J 
13.5 pseudo-eq. CHCHHSCH2CHCH2Ph),  2.90 (1H, dd, J 15.0, 3.0, pseudo-eq. 
SCHHCHCH2Ph), 2.69 (1H, dd, J 15.0, 5.5, pseudo-ax. SCHHCHCH2Ph), 2.58 
(1H, dd, J 13.5, 10.0, pseudo-ax. CHCHHSCH2CHCH2Ph) and 1.25 (9H, s, 
C(CH3)3); δC (100 MHz, CDCl3) 177.8 (CO), 173.9 (CO), 137.4 (i-Ph),  129.1 
(Ph), 128.8 (Ph), 126.9 (p-Ph),  56.2 ((CH3)3CCONHCH), 55.8 (PhCH2CHNH), 
38.8 ((CH3)3C), 38.7 (CHCH2Ph), 34.0 (SCH2CHCH2Ph), 30.8 
(CHCH2SCH2CHCH2Ph) and 27.4 (C(CH3)3); m/z (C17H24N2NaOS (M + Na+) 
requires 343.1451) found 343.1448. This compound has not previously been 
reported. 
 
(3S,6R)-6-(1'-Adamantanecarbonylamino)-3-benzyl-[1,4]-thiazepan-5-one 
((3S,6R)-2.117)) 
 
Acylation was carried out according to General Method E using (3S,6R)-2.115 
(25 mg, 0.08 mmol). The residue was purified by silica column chromatography 
with distilled solvents (eluent; EtOAc to EtOAc:MeOH (9:1)) to give a white 
crystalline solid (11 mg,  0.03 mmol, 33%); m.p.: 97-98 oC; δH (400 MHz, 
CDCl3) 7.33-7.15 (6H, m, Ph & CONHCHCONH), 6.24 (1H, d, J 7.5, 
NHCHCH2Ph), 4.86 (1H, ddd, J 10.0, 5.5, 2.5, CCONHCH), 3.82-3.70 (1H, m, 
NHCHCH2Ph), 3.35 (1H, dd, J 13.5, 8.0, NHCHCHHPh), 3.11 (1H, dd, J 13.5, 
7.0, NHCHCHHPh), 2.99 (1H, dd, J 14.0, 1.0 pseudo-eq. 
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CHCHHSCH2CHCH2Ph),  2.89 (1H, dd, J 15.0, 3.0, pseudo-eq. 
SCHHCHCH2Ph), 2.68 (1H, dd, J 15.0, 5.5, pseudo-ax. SCHHCHCH2Ph), 2.56 
(1H, dd, J 14.0, 10.0, pseudo-ax. CHCHHSCH2CHCH2Ph), 2.06 (3H, m, 3 × 
CHCH2 adamantane), 1.89 (6H, d, J 2.5, 3 × C(CH2) adamantane) and 1.79-1.67 
(6H, m, 3 × CHCH2CH adamantane); δC (100 MHz, CDCl3) 177.3 (CO), 173.9 
(CO), 137.4 (i-Ph),  129.1 (Ph), 128.8 (Ph), 126.9 (p-Ph),  56.00 ((C)CONHCH), 
55.96 (PhCH2CHNH), 39.14 (3 × CH2 adamantane), 39.12 (CHCH2Ph), 37.1 
((C)CONH), 36.5 (3 × CH2 adamantane), 34.1 (SCH2CHCH2Ph), 30.9 
(CHCH2SCH2CHCH2Ph) and 28.1 (3 × CH adamantane); m/z (C23H30N2NaO2S 
(M + Na+) requires 421.1920) found 421.1920, (C12H15NOS (M – 
adamantanecarboxamide) requires 221.1260) found 221.1261. This compound 
has not previously been reported. 
 
(3S, 6R)-6-(2’,2’-Dimethyldodecanoylamino)-3-benzyl-[1,4]-thiazepan-5-one  
((3S, 6R)-2.118)  
 
Acylation was carried out according to General Method E using (3S,6R)-2.115 
(25 mg, 0.08 mmol) and 2.138 (20 mg, 0.08 mmol). The residue was purified by 
silica column chromatography with distilled solvents (eluent: 1:1 
EtOAc:Petroleum Ether 40-60 to EtOAc) to give a white crystalline solid. (23 
mg,  0.05 mmol, 65%); υmax (cm-1) 3393, 3238 (CONH), 2922, 2852 (CH2, CH3), 
1641 (CONH lactam), 1476 (NH), 1356 (C(CH3)2),  1299 (CO), 740, 699 (Ph); 
δH (400 MHz, CDCl3) 7.30-7.13 (6H, m, Ph + CONHCHCONH), 6.30 (1H, d, J 
7.5, NHCHCH2Ph), 4.84 (1H, ddd, J 10.5, 5.5, 2.5, CONHCHCONH), 3.73 (ddt, 
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1H, J 15.0, 8.0, 2.0, NHCHCH2Ph), 3.32 (1H, dd, J 13.5, 8.0, NHCHCHHPh), 
3.10 (1H, dd, J 13.5, 7.0, NHCHCHHPh),  2.96 (1H, br d, J 14.0 pseudo-eq. 
CHCHHSCH2CHCH2Ph), 2.86 (1H, dd, J 15.0, 2.0, pseudo-eq. 
SCHHCHCH2Ph), 2.64 (1H, dd, J 15.0, 5.5, pseudo-ax. SCHHCHCH2Ph), 2.53 
(1H, dd, J 14.0, 10.5, pseudo-ax. CHCHHSCH2CHCH2Ph), 1.54-1.42 (2H, m, 
CH2C(CH3)2), 1.29-1.17 (16H, m, CH3(CH2)8), 1.16 (3H, s, C(CH3)2), 1.15 (3H, 
s, C(CH3)2) and 0.84 (3H, t, J 7.0, CH3CH2); δC (100 MHz, CDCl3) 177.3 (CO), 
173.9 (CO), 137.4 (i-Ph), 129.1 (Ph), 128.8 (Ph), 126.9 (p-Ph), 56.2 
(CONHCHCONH), 55.9 (CHCH2Ph), 42.1 (C(CH3)2), 41.3 (CH2C(CH3)2), 38.8 
(CH2Ph), 34.0 (SCH2CHCH2Ph), 31.9 (CH3CH2CH2), 30.8 
(NHCHCH2SCH2CHCH2Ph), 30.2, 29.62, 29.58, 29.5, 29.3 
(CH3CH2CH2CH2CH2CH2CH2CH2), 25.2 (C(CH3)2), 24.8 (CH2CH2C(CH3)2), 
22.7 (CH3CH2) and 14.1 (CH3CH2); m/z (C26H42N2NaO2S (M + Na+) requires 
469.2859) found 469.2864. This compound has not previously been reported. 
 
(R)-N-(tert-Butoxycarbonyl)-phenylalanine (2.120) 
 
To a solution of D-phenylalanine (0.4 g, 2.7 mmol) in H2O and NEt3 (0.45 mL, 
3.2 mmol) stirred at 0 oC was added a 0 oC solution of di-tert-butyl dicarbonate 
(0.7 g, 3.2 mmol) in THF. The mixture was stirred at 0 oC for 1 h and allowed to 
warm to room temperature overnight. The resulting solution was concentrated in 
vacuo, diluted with H2O and acidified with 1M HCl. The aqueous mixture was 
extracted with ethyl acetate and the combined organic extracts washed with H2O, 
sat. aq. NaCl, dried over sodium sulfate and concentrated in vacuo. The residue 
was purified by column chromatography (eluent; EtOAc:Petroleum Ether 40-60 
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(1:1) to EtOAc) to give a white crystalline solid (0.3 g, 1.3 mmol, 42%); m.p.: 
86-87 oC; [ߙ]஽ଵଽ (c = 1, MeOH) -9.7; υmax (cm-1) 3430 (NH), 3365, 3212 
(CONH), 3085, 2961, 2903 (CH, CH2, CH3), 1676, 1642 (CONH), 1479 
(C(CH3)3); δH (400 MHz, 2:1 rotamer ratio, CDCl3) 8.32 (1H, br s, COOH), 7.34-
7.14 (5H, m, Ph), mi6.44 (1H, d, J 7.0, NH), mj5.32 (1H, d, J 8.0, NH), mj4.68-
4.63 (1H, m, CH), mi4.44-4.33 (1H, m, CH), 3.27-2.82 (2H, m, CH2), mj1.42 (9H, 
s, C(CH3)3) and mi1.33 (9H, s, C(CH3)3); δC (100 MHz, CDCl3) 175.0 (CO), 
mi156.7 (CONH), mj155.6 (CONH), mi136.6 (i-Ph), mj136.3 (i-Ph), 129.5 (Ph), 
128.5 (Ph), 126.9 (p-Ph), mi81.5 (C(CH3)3), mj80.1 (C(CH3)3), mi56.3 (CH), mj54.4 
(CH), mi38.8 (CH2), mj37.9 (CH2), mj28.3 (C(CH3)3) and mi28.0 (C(CH3)3); m/z 
266.1 (M + H+) and 268 (M + Na+). This data is consistent with that previously 
reported.323 
 
D-Phenylalaninol (2.123) 
 
D-Phenylalanine (10.0 g, 60.5 mmol) was added to NaBH4 (5.7 g, 151.3 mmol) 
in dry THF (80 mL) and cooled to 0 oC. A solution of H2SO4 (4.0 mL, 75.7 
mmol) in diethyl ether (8 mL) was added dropwise at such a rate as to maintain 
the reaction temperature below 20 oC. Stirring of the reaction mixture was 
continued overnight at room temperature whereupon MeOH (6.05 mL) was 
added slowly followed by the slow addition of 5 M NaOH (61.75 mL, 308.7 
mmol) until all solids were consumed. The MeOH and diethyl ether were 
removed by distillation and the remaining mixture refluxed overnight. After 
cooling the mixture was filtered through a thin pad of celite©, washed with H2O, 
extracted using dichloromethane (3 × 50 mL) and concentrated in vacuo. The 
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crude product was recrystallised from ethyl acetate and hexane to give a white 
crystalline solid (5.6 g, 37 mmol, 61%); m.p.: 91-92 oC; [ߙ]஽ଶଶ (c = 1, MeOH) 
+21.6; υmax (cm-1) 3432, 3334 (NH2, OH), 2961, 2887 (CH, CH2), 1561 (NH2), 
1127 (COH), 790, 729, 699 (Ph); δH (400 MHz, CDCl3) 7.34-7.28 (2H, m, o-Ph), 
7.23 (1H, dt, J 8.5, 1.5, p-Ph), 7.21-7.17 (2H, m, m-Ph), 3.63 (1H, dd, J 10.5, 4.0, 
CHHOH), 3.38 (1H, dd, J 10.5, 7.0, CHHOH), 3.12 (1H, dddd, J 10.5, 8.5, 5.5, 
4.0, CH), 2.79 (1H, dd, J 13.5, 5.5, CHHC), 2.53 (1H, dd, J 13.5, 8.5, CHHC), 
2.0-1.3 and (3H, br s, NH2 & OH); δC (100 MHz, CDCl3) 138.6 (i-Ph), 129.2 
(Ph), 128.6 (Ph), 126.4 (p-Ph), 66.5 (CH2OH), 54.1 (CH) and 41.1 (CH2C); m/z 
152.2 (M + H+) and 174.1 (M + Na+). This data is consistent with that previously 
reported.324 
 
N-(tert-Butoxycarbonyl)-D-phenylalaninol (2.122) 
 
Di-tert-butyl dicarbonate (2.2 g, 10 mmol) in dichloromethane (40 mL) was 
added dropwise to a solution of 2.123 (1.5 g, 10 mmol) in dichloromethane (40 
mL) and 1 M NaOH (32 mL). The solution was stirred for 3 days at room 
temperature whereupon the organic layer was separated and the aqueous layer 
extracted with dichloromethane (2 × 40 mL). The organics were combined, 
washed with H2O (2 × 20 mL), over sodium sulfate and concentrated in vacuo. 
The residue was purified by silica column chromatography (eluent; 
EtOAc:Petroleum Ether 40-60 (1:9) to EtOAc:Petroleum Ether 40-60 (1:1)) to 
give a white crystalline solid (1.6 g, 6.4 mmol, 65.0%); m.p.: 102-103 oC; [ߙ]஽ଶ଼ 
(c = 0.16, MeOH) +28.4;  υmax (cm-1) 3346 (NH), 3026 (CONH), 2983, 2937, 
2875 (CH, CH2, CH3), 1684, 1603 (NH2), 1526 (CONH), 1497, 1442 (C(CH3)3, 
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CH2), 1365 (CH3), 1314 (OH), 1269, 1250 (CO), 1166, 1004 (COH), 775, 754 
(Ph), 737 (CH2), 700 (Ph); δH (400 MHz, CDCl3) 7.32-7.19 (5H, m, Ph), 5.04 
(1H, br s, NH), 3.88 (1H, br s, CH), 3.63 (1H, dd, J 11.0, 4.0, CH2OH), 3.54 (1H, 
dd, J 11.0, 5.0, CH2OH), 3.38 (1H, br s, OH), 2.85 (2H, d, J 7.0, CH2C) and 1.42 
(9H, s, C(CH3)3); δC (100 MHz, CDCl3) 156.1 (CO), 137.9 (i-Ph), 129.2, 128.3 
(o-, m-Ph), 126.3 (p-Ph), 79.5 (C(CH3)3), 63.6 (CH2OH), 53.5 (CH), 37.3 (CH2C) 
and 28.2 (C(CH3)3); m/z 100 %, 274.1 ([M + Na]+) and 24 %, 524.8 ([(2 × M) – 
H + Na]+). This data is consistent with that previously reported.325 
 
(R)-2-tert-butoxycarbonylamino-3-phenyl-1-propylbromide ((R)-2.112) 
 
Bromination was carried out according to General Method G using 2.122 (1.6 
g, 6.5 mmol) and dichloromethane in place of THF. The residue was purified by 
silica column chromatography (eluent; EtOAc:Petroleum Ether 40-60 (1:9) to 
EtOAc:Petroleum Ether 40-60 (1:1)) to give an off white crystalline product (0.9 
g, 2.8 mmol, 44%); m.p.: 101-102 oC; [ߙ]஽ଶଶ (c = 1, MeOH) +5.4; υmax (cm-1): 
3348 (CONH), 3064, 2974 (CH2, CH3), 2932 (C(CH3)3), 1690 (CONH), 1525 
(CO), 1365, 1356 (CH3), 1267, 1251 (CO), 1052, 1020 (COC), 773, 745, 703 
(Ph), 653 (CBr); δH (400 MHz, CDCl3) 7.35-7.23 (5H, m, Ph), 4.90 (1H, d, J 7.5 
NH), 4.12-3.99 (1H, m, CH), 3.54 (1H, dd, J 10.5, 4.0, CHHBr), 3.37 (1H, dd, J 
10.5, 3.5, CHHBr), 2.95 (1H, dd, J 13.5, 5.5, CHHC), 2.87 (1H, dd, J 13.5, 8.5, 
CHHC), and 1.46 (9H, s, C(CH3)3); δC (100 MHz, CDCl3) 154.8 (CO), 137.0 (i-
Ph), 129.1 (Ph), 128.5 (Ph), 126.7 (p-Ph), 79.6 (C(CH3)3), 51.4 (CH), 38.7 
(CH2C), 37.2 (CH2Br), and 28.2 (C(CH3)3); m/z (C14H20BrNNaO2 (M + Na+) 
requires 336.0570 & 338.0550) found 336.0566 and 338.0548. This compound is 
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known but has previously only been reported with 1H & 13C NMR spectroscopic 
data, which is consistent with that reported here.326 
 
2-Benzyloxycarbonylamino-3-(2-tert-butoxycarbonylamino-3-phenyl-
propylsulfanyl)-propionic acid tert-butyl ester ((2R,2’R)-2.113) 
 
Coupling was carried out according to General Method B using (R)-2.112 (0.9 
g, 2.8 mmol) and 2.91 (0.9 g, 2.8 mmol). The residue was purified by silica 
column chromatography (eluent; EtOAc:Hexane (1:9) to EtOAc:Hexane (1:1))  
to give a white crystalline solid (0.4 g, 0.7 mmol, 25%); m.p.: 89-90 oC; [ߙ]஽ଶ଼ (c 
= 1, MeOH) -36.5; υmax (cm-1) 3369 (CONH), 2981 (CH), 1733 (COO),  1686 
(CONH), 1503 (Ph), 1382, 1367, 1351 (CHs & C(CH3)3), 1211, 1156 (CO), 843 
(CH2), 774, 756, 696 (p-Ph); δH (400 MHz, CDCl3) 7.38-7.16 (10H, m, Ph), 5.75 
(1H, d, J 7.5, PhCH2OCONHCH), 5.13 (2H, s, CH2OCO), 4.85 (1H, dd, J 6.5, 
NHCHCH2Ph,), 4.49 (1H, m, CHCOOC(CH3)3), 4.08-3.78 (1H, m, CHCH2Ph), 
3.04 (1H, dd, J 13.5, 4.5, CHCHHSCH2CHCH2Ph), 2.97 (1H, dd, J 13.5, 5.5, 
CHCHHSCH2CHCH2Ph) 2.92-2.76 (2H, m, SCH2CHCH2Ph), 2.74-2.56 (2H, m, 
SCH2CHCH2Ph), 1.49 (9H, s, C(CH3)3) and 1.43 (9H, s, C(CH3)3); δC (100 MHz, 
CDCl3) 169.4 (CHCOOC(CH3)3), 155.6 (OCONH), 155.0 (OCONH), 137.4 (i-
Ph), 136.1 (i-Ph), 129.2 (Ph), 128.3 (Ph), 128.0 (Ph), 127.9 (Ph), 126.4 (p-Ph), 
82.6 (CHCOOC(CH3)3), 79.2 (NHCOOC(CH3)3), 66.8 (CH2OCO), 54.2 
(CONHCHCO), 51.0 (CHCH2Ph), 39.4 (PhCH2CH), 36.8 (PhCH2CHCH2S), 
35.4 (OCOCHCH2S), 28.2 (CHCOOC(CH3)3) and 27.8 (NHCOOC(CH3)3); m/z 
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(C29H40N2NaO6S (M + Na+) requires 567.2499) found 567.2495. This compound 
has not previously been reported. 
 
(3R,6R)-6-(Carboxybenzylamino)-3-benzyl-[1,4]-thiazepan-5-one  
((3R,6R)-2.114) 
 
Cyclisation was carried out according to General Method C using (2R,2’R)-
2.113 (0.4 g, 0.7 mmol). The residue was purified by silica column 
chromatography (eluent; EtOAc:Hexane (4:6) to EtOAc) to give a white 
crystalline solid (44 mg, 0.1 mmol, 17%); m.p.: 128-129 oC; [ߙ]஽ଶସ (c = 0.2, 
MeOH) +33.6; υmax (cm-1) 3406, 3223 (CONH), 3066, 2916 (CH’s, Ph), 1726, 
1713 (CO), 1670 (CONH lactam), 1483, 1452 (Ph), 1358 (COCH2), 1213, 1058 
(CO), 774, 741, 694 (Ph); δH (400 MHz, CDCl3) 7.40-7.24 (8H, m, Ph), 7.20-
7.14 (2H, m, 2 × p-Ph), 6.26 (1H, d, J 6.0, CONHCHCONH), 6.21 (1H, d, J 5.5, 
CONHCHCH2Ph), 5.12 (1H, d, J 12.0, PhCHHOCO), 5.09 (1H, d, J 12.0, 
PhCHHOCO), 4.75 (1H, ddd, J 8.5, 6.0, 2.0, CHCONH), 4.11-4.03 (1H, m, 
CHCH2Ph), 2.86 (2H, d, J 7.5, CHCH2Ph), 2.85-2.79 (1H, m, pseudo-eq. 
SCHHCHCH2Ph), 2.74 (1H, dd, J 14.0, 9.5, pseudo-ax. SCHHCHCH2Ph), 2.61 
(1H, dd, J 14.5, 2.0, pseudo-eq. CHCHHSCH2CHCH2Ph) and 2.56 (1H, dd, J 
14.5, 8.5, pseudo-ax. CHCHHSCH2CHCH2Ph); δC (100 MHz, CDCl3) 173.1 
(CHCONHCH), 155.2 (OCONH), 136.2 (i-Ph), 135.7 (i-Ph), 129.12 (Ph), 129.11 
(Ph) 128.5 (Ph), 128.1 (Ph), 128.0 (Ph), 127.4 (Ph), 66.9 (PhCH2OCO), 58.1 
(CHCH2Ph), 57.0 (CONHCHCONH), 41.8 (CHCH2Ph), 34.9 
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(CHCH2SCH2CHCH2Ph) and 31.2 (SCH2CHCH2Ph); m/z (C20H22N2NaO3S (M + 
Na+) requires 393.1243) found 393.1243. This compound has not previously 
been reported. 
 
(3R,6R)-6-(ammonium bromide)-3-benzyl-[1,4]thiazepan-5-one  
((3R,6R)-2.115)) 
 
Deprotection was carried out according to General Method D using (3R,6R)-
2.114 (44 mg, 0.1 mmol) to produce a white crystalline solid (37 mg, 0.1 mmol, 
99%); m.p.: > 250 oC; [ߙ]஽ଶ଼ (c = 0.57, MeOH) +58.8; υmax (cm-1) 3420, 3183 
(CONH),  3084, 3002, 2823 (CH2 & NH3+), 1642, 1638 (CONH lactam & NH3+), 
1492 (NH3+), 772, 755, 707 (Ph); δH (400 MHz, CD3OD) 7.34-7.20 (5H, m, Ph), 
4.57 (1H, dd, J 9.0, 3.5, +NH3CHCH2S), 4.05 (1H, dddd, J 9.5, 7.5, 6.0, 2.0, 
NHCHCH2Ph), 2.96 (1H, dd, J 14.0, 7.5, pseudo-ax. NHCHCHHPh), 2.89 (1H, 
dd, J 14.5, 9.0, pseudo-ax. COCHCHHSCH2), 2.87 (1H, dd, J 14.0, 6.0, pseudo-
eq. NHCHCHHPh), 2.80 (1H, dd, J 14.5, 3.5, pseudo-eq. COCHCHHSCH2), 
2.70 (1H, dd, J 14.0, 1.5, pseudo-eq. SCHHCHCH2Ph) and 2.60 (1H, dd, J, 14.0, 
9.5, pseudo-ax. SCHHCHCH2Ph); δC (100 MHz, CD3OD) 130.4 (Ph), 129.8 
(Ph), 128.1 (Ph), 59.0 (PhCH2CHNH), 56.8 (NH3CHCONH), 41.8 (CHCH2Ph), 
35.8 (SCH2CHCH2Ph) and 28.7 (CHCH2SCH2CHCH2Ph); m/z (C12H17N2OS (M 
– Br-) requires 237.1056) found 237.1054. This compound has not previously 
been reported. 
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(3R,6R)-6-(2',2'-Dimethylpropionylamino)-3-benzyl-[1,4]-thiazepan-5-one 
((3R,6R)-2.116)) 
 
Acylation was carried out according to General Method E using (3R,6R)-
2.115), 13 mg, 0.04 mmol). The residue was purified by silica column 
chromatography (eluent; EtOAc (distilled)) to give a white crystalline solid (8 
mg,  0.02 mmol, 61 %); m.p.: 228-229 oC; [ߙ]஽ଵଽ (c = 0.16, MeOH) +19.7; υmax 
(cm-1) 3404, 3361 (CONH), 2956 (CH2), 1641 (CONH lactam), 1632 (CO), 1491 
(NH), 1361 (C(CH3)3),  1271, 1220 (CO), 772, 753, 701 (Ph); δH (400 MHz, 
CDCl3) 7.37-7.27 (3H, m, Ph), 7.20-7.15 (3H, m, Ph & NHCOC(CH3)3) 5.74 
(1H, d, J 6.0, NHCHCH2Ph), 4.85 (1H, ddd, J 9.5, 5.5, 2.5, (CH3)3CONHCH), 
4.16-4.06 (1H, m, NHCHCH2Ph), 2.92 (1H, dd, J 14.0, 7.0, NHCHCHHPh), 
2.87-2.75 (2H, m, NHCHCHHPh & CHCHHSCH2CHCH2Ph), 2.70-2.61 (2H, m, 
CHCHHSCH2CHCH2Ph & SCHHCHCH2Ph), 2.59 (1H, dd, J 14.5, 8.5, 
CHCH2SCHHCHCH2Ph) and 1.20 (9H, s, C(CH3)3); δC (100 MHz, CDCl3) 
177.8 (CO), 173.5 (CO), 135.5 (i-Ph),  129.1 (Ph), 129.0 (Ph), 127.5 (p-Ph),  
58.0 (PhCH2CHNH), 55.6 (tBuCONHCH), 42.0 (CHCH2Ph), 38.7 (C(CH3)3), 
35.2 (SCH2CHCH2Ph), 30.8 (CHCH2SCH2CHCH2Ph) and 27.4 (CH3); m/z 
(C17H24N2NaOS (M + Na+) requires 343.1451) found 343.1451. This compound 
has not previously been reported. 
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(R)-tert-Butyl-2-(benzyloxycarbonylamino)-3-(2-(tert-butoxycarbonyl(methyl) 
amino)ethylthio)propanoate (2.124) 
 
Thiol coupling was carried out according to General Method B using 1-bromo-
2-[N-(tert-butoxycarbonyl)-N-methylamino]ethane (2.4 g, 10 mmol) and 2.91 
(3.1 g, 10 mmol). The residue was purified by silica column chromatography 
(eluent; EtOAc:Hexane (1:9) to EtOAc) to give a colourless oil (1.3 g, 2.8 mmol, 
28%); υmax (cm-1): 2979, 2930 (COC(CH3)3), 1699 (CO), 1513 (CH), 1376, 1341 
(C(CH3)3), 1161 (CO); δH (400 MHz, CDCl3) 7.39-7.28 (5H, m, Ph), 5.79 (1H, d, 
J 6.0, CH2OCONH), 5.13 (2H, s, CH2Ph), 4.61 (1H, dt, J 12.5, 6.0, CHNH), 3.46 
(3H, s, NCH3), 3.35 (2H, t, J 6.0, CH2NCH3), 3.12 (1H, dd, J 14.0, 5.5, 
CHCHHS), 2.92 (1H, dd, J 14.0, 5.5, CHCHHS), 2.69 (2H, t, J 6.0, SCH2CH2N), 
1.42 (s, 9H, C(CH3)3) and 1.39 (s, 9H, C(CH3)3); δC (100 MHz, CDCl3) 171.0 
(CHCOOtBu), 155.9 (NHCO), 154.4 (NCO), 136.1 (i-Ph), 128.8 (Ph), 128.1 (p-
Ph), 127.7 (Ph), 82.5 (CHCOOC(CH3)3), 79.9 (NCOOC(CH3)3, 66.9 (CH2OCO), 
57.9 (CONHCHCO), 56.0 (CH2NCH3), 35.5 (NCH3), 34.1 (CHCH2S), 30.6 
(SCH2CH2N), 28.6 (C(CH3)3) and 28.2 (C(CH3)3); m/z (C23H36N2NaO6S (M + 
Na+) requires 491.2192) found 491.2191. This compound has not previously 
been reported. 
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(R)-Methyl-6,6,13,13-tetramethyl-3,11-dioxo-1-phenyl-2,12-dioxa-7-thia-4,10-
diazatetradecane-5-carboxylate (2.130) 
 
Thiol coupling was carried out according to General Method B using (R)-
methyl-2-(benzyloxycarbonylamino)-3-mercapto-3-methylbutanoate (0.3 g, 1 
mmol) and 2.95 (0.2 g, 1 mmol). The residue was purified by silica column 
chromatography (eluent; EtOAc:Hexane (1:1) to MeOH:EtOAc (1:9)) to give a 
colourless oil (0.1 g, 0.3 mmol, 31%); υmax (cm-1): 3330 (NH), 2992, 2935 
(COC(CH3)3), 1698 (CO), 1511 (CH), 1398, 1346 (C(CH3)3), 1151 (CO); δH (400 
MHz, CDCl3) 7.43-7.31 (5H, m, Ph), 5.81 (1H, d, J 6.0, CH2OCONH), 5.09 (2H, 
s, CH2Ph), 4.99-5.06 (1H, s, CH2NH), 4.48 (1H, d, J 6.0, CHNH), 3.71 (3H, s, 
OCH3), 3.35-3.17 (2H, m, CH2NH), 2.69 (2H, t, J 5.5, SCH2CH2NH), 1.55 (s, 
6H, C(CH3)2) and 1.42 (s, 9H, C(CH3)3); δC (100 MHz, CDCl3) 171.1 
(CHCOOCH3), 155.9 (NHCO), 136.1 (i-Ph), 128.8 (Ph), 127.9 (p-Ph), 127.1 
(Ph), 79.9 (COOC(CH3)3), 74.5 (CH(C)), 66.9 (CH2OCO), 53.1 (OCH3), 41.5 
(C(CH3)2), 39.6 (CH2NHCO), 30.3 (C(CH3)2), 28.4 (CH3) and 27.0 (SCH2); m/z 
(C21H32N2NaO6S (M + Na+) requires 463.1879) found 463.1883. This compound 
has not previously been reported.  
 
General Method H: Lithium enolate alkylation 
Methyl 2,2-dimethyl dodecanote (2.136) 
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Diisopropylamine (10.6 mL, 75 mmol) in THF (43.5 mL) with a small amount of 
phenanthroline indicator was cooled to -78 oC and 2.5 M  nBuLi (25.0 mL, 62.5 
mmol) was added dropwise and left stirring for 30 minutes, after which time 
methyl isobutyrate (8.6 ml, 75 mmol) was added and left stirring for a further 30 
minutes. 1-Iododecane (12.3 mL, 57.7 mmol) was finally added to the solution 
and brought to room temperature overnight. The reaction mixture was 
concentrated in vacuo and the remaining mixture washed with pH 2 buffer and 
extracted with Petroleum Ether 40-60. The organics were collected and washed 
with sat. NaCl, dried over sodium sulfate, filtered and concentrated in vacuo to 
give a crude viscous liquid that was used without further purification; (14.5 g, 
59.7 mmol, > 99%); δH (300 MHz, CDCl3) 3.66-3.54 (3H, m, OCH3), 1.52-1.37 
(2H, m, CH2C(CH3)2), 1.31-1.20 (10H, m, 5 × CH2), 1.20 (6H, s, C(CH3)2), 1.12-
1.10 (6H, m, 3 × CH2) and 0.90-0.73 (3H, m, CH3CH2); m/z (C15H30NaO2 (M + 
Na+) requires 265.2138) found 265.2139. This compound is known but has 
previously been reported without any characterisation.327-328 
 
General Method I: Ester hydrolysis 
2,2-Dimethyl dodecanoic acid (2.137) 
 
Crude ester 2.136 (14.5 g, 53.5 mmol) was refluxed overnight in EtOH (50 mL) 
and H2O (3.5 mL) using KOH (6 g, 107 mmol). The mixture was cooled to room 
temperature and concentrated in vacuo. The mixture was then taken up in H2O 
and extracted using a 1:1 mixture of Et2O:Petroleum Ether 40-60 while 
maintaining the pH at ~8 using sodium phosphate buffer. The organics were 
combined, dried over sodium sulfate, filtered and concentrated in vacuo to give a 
clean colourless semi solid which required no further purification (8.3 g. 36.3 
158 
 
mmol, 63%); m.p.: 27-28 oC; υmax (cm-1) 2954, 2915, 2849 (CH2, CO2H), 1698 
(CO2H), 1464, 1454 (CH2, CH3), 1384 (C(CH3)2),  1326, 1309 (OH), 1290, 1272, 
1245 (CO), 1189 (COH), 725 (CH2); δH (400 MHz, CDCl3) 10.40 (1H, br s, 
COOH), 1.60-1.50 (2H, m, CH2C(CH3)2), 1.37-1.23 (16H, m, CH3(CH2)8), 1.21 
(6H, s, C(CH3)2) and 0.91 (3H, t, J 7.0, CH3CH2); δC (100 MHz, CDCl3) 185.0 
(CO), 42.2 (C(CH3)2), 40.6 (CH2C(CH3)2), 31.9 (CH3CH2CH2), 30.1, 29.65, 
29.63, 29.5, 29.3 (CH3CH2CH2CH2CH2CH2CH2CH2), 24.9 (C(CH3)2), 24.8 
(CH2CH2C(CH3)2), 22.6 (CH3CH2) and 14.1 (CH3CH2); m/z (C14H28NaO2 (M + 
Na+) requires 251.1982) found 251.1981. This compound is known but has 
previously only been reported with 1H & 13C NMR spectroscopic data. 
 
2,2-Dimethyldodecanoyl chloride (2.138) 
 
2,2-Dimethyldodecanoyl chloride (2.138) was synthesised according to General 
Method F using 2.137 (0.2 g, 1 mmol) to give a colourless oil which was not 
isolated and used immediately without further purification (0.3 g, 1 mmol, > 
99%). This compound is known but has previously been reported without any 
characterisation.329 
 
5.2.2 Long Chain Investigation Experimental 
Methyl 2,2-dimethylundecanoate (2.139) 
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Lithium enolate alkylation was carried out according to General Method H 
using 1-iodononane (5.7 mL, 29 mmol) to give a crude viscous liquid that was 
used without further purification; (7.5 g, 33 mmol, > 99%); δH (300 MHz, 
CDCl3) 3.68-3.58 (3H, m, OCH3), 1.50-1.38 (2H, m, CH2C(CH3)2), 1.28-1.12 
(14H, m, CH3(CH2)7CH2), 1.13-1.05 (6H, 2 × s, C(CH3)2) and 0.89-0.75 (3H, m, 
CH3CH2); m/z (C14H29O2 (M + H+) requires 229.2162) found 229.2160. This 
compound has not previously been reported. 
 
Methyl 2,2-dimethyldecanoate (2.140) 
 
Lithium enolate alkylation was carried out according to General Method H 
using 1-iodooctane (5.2 mL, 29 mmol) to give a crude viscous liquid that was 
used without further purification; (7.0 g, 33 mmol, > 99%); δH (300 MHz, 
CDCl3) 3.65-3.54 (3H, m, OCH3), 1.48-1.36 (2H, m, CH2C(CH3)2), 1.24-1.11 
(12H, m, CH3(CH2)6CH2), 1.11-1.03 (6H, 2 × s, C(CH3)2) and 0.80 (3H, t, J 7.0, 
CH3CH2); m/z (C13H27O2 (M + H+) requires 215.2006) found 215.2001. This 
compound is known but has previously only been reported with IR data.330-331 
 
Methyl 2,2-dimethylnonanoate (2.141) 
 
Lithium enolate alkylation was carried out according to General Method H 
using 1-iodoheptane (4.7 mL, 29 mmol) to give a crude viscous liquid that was 
used without further purification; (6.3 g, 31 mmol, > 99%); δH (300 MHz, 
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CDCl3) 3.68-3.56 (3H, m, OCH3), 1.50-1.39 (2H, m, CH2C(CH3)2), 1.26-1.12 
(10H, m, CH3(CH2)5CH2), 1.12-1.05 (6H, 2 × s, C(CH3)2) and 0.82 (3H, t, J 7.0, 
CH3CH2); m/z (C12H25O2 (M + H+) requires 201.1849) found 201.1848. This 
compound is known.332 
 
Methyl 2,2-dimethyloctanoate (2.142) 
 
Lithium enolate alkylation was carried out according to General Method H 
using 1-iodohexane (4.3 mL, 29 mmol); (5.4 g, 29  mmol, >99 %); δH (300 MHz, 
CDCl3) 3.66-3.52 (3H, m, OCH3), 1.49-1.34 (2H, m, CH2C(CH3)2), 1.24-1.11 
(8H, m, CH3(CH2)4CH2), 1.11-1.02 (6H, 2 × s, C(CH3)2) and 0.78 (3H, t, J 7.0, 
CH3CH2); m/z (C11H23O2 (M + H+) requires 187.1693) found 187.1695. This data 
is consistent with that previously reported.333  
 
Methyl 2,2-dimethylheptanoate (2.143) 
 
Lithium enolate alkylation was carried out according to General Method H 
using 1-iodopentane (3.8 mL, 29 mmol) to give a crude viscous liquid that was 
used without further purification; (5.0 g, 29 mmol, 99%); δH (400 MHz, CDCl3) 
3.54 (3H, s, OCH3), 1.44-1.34 (2H, m, CH2C(CH3)2), 1.21-1.06 (6H, m, 
CH3(CH2)3), 1.05-1.03 (6H, 2 × s, C(CH3)2) and 0.80-0.74 (3H, m, CH3CH2); m/z 
(C10H21O2 (M + H+) requires 173.1536) found 173.1536. This data is consistent 
with that previously reported.333 
161 
 
Methyl 2,2-dimethylhexanoate (2.144) 
 
Lithium enolate alkylation was carried out according to General Method H 
using 1-iodobutane (2.8 mL, 29 mmol) to give a crude viscous liquid that was 
used without further purification; (2.9 g, 18  mmol, 63%); δH (400 MHz, CDCl3) 
3.54-3.46 (3H, m, OCH3), 1.41-1.31 (2H, m, CH2C(CH3)2), 1.13-1.02 (4H, m, 
CH3(CH2)2), 1.03-0.97 (6H, 2 × s, C(CH3)2) and 0.77-0.68 (3H, m, CH3CH2); m/z 
(C9H19O2 (M + H+) requires 159.1380) found 159.1384. This data is consistent 
with that previously reported.333 
 
Methyl 2,2-dimethylpentanoate (2.145) 
 
Lithium enolate alkylation was carried out according to General Method H 
using 1-iodopropane (2.4 mL, 25 mmol) to give a crude viscous liquid that was 
used without further purification; (2.8 g, 20  mmol, 78%); δH (400 MHz, CDCl3) 
3.62-3.50 (3H, m, OCH3), 1.41-1.29 (2H, m, CH2CCO), 1.28-1.21 (8H, m, 
CH3CH2CH2C(CH3)2) and 0.76 (3H, t, J 7.0, CH3CH2); m/z (C8H17O2 (M + H+) 
requires 145.1223) found 145.1222. This data is consistent with that previously 
reported.334 
 
2,2-Dimethylundecanoic acid (2.146) 
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Ester hydrolysis was carried out according to General Method I using crude 
methyl 2,2-dimethylundecanote (2.139, 6.6 g, 29 mmol) to give a clean 
colourless oil (5.2 g, 24 mmol, 84%); υmax (cm-1) 2923, 2854 (CH2, CH3), 1698 
(CO), 1466 (OH), 1408, 1365 (C(CH3)2),  1287, 1193 (CO); δH (400 MHz, 
CDCl3) 11.15 (1H, br s, COOH), 1.58-1.47 (2H, m, CH2C(CH3)2), 1.33-1.21 
(14H, m, CH3(CH2)7), 1.17 (6H, s, C(CH3)2) and 0.90-0.83 (3H, m, CH3CH2); δC 
(100 MHz, CDCl3), 185.0 (CO), 42.1 (C(CH3)2), 40.5 (CH2C(CH3)2), 35.6 
(CH2CH2CH2C(CH3)2), 30.1 (CH3CH2CH2), 29.6, 29.5, 29.3 
(CH3CH2CH2CH2CH2CH2), 24.9 (C(CH3)2), 24.8 (CH2CH2C(CH3)2), 22.7 
(CH3CH2) and 14.0 (CH3CH2); m/z (C13H26NaO2 (M + Na+) requires 237.1825) 
found 237.1830. This compound is known but has previously been reported 
without any characterisation.335 
 
2,2-Dimethyldecanoic acid (2.147) 
 
Ester hydrolysis was carried out according to General Method I using crude 
methyl 2,2-dimethyldecanote (2.140, 6.2 g, 29 mmol) to give a clean colourless 
oil (4.7 g, 23 mmol, 81%); υmax (cm-1) 2923, 2854 (CH2, CH3), 1698 (CO), 1474 
(OH), 1407, 1365 (C(CH3)2),  1271, 1194 (CO); δH (400 MHz, CDCl3) 10.71 
(1H, br s, COOH), 1.57-1.45 (2H, m, CH2C(CH3)2), 1.34-1.21 (12H, m, 
CH3(CH2)6), 1.17 (6H, s, C(CH3)2) and 0.88 (3H, t, J 7.0, CH3CH2); δC (100 
MHz, CDCl3), 184.8 (CO), 42.2 (C(CH3)2), 40.6 (CH2C(CH3)2), 31.9 
(CH2CH2CH2C(CH3)2), 30.2 (CH3CH2CH2), 29.5, 29.3 (CH3CH2CH2CH2CH2), 
25.0 (C(CH3)2), 24.9 (CH2CH2C(CH3)2), 22.7 (CH3CH2) and 14.1 (CH3CH2); m/z 
(C12H24NaO2 (M + Na+) requires 223.1669) found 223.1672. This compound is 
known but has previously been reported without any NMR characterisation.335 
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2,2-Dimethylnonanoic acid (2.148) 
 
Ester hydrolysis was carried out according to General Method I using crude 
methyl 2,2-dimethylnonanote (2.141, 5.8 g, 29 mmol) to give a clean colourless 
oil (3.7 g, 20 mmol, 69%); υmax (cm-1) 2923, 2855 (CH2, CH3), 1697 (CO), 1475 
(OH), 1408, 1365 (C(CH3)2),  1282, 1247, 1198 (CO); δH (400 MHz, CDCl3) 
11.46 (1H, br s, COOH), 1.56-1.47 (2H, m, CH2C(CH3)2), 1.35-1.21 (10H, m, 
CH3(CH2)5), 1.18 (6H, s, C(CH3)2) and 0.86 (3H, t, J 7.0, CH3CH2); δC (100 
MHz, CDCl3), 185.2 (CO), 42.1 (C(CH3)2), 40.6 (CH2C(CH3)2), 31.8 
(CH2CH2CH2C(CH3)2), 30.1 (CH3CH2CH2), 29.2 (CH3CH2CH2CH2), 24.9 
(C(CH3)2), 24.8 (CH2CH2C(CH3)2), 22.6 (CH3CH2) and 14.1 (CH3CH2); m/z 
(C11H22NaO2 (M + Na+) requires 209.1512) found 209.1518. This compound is 
known but has previously been reported with only 13C NMR data.336  
 
2,2-Dimethyloctanoic acid (2.149) 
 
Ester hydrolysis was carried out according to General Method I using crude 
methyl 2,2-dimethyloctanote (2.142, 5.4 g, 29 mmol) to give a clean colourless 
oil (4.7 g, 27 mmol, 94%); υmax (cm-1) 2925, 2858 (CH2, CH3), 1697 (CO), 1475 
(OH), 1409, 1366 (C(CH3)2),  1292, 1259, 1203 (CO); δH (400 MHz, CDCl3) 
11.52 (1H, br s, COOH), 1.57-1.48 (2H, m, CH2C(CH3)2), 1.31-1.20 (8H, m, 
CH3(CH2)4), 1.18 (6H, s, C(CH3)2) and 0.87 (3H, t, J 7.0, CH3CH2); δC (100 
MHz, CDCl3), 185.3 (CO), 42.2 (C(CH3)2), 40.6 (CH2C(CH3)2), 31.7 
(CH3CH2CH2), 29.8 (CH3CH2CH2CH2), 24.9 (C(CH3)2), 24.8 
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(CH2CH2C(CH3)2), 22.6 (CH3CH2) and 14.1 (CH3CH2); m/z (C10H20NaO2 (M + 
Na+) requires 195.1356) found 195.1351. This data is consistent with that 
previously reported.337 
 
2,2-Dimethylheptanoic acid (2.150) 
 
Ester hydrolysis was carried out according to General Method I using crude 
methyl 2,2-dimethylheptanoate (2.143, 5.0 g, 29 mmol) to give a clean colourless 
oil (2.2 g, 14 mmol, 47%); υmax (cm-1) 2926, 2857 (CH2, CH3), 1697 (CO), 1475 
(OH), 1409, 1366 (C(CH3)2),  1292, 1259, 1203 (CO); δH (400 MHz, CDCl3) 
10.81 (1H, br s, COOH), 1.56-1.45 (2H, m, CH2C(CH3)2), 1.35-1.20 (6H, m, 
CH3(CH2)3), 1.17 (6H, s, C(CH3)2) and 0.86 (3H, m, CH3CH2); δC (100 MHz, 
CDCl3), 185.1 (CO), 42.1 (C(CH3)2), 40.5 (CH2C(CH3)2), 32.3 (CH3CH2CH2), 
24.9 (C(CH3)2), 24.5 (CH2CH2C(CH3)2), 22.5 (CH3CH2) and 14.0 (CH3CH2); m/z 
(C9H18NaO2 (M + Na+) requires 181.1199) found 181.1207. This data is 
consistent with that previously reported.338 
 
2,2-Dimethylhexanoic acid (2.151) 
 
Ester hydrolysis was carried out according to General Method I using crude 
methyl 2,2-dimethylhexanote (2.144, 4.6 g, 29 mmol) to give a clean colourless 
oil (0.3 g, 2 mmol, 8%); υmax (cm-1) 2957, 2933, 2861 (CH2, CH3), 1698 (CO), 
1475 (OH), 1408, 1366 (C(CH3)2),  1284, 1261, 1166 (CO); δH (400 MHz, 
CDCl3) 9.89 (1H, br s, COOH), 1.52-1.46 (2H, m, CH2C(CH3)2), 1.32-1.17 (4H, 
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m, CH3(CH2)2), 1.15 (6H, s, C(CH3)2) and 0.86 (3H, m, CH3CH2); δC (100 MHz, 
CDCl3), 184.7 (CO), 42.1 (C(CH3)2), 40.3 (CH2C(CH3)2), 27.1 (CH3CH2CH2), 
24.9 (C(CH3)2), 23.2 (CH3CH2) and 13.9 (CH3CH2); m/z (C8H16NaO2 (M + Na+) 
requires 167.1043) found 167.1043. This data is consistent with that previously 
reported.336 
 
2,2-Dimethylhexanoic acid (2.152) 
 
Ester hydrolysis was carried out according to General Method I using crude 
methyl 2,2-dimethylpentanote (2.145, 2.8 g, 19 mmol) to give a clean colourless 
oil (85 mg, 0.65 mmol, 3%); δH (400 MHz, CDCl3) 9.44 (1H, br s, COOH), 1.56-
1.46 (2H, m, CH2C(CH3)2), 1.35-1.20 (2H, m, CH3CH2), 1.17 (6H, s, C(CH3)2) 
and 0.89 (3H, t, J 7.0, CH3CH2); δC (100 MHz, CDCl3), 184.8 (CO), 42.0 
(C(CH3)2), 41.1 (CH2C(CH3)2), 24.9 (C(CH3)2), 18.2 (CH3CH2) and 14.0 
(CH3CH2); m/z (C7H14KO2 (M + K+) requires 169.0625) found 169.0627. This 
data is consistent with that previously reported.336 
 
2,2-Dimethylundecanoyl chloride (2.154) 
 
Acyl chloride was synthesised according to General Method F using 2,2-
dimethylundecanoic acid (2.146, 0.2 g, 1 mmol) to give 2.154 (0.2 g, 1 mmol, 
98%) a colourless oil which was not isolated and used immediately without 
further purification. 
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2,2-Dimethyldecanoyl chloride (2.155) 
 
Acyl chloride was synthesised according to General Method F using 2,2-
dimethyldecanoic acid (2.147, 0.2 g, 1 mmol) to give 2.155 (0.2 g, 1 mmol, 99%) 
a colourless oil which was not isolated and used immediately without further 
purification. 
 
2,2-Dimethylnonanoyl chloride (2.156) 
 
Acyl chloride was synthesised according to General Method F using 2,2-
dimethylnonanoic acid (2.148, 0.2 g, 1 mmol) to give 2.156 (0.2 g, 1 mmol, 
97%) a colourless oil which was not isolated and used immediately without 
further purification. 
 
2,2-Dimethyloctanoyl chloride (2.157) 
 
Acyl chloride was synthesised according to General Method F using 2,2-
dimethyloctanoic acid (2.149, 0.2 g, 1 mmol) to give 2.157 (0.2 g, 1 mmol,  
99%) a colourless oil which was not isolated and used immediately without 
further purification. 
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2,2-Dimethylheptanoyl chloride (2.158) 
 
Acyl chloride was synthesised according to General Method F using 2,2-
dimethylheptanoic acid (2.150, 0.2 g, 1 mmol) to give 2.158 (0.2 g, 1 mmol,  
99%) a colourless oil which was not isolated and used immediately without 
further purification. 
 
2,2-Dimethylhexanoyl chloride (2.159) 
 
Acyl chloride was synthesised according to General Method F using 2,2-
dimethylhexanoic acid (2.151, 0.1 g, 1 mmol) to give 2.159 (0.2 g, 1 mmol,  
98%) a colourless oil which was not isolated and used immediately without 
further purification. 
 
2,2-Dimethylpentanoyl chloride (2.160) 
 
Acyl chloride was synthesised according to General Method F using 2,2-
dimethylpentanoic acid (2.152, 85 mg, 0.65 mmol) to give 2.160 (97 mg, 0.65 
mmol, 99%) a colourless oil which was not isolated and used immediately 
without further purification. 
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2,2-Dimethylbutanoyl chloride (2.161) 
 
Acyl chloride was synthesised according to General Method F using 
commercially available 2,2-dimethylbutyric acid (2.153, 1.3 mL, 10 mmol) to 
give 2.161 (1.3 g, 9.6 mmol, 96%) a white solid which was not isolated and used 
immediately without further purification. 
 
(S)-3-Aminopiperidin-2-one hydrochloride (2.162) 
 
To a solution of (S)-3-benzyloxycarbonylaminopiperidin-2-one (5 g, 20 mmol, 
prepared according to the method described by Abe339) in MeOH (20.0 mL) was 
added Palladium on activated charcoal (0.2 g), and the suspension was stirred for 
20 h at room temperature under a hydrogen atmosphere and filtered through a 
thin pad of celite©. After addition of 1 M HCl (20.0 mL, 20 mmol) to the filtrate, 
the mixture was evaporated under reduced pressure. The residue was crystallised 
by trituration in diethylether to give the product as a colourless powder (2.9 g, 19 
mmol, 96%); [ߙ]஽ଶ଻ (c = 1, MeOH) -9.2; δH (400 MHz, D2O) 3.97 (1H, dd, J 
11.5, 6.5, CHCONH), 3.40 (2H, td, J 4.0, 6.0, CH2NH), 2.32 (1H, m, CHCHH), 
2.01 (1H, m, CHCH2CHH), 1.81–1.97 (2H, m, CHCHHCHH); δC (100 MHz, 
D2O) 171.6 (CO), 52.3 (CH), 44.0 (CH2NH), 27.6 (CHCH2), 22.7 (CHCH2CH2); 
m/z (C5H11N2O ([M + H]+) requires 115.0866) found 115.0867. This data is 
consistent with that previously reported.340 
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(S)-3-(Dimethylundecanoylamino)tetrahydropyridin-2-one (2.163) 
 
Acylation was carried out according to General Method E using 2.162 (0.2 g, 1 
mmol), 2.154 (0.2 g, 1 mmol) and 2 mL of H2O and dichloromethane. The 
residue was purified by hydrogenation and silica column chromatography 
(eluent; EtOAc:Petroleum Ether 40-60 (2:8) to EtOAc:Petroleum Ether 40-60  
(1:1)) to give a clear viscous liquid (50 mg, 0.16 mmol, 16%); υmax (cm-1) 3321 
(CONH), 2922, 2853 (CH2, CH3), 1637 (CONH lactam), 1523, 1491 (NH), 1360 
(C(CH3)2) and 1331 (CH3); δH (400 MHz, CDCl3) 6.65 (1H, d, J 5.0, NHCH), 
6.59 (1H, br s, NHCH2), 4.16 (1H, dt, J 11.5, 5.5, NHCH), 3.30 (2H, td, J 6.5, 
2.5 NHCH2), 2.53 (1H, tdd, J 13.0, 6.0, 4.5, CHCHH), 1.92-1.82 (2H, m, 
CHCH2CH2), 1.54-1.37 (3H, m, CH2C(CH3)2 & CHCHH), 1.30-1.16 (14H, m, 
CH3(CH2)7), 1.14 (3H, s, CH2C(CH3)2), 1.13 (3H, s, CH2C(CH3)2) and 0.84 (3H, 
t, J 7.0, CH3CH2); δC (100 MHz, CDCl3) 178.1 (CONHCH), 172.2 (CONHCH2), 
50.5 (CONHCH), 42.0 (C(CH3)2), 41.4, 41.3 (CH2C(CH3)2 & NHCH2), 31.8, 
30.8 (CH3CH2CH2CH2CH2CH2CH2), 29.50, 29.47, 29.2 
(CH3CH2CH2CH2CH2CH2), 26.9 (CHCH2), 25.25 (C(CH3)2), 25.20 (C(CH3)2), 
24.7 (CH2CH2C(CH3)2), 22.6 (CH3CH2), 20.9 (CHCH2CH2) and 14.0 (CH3CH2); 
m/z (C18H35N2O2 (M + H+) requires 311.2693) found 311.2692. This compound 
has not previously been reported. 
 
(S)-3-(Dimethyldecanoylamino)tetrahydropyridin-2-one (2.164) 
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Acylation was carried out according to General Method E using 2.162 (0.2 g, 1 
mmol), 2.155 (0.2 g, 1 mmol) and 2 mL of H2O and dichloromethane. The 
residue was purified by hydrogenation and silica column chromatography 
(eluent; EtOAc to EtOAc:MeOH (9:1)) to give a clear viscous liquid (91 mg, 
0.31 mmol, 31%); υmax (cm-1) 3302 (CONH), 2923, 2854 (CH2, CH3), 1637 
(CONH lactam), 1524, 1491 (NH), 1360 (C(CH3)2) and 1330 (CH3); δH (400 
MHz, CDCl3) 6.82 (1H, br s, NHCH2), 6.65 (1H, d, J 5.0, NHCH), 4.13 (1H, dt, 
J 11.5, 5.5, NHCH), 3.33-3.21 (2H, m, NHCH2), 2.55-2.43 (1H, m, CHCHH), 
1.90-1.78 (2H, m, CHCH2CH2), 1.55-1.35 (3H, m, CH2C(CH3)2 & CHCHH), 
1.26-1.14 (12H, m, CH3(CH2)6), 1.12 (3H, s, CH2C(CH3)2), 1.11 (3H, s, 
CH2C(CH3)2) and 0.81 (3H, t, J 6.5, CH3CH2); δC (100 MHz, CDCl3) 178.0 
(CONHCH), 172.2 (CONHCH2), 50.4 (CONHCH), 42.0 (C(CH3)2), 41.34, 41.26 
(CH2C(CH3)2 & NHCH2), 31.7, 30.8 (CH3CH2CH2CH2CH2CH2), 29.4, 29.1 
(CH3CH2CH2CH2CH2), 26.8 (CHCH2), 25.2 (C(CH3)2), 25.1 (C(CH3)2), 24.6 
(CH2CH2C(CH3)2), 22.5 (CH3CH2), 20.9 (CHCH2CH2) and 14.0 (CH3CH2); m/z 
(C17H33N2O2 (M + H+) requires 297.2537) found 297.2532. This compound has 
not previously been reported. 
 
(S)-3-(Dimethylnonanoylamino)tetrahydropyridin-2-one (2.165) 
 
Acylation was carried out according to General Method E using 2.162 (0.2 g, 1 
mmol), 2.156 (0.2 g, 1 mmol) and 2 mL of H2O and dichloromethane. The 
residue was purified by hydrogenation and silica column chromatography 
(eluent; EtOAc to EtOAc:MeOH (9:1)) to give a clear viscous liquid (47 mg, 
0.16 mmol, 17%); υmax (cm-1) 3302 (CONH), 2924 (CH2, CH3), 1637 (CONH 
lactam), 1525, 1491 (NH), 1361 (C(CH3)2) and 1331 (CH3); δH (400 MHz, 
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CDCl3) 6.64 (1H, d, J 5.0, NHCH), 6.48 (1H, br s, NHCH2), 4.17 (1H, dt, J 11.5, 
5.5, NHCH), 3.31 (2H, td, J 6.5, 2.5 NHCH2), 2.55 (1H, tdd, J 13.0, 6.0, 4.5, 
CHCHH), 1.94-1.84 (2H, m, CHCH2CH2), 1.55-1.41 (3H, m, CH2C(CH3)2 & 
CHCHH), 1.31-1.18 (10H, m, CH3(CH2)5), 1.15 (3H, s, CH2C(CH3)2), 1.14 (3H, 
s, CH2C(CH3)2) and 0.84 (3H, t, J 7.0, CH3CH2); δC (100 MHz, CDCl3) 178.2 
(CONHCH), 172.2 (CONHCH2), 50.5 (CONHCH), 42.1 (C(CH3)2), 41.5, 41.3 
(CH2C(CH3)2 & NHCH2), 31.8, 30.1 (CH3CH2CH2CH2CH2), 29.1 
(CH3CH2CH2CH2), 26.9 (CHCH2), 25.26 (C(CH3)2), 25.22 (C(CH3)2), 24.7 
(CH2CH2C(CH3)2), 22.6 (CH3CH2), 20.9 (CHCH2CH2) and 14.0 (CH3CH2); m/z 
(C16H30N2NaO2 (M + Na+) requires 305.2199) found 305.2196. This compound 
has not previously been reported. 
 
(S)-3-(Dimethyloctanoylamino)tetrahydropyridin-2-one (2.166) 
 
Acylation was carried out according to General Method E using 2.162 (0.2 g, 1 
mmol), 2.157 (0.2 g, 1 mmol) and 2 mL of H2O and dichloromethane. The 
residue was purified by hydrogenation and silica column chromatography 
(eluent; EtOAc to EtOAc:MeOH (9:1)) to give a clear viscous liquid (37 mg, 
0.14 mmol, 14%); υmax (cm-1) 3311 (CONH), 2927 (CH2, CH3), 1636 (CONH 
lactam), 1525, 1491 (NH), 1360 (C(CH3)2) and 1331 (CH3); δH (400 MHz, 
CDCl3) 6.63 (1H, d, J 5.0, NHCH), 6.47 (1H, br s, NHCH2), 4.17 (1H, dt, J 11.5, 
5.5, NHCH), 3.31 (2H, td, J 6.5, 2.5 NHCH2), 2.55 (1H, tdd, J 13.0, 6.0, 4.5, 
CHCHH), 1.94-1.84 (2H, m, CHCH2CH2), 1.55-1.40 (3H, m, CH2C(CH3)2 & 
CHCHH), 1.29-1.18 (8H, m, CH3(CH2)4), 1.15 (3H, s, CH2C(CH3)2), 1.14 (3H, s, 
CH2C(CH3)2) and 0.84 (3H, t, J 6.5, CH3CH2); δC (100 MHz, CDCl3) 178.2 
(CONHCH), 172.2 (CONHCH2), 50.5 (CONHCH), 42.1 (C(CH3)2), 41.5, 41.3 
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(CH2C(CH3)2 & NHCH2), 31.7 (CH3CH2CH2), 29.7 (CH3CH2CH2CH2), 26.9 
(CHCH2), 25.26 (C(CH3)2), 25.21 (C(CH3)2), 24.6 (CH2CH2C(CH3)2), 22.5 
(CH3CH2), 20.9 (CHCH2CH2) and 14.0 (CH3CH2); m/z (C15H28N2NaO2 (M + 
Na+) requires 291.2043) found 291.2043. This compound has not previously 
been reported. 
 
(S)-3-(Dimethylheptanoylamino)tetrahydropyridin-2-one (2.167) 
 
Acylation was carried out according to General Method E using 2.162 (0.2 g, 1 
mmol), 2.158 (0.2 g, 1 mmol) and 2 mL of H2O and dichloromethane. The 
residue was purified by hydrogenation and silica column chromatography 
(eluent; EtOAc to EtOAc:MeOH (9:1)) to give a clear viscous liquid (105 mg, 
0.41 mmol, 41%); υmax (cm-1) 3321 (CONH), 2930 (CH2, CH3), 1636 (CONH 
lactam), 1524, 1491 (NH), 1360 (C(CH3)2) and 1330 (CH3); δH (400 MHz, 
CDCl3) 6.87 (1H, br s, NHCH2), 6.66 (1H, d, J 5.0, NHCH), 4.12 (1H, dt, J 11.5, 
5.5, NHCH), 3.31-3.21 (2H, m, NHCH2), 2.52-2.41 (1H, m, CHCHH), 1.89-1.78 
(2H, m, CHCH2CH2), 1.53-1.36 (3H, m, CH2C(CH3)2 & CHCHH), 1.28-1.13 
(6H, m, CH3(CH2)3), 1.11 (3H, s, CH2C(CH3)2), 1.10 (3H, s, CH2C(CH3)2) and 
0.79 (3H, t, J 7.0, CH3CH2); δC (100 MHz, CDCl3) 178.0 (CONHCH), 172.2 
(CONHCH2), 50.3 (CONHCH), 41.9 (C(CH3)2), 41.3, 41.2 (CH2C(CH3)2 & 
NHCH2), 32.2 (CH3CH2CH2), 26.8 (CHCH2), 25.18 (C(CH3)2), 25.11 (C(CH3)2), 
24.2 (CH2CH2C(CH3)2), 22.4 (CH3CH2), 20.9 (CHCH2CH2) and 13.9 (CH3CH2); 
m/z (C14H26N2NaO2 (M + Na+) requires 277.1886) found 277.1888. This 
compound has not previously been reported. 
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(S)-3-(Dimethylhexanoylamino)tetrahydropyridin-2-one (2.168) 
 
Acylation was carried out according to General Method E using 2.162 (0.2 g, 1 
mmol), 2.159 (0.2 g, 1 mmol) and 2 mL of H2O and dichloromethane. The 
residue was purified by hydrogenation and silica column chromatography 
(eluent; EtOAc to EtOAc:MeOH (9:1)) to give a clear viscous liquid (83 mg, 
0.34 mmol, 34%); υmax (cm-1) 3305 (CONH), 2930, 2860 (CH2, CH3), 1636 
(CONH lactam), 1524, 1491 (NH), 1359 (C(CH3)2) and 1330 (CH3); δH (400 
MHz, CDCl3) 6.72 (1H, br s, NHCH2), 6.65 (1H, d, J 5.0, NHCH), 4.19-4.10 
(1H, m, NHCH), 3.32-3.25 (2H, m, NHCH2), 2.56-2.46 (1H, m, CHCHH), 1.91-
1.81 (2H, m, CHCH2CH2), 1.54-1.38 (3H, m, CH2C(CH3)2 & CHCHH), 1.30-
1.14 (4H, m, CH3CH2CH2), 1.13 (3H, s, CH2C(CH3)2), 1.12 (3H, s, CH2C(CH3)2) 
and 0.85-0.80 (3H, m, CH3CH2); δC (100 MHz, CDCl3) 178.1 (CONHCH), 172.2 
(CONHCH2), 50.4 (CONHCH), 42.0 (C(CH3)2), 41.4, 41.0 (CH2C(CH3)2 & 
NHCH2), 26.9 (CH3CH2CH2), 26.8 (CHCH2), 25.23 (C(CH3)2), 25.16 (C(CH3)2), 
23.1 (CH3CH2), 20.9 (CHCH2CH2) and 13.9 (CH3CH2); m/z (C13H24N2NaO2 (M 
+ Na+) requires 263.1730) found 263.1731. This compound has not previously 
been reported. 
 
(S)-3-(Dimethylpentanoylamino)tetrahydropyridin-2-one (2.169) 
 
Acylation was carried out according to General Method E using 2.162 (100 mg, 
0.65 mmol), 2.160 (97 mg, 0.65 mmol) and 2 mL of H2O and dichloromethane. 
The residue was purified by silica column chromatography (eluent; EtOAc to 
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EtOAc:MeOH (9:1)) to give a white crystalline solid (10 mg, 0.04 mmol, 7%); 
m.p.: 105-106 oC; υmax (cm-1) 3342 (CONH), 2960, 2905 (CH2, CH3), 1641 
(CONH lactam), 1580, 1499 (NH), 1333 (C(CH3)2); δH (400 MHz, CDCl3) 6.60 
(1H, d, J 5.0, NHCH), 5.82 (1H, br s, NHCH2), 4.21 (1H, dt, J 11.5, 5.5, NHCH), 
3.37-3.32 (2H, m, NHCH2), 2.66-2.57 (1H, m, CHCHH), 1.99-1.88 (2H, m, 
CHCH2CH2), 1.56-1.43 (3H, m, CH2C(CH3)2 & CHCHH), 1.34-1.20 (2H, m, 
CH3CH2), 1.18 (3H, s, CH2C(CH3)2), 1.17 (3H, s, CH2C(CH3)2) and 0.89 (3H, t, 
J 7.0, CH3CH2); δC (100 MHz, CDCl3) 178.1 (CONHCH), 172.2 (CONHCH2), 
50.7 (CONHCH), 42.4 (C(CH3)2), 41.7, 41.5 (CH2C(CH3)2 & NHCH2), 26.9 
(CHCH2), 25.3 (C(CH3)2), 25.2 (C(CH3)2), 20.8 (CHCH2CH2), 17.2 (CH3CH2) 
and 14.0 (CH3CH2); m/z (C12H22N2NaO2 (M + Na+) requires 249.1579) found 
249.1581. This compound has not previously been reported. 
 
(S)-3-(Dimethylbutanoylamino)tetrahydropyridin-2-one (2.170) 
 
Acylation was carried out according to General Method E using 2.162 (1.5 g, 1 
mmol), 2.160 (1.3 g, 1 mmol) and 10 mL of H2O and dichloromethane. The 
residue was purified by silica column chromatography (eluent; EtOAc to 
EtOAc:MeOH (9:1)) to give a viscous liquid with impurities. The compound was 
purified further by silica column chromatography (eluent; EtOAc:MeOH (99:1)) 
to give a white solid (12 mg, 0.06 mmol, 0.6%); m.p.: 108-109 oC; υmax (cm-1) 
3372 (CONH), 2901, 2899 (CH2, CH3), 1639 (CONH lactam), 1564, 1484 (NH), 
1302 (C(CH3)2); δH (400 MHz, CDCl3) 6.78 (1H, br s, NHCH2), 6.65 (1H, d, J 
5.0, NHCH), 4.14 (1H, dt, J 11.5, 5.5, NHCH), 3.27 (2H, td, J 6.5, 2.5 NHCH2), 
2.49 (1H, tdd, J 13.0, 6.0, 4.5, CHCHH), 1.89-1.80 (2H, m, CHCH2CH2), 1.56-
1.41 (3H, m, CH3CH2 & CHCHH), 1.11 (3H, s, CH2C(CH3)2), 1.10 (3H, s, 
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CH2C(CH3)2) and 0.78 (3H, t, J 7.5, CH3CH2); δC (100 MHz, CDCl3) 177.9 
(CONHCH), 172.1 (CONHCH2), 50.3 (CONHCH), 42.3 (C(CH3)2), 41.3 
(NHCH2), 33.8 (CH3CH2), 26.9 (CHCH2), 24.8 (C(CH3)2), 24.6 (C(CH3)2), 20.9 
(CHCH2CH2) and 9.0 (CH3CH2); m/z (C11H20N2NaO2 (M + Na+) requires 
235.1417) found 235.1418. This compound has not previously been reported. 
 
5.3 Chapter 3 Experimental 
4-Methyl-4-nitropentanal (3.51) 
 
To a solution of 2-nitropropane (3.49, 20.0 mL, 0.22 mol) in acetonitrile (100 
mL) at 0 oC was added freshly distilled acrolein (3.50, 24.0 mL, 0.36 mol) 
followed by the dropwise addition of triethylamine (2.0 mL). The reaction was 
stirred at room temperature for three days. The mixture was concentrated in 
vacuo to give a crude viscous yellow oil which was used without further 
purification (32 g, > 99%); υmax (cm-1) 2922, 2851 (CH2, CH3),  2831, 2720 
(CHO), 1728 (CO), 1523 (CNO2), 1360 (C(CH3)2) and 1349 (NO2); δH (400 
MHz, CDCl3) 9.78 (1H, s, CHO), 2.51 (2H, t, J  8.0, CH2CHO), 2.24 (2H, t, J 
8.0, CH2CH2CHO) and 1.60 (6H, s, C(CH3)2); δC (100 MHz, CDCl3) 199.9 
(CHO), 86.9 (CNO2), 38.1 (CH2CHO), 31.7 (CH2CH2CHO) and 25.1 (C(CH3)2); 
m/z (C6H12NO3 (M + H+) requires 146.0812) found 146.0814. This data is 
consistent with that previously reported.274 
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General Method J: Trichlorocarbinol synthesis from its aldehyde 
1,1,1-Trichloro-5-methyl-5-nitrohexan-2-ol (3.52) 
 
To a stirred solution of 3.51 (35.0 g, 0.24 mol) and trichloroacetic acid (59.0 g, 
0.36 mol) in DMF (240 mL) at 0 oC was added sodium trichloroacetate (67.0 g, 
0.36 mol) portion wise with stirring. The reaction mixture was brought to room 
temperature and left stirring overnight during which time the reaction mixture 
slightly solidified and a distinct colour change from orange to dark brown was 
observed. After 18 h 1H-NMR showed complete consumption of 3.51. The 
reaction mixture was cooled to 0 oC and quenched with H2O and extracted with 
EtOAc:Hexane (4:6). The combined organic extracts were washed with H2O:sat. 
NH4Cl (1:1), dried over sodium sulfate, filtered and concentrated in vacuo to 
give a viscous brown oil. The residue was purified by silica column 
chromatography (eluent; Petroleum Ether 40-60:EtOAc (9:1) to EtOAc) to give a 
light yellow oil (48.0 g, 0.18 mol, 76%); υmax (cm-1) 3279 (OH), 3067, 2993, 
2943 (CH2, CH3), 1554, 1536 (CNO2), 1485 (NO2), 1371 (C(CH3)2), 1353 
(CNO2), 1254, 1136, 1102 (CO), 719 (CH2); δH (400 MHz, CDCl3) 3.97 (1H, 
ddd, J 10.0, 5.0, 1.5, CHOH), 3.30 (1H, br s, OH), 2.27 (1H, ddd, J 13.5, 12.0, 
5.0, CHHCH2CH), 2.12-1.95 (2H, m, CHHCHOH & CHHCH2CH), 1.68-1.63 
(1H, m, CHHCHOH), 1.62 (3H, s, C(CH3)2) and 1.61 (3H, s, C(CH3)2); δC (100 
MHz, CDCl3) 103.5 (CCl3), 87.7 (CNO2), 82.6 (CH), 37.1 (CH2CH2CH), 26.5 
(C(CH3)2), 26.4 (CH2CHOH) and 25.3 (C(CH3)2); m/z (C7H11NNaO3 ([M – HCl3 
+ Na]+) requires 180.0631) found 180.0636. This compound has not previously 
been reported. 
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General Method K: α-Azido acid synthesis from its trichlorocarbinol 
2-Azido-5-methyl-5-nitrohexanoic acid (3.53) 
 
Trichlorocarbinol 3.52 (0.6 g, 2.3 mmol) was dissolved in 1,2-dimethoxyethane 
(4 mL) and cooled to 0 oC. Sodium azide (0.3 g, 4.6 mmol) was carefully added 
to a cooled solution of sodium hydroxide (0.36 g, 9 mmol) in H2O (18 mL). Both 
cold solutions were combined slowly behind a blast shield and after 1 hr was 
brought to room temperature and left stirring vigorously until the reaction was 
deemed complete by TLC analysis (18 h). The solution was quenched with 
diethyl ether and extracted with 5% aq. NaOH solution. The aqueous layers were 
combined, acidified to pH 2 with 1M HCl, extracted with ethyl acetate, and the 
combined organic layers dried over sodium sulfate, filtered and concentrated in 
vacuo to give an orange crystalline product (0.5 g, 2.1 mol, 92%); υmax (cm-1) 
3064, 2940 (CH2, CH3), 2871 (OH), 2144 (N3), 1723 (COOH), 1558, 1536 
(CNO2), 1487 (NO2), 1368 (C(CH3)2), 1352 (CNO2), 1249, 1135 (CO), 718 
(CH2); δH (400 MHz, CDCl3) 8.58 (1H, br s, COOH), 3.99 (1H, dd, J 8.0, 5.0, 
CHN3), 2.05 (2H, t, J 8.5, CH2CH2CHN3), 1.92-1.69 (2H, m, CH2CHN3), 1.61 
(3H, s, C(CH3)2) and 1.60 (3H, s, C(CH3)2); δC (100 MHz, CDCl3) 174.7 
(COOH), 87.4 (CNO2), 61.2 (CHN3), 36.4 (CH2CHN3), 26.1 (CH2CH2CH), 26.0 
(C(CH3)2) and 25.6 (C(CH3)2); m/z (C7H12N4NaO4 (M + Na+) requires 239.0751) 
found 239.0753. This compound has not previously been reported. 
 
Methyl 2-azido-5-methyl-5-nitrohexanoate (3.59) 
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Acetyl chloride (0.1 mL, 1.1 mmol) was added dropwise to an ice cold solution 
of 3.53 (0.2 g, 1 mmol) in ethyl acetate (5 mL) and MeOH (0.2 mL) under 
nitrogen. After 2 h the reaction mixture was allowed to warm to room 
temperature and the mixture concentrated in vacuo to give an orange crystalline 
product (0.2 g, 0.8 mmol, 82%); υmax (cm-1) 3062, 2938 (CH2, CH3), 2144 (N3), 
1715 (CO), 1559, 1540 (CNO2), 1472 (NO2), 1368 (C(CH3)2), 1351 (CNO2), 
1239, 1134 (CO), 718 (CH2); δH (400 MHz, CDCl3) 3.95 (1H, dd, J 8.0, 5.0, 
CHN3), 3.66 (3H, s, COOCH3), 2.11 (2H, t, J 9.0, CH2CH2CHN3), 1.89-1.67 
(2H, m, CH2CHN3), 1.68 (3H, s, C(CH3)2) and 1.61 (3H, s, C(CH3)2); δC (100 
MHz, CDCl3) 171.0 (COOH), 87.5 (CNO2), 63.5 (CHN3), 51.5 (OCH3), 34.6 
(CH2CHN3), 26.8 (CH2CH2CH), 25.8 (C(CH3)2) and 25.1 (C(CH3)2); m/z 
(C8H14N4NaO4 (M + Na+) requires 253.0913) found 253.0916. This compound 
has not previously been reported. 
 
1,1,1-trichloropentan-2-ol (3.62) 
 
Trichloroalconation was carried out according to General Method J using 
butyraldehyde (1.0 g, 14 mmol) to give a viscous orange oil. The residue was 
purified by silica column chromatography (eluent; Petroleum Ether 40-60:EtOAc 
(1:1) to EtOAc) to give a colourless oil (2.0 g, 10 mol, 72%); υmax (cm-1) 3595 
(OH), 3058, 2951, 1423, 1390 (CH2, CH3); δH (400 MHz, CDCl3) 3.95 (1H, dd, J 
9.5, 2.0 CHOH), 3.67 (1H, br s, OH), 1.95-1.86 (1H, m, CHHCH), 1.67-1.52 
(2H, m, CHHCHHCH), 1.45-1.36 (1H, m, CHHCH2CH) and 0.93 (3H, t, J 7.5, 
CH3CH2); δC (100 MHz, CDCl3) 104.4 (CCl3), 82.5 (CHOH), 33.5 (CH2CH), 
19.2 (CH2CH2CH) and 13.6 (CH3). This data is consistent with that previously 
reported.341  
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2-Azidopentanoic acid (3.63) 
 
The α-azido acid 3.63 was generated by General Method K using 3.62 (1.9 g, 
10 mmol) to give a viscous oil which was used without further purification (1.1 
g, 7.6 mol, 77%); υmax (cm-1) 2953, 2928, (CH2, CH3) 2870 (COOH), 2144 (N3), 
1712 (CO), 1571 (COO), 1414, 1376 (CH2, CH3); δH (400 MHz, CDCl3) 10.10 
(1H, br s, COOH), 3.87 (1H, dd, J 8.5, 5.5, CHN3), 1.91-1.71 (2H, m, 
CH2CHN3), 1.57-1.38 (2H, m, CH3CH2) and 0.96 (3H, t, J 7.5 CH3); δC (100 
MHz, CDCl3) 176.3 (COOH), 61.5 (CHN3), 33.2 (CH2CHN3), 19.0 (CH3CH2) 
and 13.4 (CH3); m/z 143.1 (M + Na+). This data is consistent with that previously 
reported.342 
 
2-Aminopentanoic acid (3.64) 
 
To a solution of 3.63 (0.43 g, 3 mmol) in the minimum amount of MeOH was 
added Palladium on carbon (5 mol %) and stirred at room temperature under an 
atmosphere of hydrogen. After the reaction was deemed complete, by TLC 
analysis, the mixture was filtered through a thin pad of celite©, and washed 
successively with MeOH. The extracts were concentrated in vacuo to give a 
white crystalline product (0.26 g, 2.2 mol, 74%); m.p.: > 250 oC; υmax (cm-1) 
3248 (NH2), 2955, 2931, (CH2, CH3) 2871 (COOH), 1719 (CO), 1573 (COO), 
1416, 1380, 1324 (CH2, CH3); δH (400 MHz, D2O) 3.80-3.72 (1H, m, CHNH2), 
1.67-1.52 (2H, m, CH2CH), 1.48-1.28 (2H, m, CH3CH2) and 0.99-0.88 (3H, m, 
CH3); δC (100 MHz, CDCl3) 174.7 (COOH), 54.6 (CHNH2), 32.5 (CH2CH), 17.8 
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(CH3CH2) and 12.9 (CH3); m/z 166.1 (M + Na+) and 144.1 (M + H+). This data is 
consistent with that previously reported.343 
 
4-Methyl-4-nitropentan-1-ol (3.66) 
 
To a solution of 3.51 (31 g, 0.21 mol) in EtOH (100 mL) cooled to 0 oC and 
under N2 was added sodium borohydride (12 g, 0.31 mol) portion wise while 
maintaining the temperature at 0 oC. After stirring at room temperature for 20 
hrs, 1H-NMR indicated complete consumption of 3.51. The reaction mixture was 
cooled to 0 oC and carefully quenched with 10% aq. HCl (300 mL). The 
quenched mixture was extracted with dichloromethane and the combined organic 
extracts were washed with H2O, dried over sodium sulfate, filtered and 
concentrated in vacuo to give an off white viscous oil (31 g, 0.21 mol, > 99%); 
υmax (cm-1) 3366 (OH), 2941, 2874 (CH2, CH3), 1532, 1472 (CNO2), 1398, 1373 
(C(CH3)2), 1347 (CNO2), 1268, 1139, 1050 (CO), 855 (CH), 735 (CH2); δH (400 
MHz, CDCl3) 3.70-3.07 (3H, m, CH2OH), 1.87-1.69 (2H, m, CH2CH2CH2OH), 
1.43 (3H, s, CCH3CH3), 1.41 (3H, s, CCH3CH3) and 1.36-1.38 (2H, m, 
CH2CH2CH2OH); δC (100 MHz, CDCl3) 87.6 (CNO2), 61.2 (CH2OH), 36.8 
(CH2CH2CH2OH), 26.8 (CH2CH2OH) and 25.2 (C(CH3)2); m/z (C12H29N2O2 ([(2 
× M) – H2 + Na]+) requires 315.1527) found 315.1527. This compound is known 
but has previously only been reported with 1H NMR and IR data, which is 
consistent with that reported here.344 
 
4-Amino-4-methylpentan-1-ol (3.67) 
 
181 
 
To a solution of 3.66 (1.0 g, 6.8 mmol) in MeOH (22.6 mL) stirred vigourously 
at 0 oC was added 6M HCl (11.3 mL, 68 mmol) followed by the cautious portion 
wise addition of Zn dust (8.9 g, 136 mmol). After 2 h stirring at room 
temperature, TLC analysis indicated the absence of the starting material and a 
sat. sol. of NaHCO3 was added slowly (effervescence) until the pH of the 
reaction mixture was ~7. 1M NaOH was then added until the pH of the reaction 
mixture was ~12. The resulting aqueous mixture was extracted with 
dichloromethane (3 × 50 mL) and the organics combined, washed with sat. NaCl, 
dried over sodium sulfate, filtered and concentrated in vacuo to give a viscous 
clear oil which required no further purification (0.8 g, 6.7 mol, 99%); υmax (cm-1) 
3334 (OH, NH), 3032, 2936 (CH2, CH3), 2873 (CNH2), 1697, 1586, 1509 (NH2), 
1453 (CH), 1388, 1365 (C(CH3)2), 1261, 1213 (CO), 1065 (COH), 736 (CH2); δH 
(400 MHz, CDCl3) 3.51 (2H, t, J 5.5, CH2OH), 2.75 (1H, br s, OH), 1.62-1.50 
(2H, m, CH2CH2CH2OH), 1.46-1.37 (2H, m, CH2CH2CH2OH) and 1.08 (6H, s, 
C(CH3)2); δC (100 MHz, CDCl3) 62.2 (CH2OH), 48.5 (C(CH3)2), 41.5 
(CH2CH2CH2OH), 30.1 (C(CH3)2) and 27.5 (CH2CH2OH); m/z (C12H29N2O2 ([(2 
× M) – H]+) requires 233.2224) found 233.2224; 118.3 (M + H+). This compound 
is known but has previously only been reported with 1H NMR.345 
 
4-Methyl-4-tert-butyloxycarbonylamino-pentan-1-ol (3.67-Boc) 
 
To a solution of 3.67 (0.12 g, 1 mmol) in acetonitrile (1 mL) at 0 oC was added 
di-tert-butyl dicarbonate (0.25 g, 1.1 mmol). The mixture was allowed to stir for 
10 minutes then triethylamine (0.2 mL) was added dropwise and the reaction 
mixture was allowed to stir at room temperature overnight. The resulting mixture 
was concentrated in vacuo and the residues purified by silica column 
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chromatography (eluent; Petroleum Ether 40-60:EtOAc (7.5:2.5) to EtOAc) to 
give a white solid (123 mg, 0.6 mmol, 55%); υmax (cm-1) 3346 (OH, NH2), 2972, 
2932 (CH2, CH3), 2871 (CNH), 1687 (CO), 1500 (CNH), 1473, 1452 (CH), 
1389, 1364 (C(CH3)2, C(CH3)3), 1274, 1252 (CO), 1165 (COH) 1051 (CO), 781, 
734 (CH2); δH (400 MHz, CDCl3) 4.53 (1H, br s, NH), 3.57 (2H, t, J 6.5, 
CH2OH), 2.49 (1H, br s, OH), 1.69-1.59 (2H, m, CH2CH2CH2OH), 1.54-1.45 
(2H, m, CH2CH2CH2OH), 1.37 (9H, s, C(CH3)3) and 1.20 (6H, s, CH2C(CH3)2); 
δC (100 MHz, CDCl3) 154.7 (CO), 78.7 (C(CH3)3), 62.8 (CH2OH), 52.2 
(C(CH3)2), 36.4 (CH2CH2CH2OH), 28.5 (COOC(CH3)3), 27.4 (CH2CH2OH) and 
27.3 (CH2C(CH3)2); m/z (C11H23NNaO3 (M + Na+) requires 240.1570) found 
240.1571. This compound is known but has previously only been reported with 
1H NMR, which is consistent with that reported here.346 
 
4-Carboxybenzylamino-4-methylpentan-1-ol (3.68) 
 
To a solution of 3.66 (1.0 g, 6.8 mmol) in MeOH (22.6 mL) stirred vigourously 
at 0 oC was added 6M HCl (11.3 mL) followed by the cautious portion wise 
addition of Zn dust (8.9 g, 136 mmol). After 2 h stirring at room temperature, 
TLC analysis indicated the absence of the starting material and a sat. sol. of 
NaHCO3 was added slowly (effervescence) until the pH of the reaction mixture 
was ~7. 1M NaOH was then added until the pH of the reaction mixture was ~12. 
The basic mixture was filtered to remove the solids and benzyl chloroformate (1 
mL) added and allowed to stir overnight. The resulting aqueous mixture was 
extracted with dichloromethane and the organics combined, washed with sat. 
NaCl, dried over sodium sulfate, filtered and concentrated in vacuo. The residues 
were purified by silica column chromatography (eluent; Hexane:EtOAc (4:1) to 
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Hexane:EtOAc (1:1)) to give a colourless oil (0.46 g, 1.8 mmol, 27%); υmax (cm-
1) 3340 (OH), 3033, 2964, 2871 (CH2, CH3, OH), 1692 (CO), 1509, 1498 (CNH, 
Ph), 1454 (OH), 1399, 1344 (C(CH3)2), 1256, 1213 (CO), 1068, 1028 (COH), 
773, 736, 696 (Ph); δH (400 MHz, CDCl3) 7.39-7.28 (5H, m, Ph), 5.05 (2H, s, 
CH2Ph), 5.00 (1H, br s, NH), 3.61 (2H, t, J 6.5, CH2OH), 2.63 (1H, br s, OH), 
1.78-1.66 (2H, m, CH2CH2CH2OH), 1.60-1.50 (CH2CH2CH2OH) and 1.31 (6H, 
s, CH2C(CH3)2); δC (100 MHz, CDCl3) 154.6 (CO), 136.6 (i-Ph), 128.3 (Ph), 
127.8 (Ph), 65.8 (CH2Ph), 62.7 (CH2OH), 52.4 (C(CH3)2), 36.4 
(CH2CH2CH2OH), 27.1 (CH2CH2OH) and 26.9 (C(CH3)2); m/z (C14H21NNaO3 
(M + Na+) requires 274.1414) found 274.1414. This compound is known but has 
previously only been reported with 1H NMR, which is consistent with that 
reported here.347 
 
4-Carbobenzyloxyamino-4-methylpentan-1-al (3.69) 
 
Method I - Swern oxidation 
To a vacuum dried round bottom flask with a magnetic stirrer, purged with 
nitrogen, was added dry dichloromethane (10 mL) and a freshly opened vial of 
DMSO-d6 (0.7 mL, 10 mmol). The mixture was cooled to −78 oC and oxalyl 
chloride (0.4 mL, 5 mmol) was added slowly to the mixture and stirred for 15 
minutes before 3.68 (0.3 g, 1 mmol) in the minimum amount of dry 
dichloromethane was added to the reaction mixture. After 45 minutes, NEt3 (1.4 
mL, 10 mmol) was added and the reaction mixture was left stirring at room 
temperature overnight. The mixture was quenched with pH2 buffer and extracted 
with EtOAc, dried over sodium sulfate, filtered and concentrated in vacuo to give 
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colourless oil which was used without further purification (32 mg, 0.13 mmol, 
13%). 
Method II – Dess-Martin Periodinane (DMP) 
To a solution of 3.68 (0.4 g, 1.6 mmol) in dichloromethane (7 mL) under 
nitrogen was added freshly made DMP (1.2 g, 2.8 mmol) in dichloromethane (13 
mL) and allowed to stir overnight. The reaction mixture was quenched with Et2O 
(150 mL) and sodium sulphite (2.8 g) in sat. NaHCO3 (25 mL) was added to the 
mixture. The organics were separated, washed with sat. NaHCO3, H2O, dried 
over sodium sulfate, filtered and concentrated in vacuo to give a colourless oil 
which was used without further purification (0.4 g, 1.6, 99%); υmax (cm-1) 3340 
(CONH), 3033 (CH2) 2964 (CHO), 1692 (CO), 1498 (NH), 1454 (OH), 1399, 
1344 (C(CH3)2), 1068, 1028 (OH), 773, 736, 696 (Ph); δH (400 MHz, CDCl3) 
9.94-10.03 (1H, m, CHO), 7.39-7.27 (5H, m, Ph), 5.02 (2H, s, CH2Ph), 4.88 (1H, 
br s, NH), 2.35-2.21 (2H, m, CH2CHO), 1.86-1.63 (2H, m, CH2CH2CHO) and 
1.27 (6H, s, CH2C(CH3)2); δC (100 MHz, CDCl3) 192.2 (CHO), 155.2 (CO), 
134.3 (i-Ph), 129.6 (Ph), 128.8 (Ph), 128.3 (Ph), 69.5 (CH2Ph), 53.8 (C(CH3)2), 
45.7 (CH2CHO), 27.1 (C(CH3)2) and 23.6 (CH2CH2CHO); m/z (C14H19NNaO3 
([M – H2 + Na]+) requires 270.1101) found 270.1107. This compound has not 
previously been reported. 
 
5-Carbobenzyloxyamino-5-methyl-1,1,1-trichlorohexan-2-ol (3.70) 
 
Trichlorocarbinol synthesis was carried out according to General Method J 
using 3.69 (0.5 g, 2 mmol) in 2 mL of DMF. The residues were purified by silica 
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column chromatography (eluent; Hexane:EtOAc (9:1) to EtOAc) to give a 
colourless oil (86 mg, 0.2 mmol, 12%); υmax (cm-1) 3346 (OH, NH), 3032, 2966 
(CH2, CH3, OH), 1702 (CO), 1586, 1499 (CNH, Ph), 1454 (OH), 1398, 1348 
(C(CH3)2), 1252, 1213 (CO), 1063, 1028 (COH), 909, 824 (CCl3), 790, 736, 696 
(Ph); δH (400 MHz, CDCl3) 7.42-7.23 (5H, m, Ph), 5.15 (2H, s, CH2Ph), 4.65 
(1H, br s, NH), 4.18-4.08 (1H, m, CHOH), 1.82-1.72 (2H, m, CH2CH2CHOH), 
1.72-1.59 (2H, m, CH2CHOH) and 1.28 (6H, s, CH2C(CH3)2); δC (100 MHz, 
CDCl3) 155.1 (CO), 135.3 (i-Ph), 128.5 (Ph), 128.0 (Ph), 127.9 (p-Ph), 105.2 
(CCl3) 88.7 (CH), 68.3 (CH2Ph), 52.5 (C(CH3)2), 36.1 (CH2CH2CHOH), 27.1 
(C(CH3)2) and 23.6 (CH2CH2OH); m/z 386.1 ([M + NH4 + H]+), 408.1 ([M + 
NH3 + Na]+), 297.1 ([M – Cl2H2]−) and 265.0 ([M – Cl3]−). This compound has 
not previously been reported. 
 
2-Iodoxybenzoic acid (IBX) 
 
Method I - Potassium Bromate in Sulfuric Acid 
To a solution of 2-iodobenzoic acid (14.2 g, 57 mmol) in 1M H2SO4 (89 mL) 
was added potassium bromate (12.6 g, 76 mmol) portion wise over a period of 30 
minutes keeping the temperature below 55 oC with vigourous stirring. The 
mixture was warmed to 65 oC and left stirring overnight. The reaction mixture 
was cooled, filtered and washed with cold H2O (200 mL) and cold EtOH (2 × 10 
mL). After drying under vacuum for 2hrs, a white solid was collected (14.6 g, 52 
mmol, 91%).  
Method II – Oxone in water 
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To a solution oxone (80.5 g, 0.13 mol) in deionised H2O (325 mL, 0.4 M) was 
added 2-iodobenzoic acid (25.0 g, 0.1 mol) in one portion. The reaction mixture 
was warmed to 73 oC over 20 minutes and stirred at this temperature for 3 hrs. 
The suspension was then cooled and left at ~ 5 oC for 1.5 h with slow stirring. 
The mixture was filtered through a sinter and the solid repeatedly washed with 
H2O (6 × 100 mL) and acetone (2 × 100 mL). The white crystalline solid was left 
to dry in the fume hood for at least a day to give a white crystalline product (26.4 
g, 94.3 mmol, 94%); m.p.: 230-231 oC; δH (400 MHz, DMSO-d6) 8.18-8.01 (2H, 
m, Ph), 7.99-7.82 (2H, m, Ph); δC (100 MHz, DMSO-d6) 168.6 (CO), 147.2 (Ph), 
133.8 (Ph), 132.1 (Ph), 131.5 (Ph), 131.0 (Ph), 126.0 (Ph). This data is consistent 
with that previously reported.348 
 
Dess-Martin periodinane (DMP) 
 
An oven dried flask charged with IBX (14.6 g, 52 mmol) and AcOH (25 mL) 
was added Ac2O (50 mL). The flask was purged with nitrogen and heated under 
stirring to 85 oC (internal temperature) and maintained at this temperature until 
all solids were consumed (~25 minutes after reaching 85 oC, colour change from 
orange to clear yellow). The reaction mixture was allowed to cool to room 
temperature and stirred overnight. The mixture was filtered under vacuum and 
the solids washed with copius amounts of diethyl ether. The residues were 
collected and dried under vacuum to give a crystalline white solid (12.6 g, 30 
mmol, 57%); m.p.: 128-129 oC; δH (400 MHz, CDCl3) 8.23-8.18 (2H, m, Ph), 
8.12-8.03 (1H, m, Ph), 7.92-7.89 (1H, m, Ph), 2.32 (3H, s, CH3), 1.95 (6H, s, 2 × 
CH3); δC (100 MHz, CDCl3) 175.9 (CO), 174.2 (CO), 166.2 (CO), 142.4 (CO), 
187 
 
135.9 (Ph), 134.0 (Ph), 131.9 (Ph), 126.8 (Ph), 126.1 (Ph), 20.5 (CH3). This data 
is consistent with that previously reported.284,349 
 
2-Carbobenzyloxyaminoethan-1-ol (3.83a) 
 
To ethanolamine (14.8 mL, 0.25 mol) in H2O (150 mL) was simultaneously 
added dropwise benzyl chloroformate (35 mL, 0.25 mol) and 2M Na2CO3 (125 
mL) over a period of 2 h while maintaining the reaction temperature at less than 
8 oC. After complete addition, the reaction mixture was stirred at 0 oC for 1 hr. 
The mixture was extracted with EtOAc (2 × 150 mL) and the organics combined, 
washed with sat. aq. NaHCO3, sat. aq. NaCl, dried over sodium sulfate, filtered, 
and concentrated in vacuo to give an oil that crystallised on standing. The 
residues were washed with hexane, re-filtered and dried under vacuum to give a 
clean crystalline white solid (25.3 g, 0.13 mol, 53%); m.p.: 58-59 oC; υmax (cm-1) 
3315 (OH, CONH), 2940, 2886 (CH2), 1691 (CONH), 1541 (NH), 1452 (CH) 
1267, 1213 (CO, OH), 1150 (COH), 780, 744, 694 (Ph); δH (400 MHz, CDCl3) 
7.39-7.29 (5H, m, Ph), 5.28 (1H, br s, NH), 5.10 (2H, s, PhCH2), 3.69 (2H, t, J 
5.0, CH2OH), 3.33 (2H, t, J 5.0, NHCH2) and 2.39 (1H, br s, OH); δC (100 MHz, 
CDCl3) 157.0 (CO), 136.3 (i-Ph), 128.4 (Ph), 128.0 (Ph), 127.9 (p-Ph), 66.8 
(PhCH2), 61.8 (CH2OH), and 43.3 (NHCH2); m/z 196.1 (M + H+) and 218.1 (M + 
Na+). This data is consistent with that previously reported.350 
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3-Carbobenzyloxyaminopropan-1-ol (3.83b) 
 
To a solution of 3-aminopropan-1-ol (3 mL, 40 mmol) in 1 M NaOH (44 mL, 44 
mmol) with stirring at 0 oC was added benzyl chloroformate (6.3 mL, 44 mmol) 
dropwise over a period of 5 minutes and left stirring at 0 oC for 2 h. The mixture 
was then allowed to stir at room temperature for a further 1.5 h, whereupon 
dichloromethane (30 mL) was added and left stirring for 2 days. The 
dichloromethane was separated and the aqueous extracted further with 
dichloromethane (2 × 20 mL). The combined organics were concentrated in 
vacuo and crystallised on standing to give a white solid (8.5 g, 40 mmol, 99%); 
m.p.: 49-50 oC; υmax (cm-1) 3320 (OH, CONH), 2956, 2930, 2885, 2872 (CH2), 
1680 (CONH), 1530 (NH), 1462, 1453, 1443 (CH) 1325, 1267, 1213 (CO, OH), 
1142 (COH), 1022 (CO) 773, 749 (Ph), 724 (CH2), 697 (Ph); δH (400 MHz, 
CDCl3) 7.41-7.28 (5H, m, Ph), 5.11 (2H, s, PhCH2), 5.07 (1H, br s, NH), 3.67 
(2H, t, J 5.5, CH2OH), 3.33 (2H, dd, J 12.0, 6.0, NHCH2), 2.24 (1H, br s, OH) 
and 1.70 (2H, quint, J 6.0, CH2CH2OH); δC (100 MHz, CDCl3) 157.2 (CO), 
136.4 (i-Ph), 128.4 (Ph), 128.1 (Ph), 128.0 (Ph), 66.7 (PhCH2), 59.5 (CH2OH), 
37.7 (NHCH2) and 32.4 (NHCH2CH2); m/z 210.1 (M + H+) and 232.1 (M + Na+). 
This data is consistent with that previously reported.351 
 
4-Carbobenzyloxyaminobutan-1-ol (3.83c) 
 
To a solution of 4-aminobutan-1-ol (5 mL, 54 mmol) and NEt3 (8.3 mL, 60 
mmol) in dichloromethane (33 mL) at 0 oC was added benzyl chloroformate (8.5 
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mL, 60 mmol) in dichloromethane (10 mL) dropwise over a period of 10 minutes 
and left stirring at 0 oC for 6 h. The reaction mixture was then washed with sat. 
aq. NH4Cl (2 × 25 mL) and sat. aq. NaCl (25 mL). The combined organic 
extracts were dried over sodium sulfate, filtered and concentrated in vacuo. The 
residue was purified by silica column chromatography (eluent; Hexane:EtOAc 
(1:1) to EtOAc) to give a white crystalline solid (9.9 g, 44 mmol, 82%); m.p.: 76-
77 oC; υmax (cm-1) 3362, 3321 (OH, CONH), 2950, 2904, 2887, 2864 (CH2), 
1683 (CONH), 1530 (NH), 1488, 1463, 1454 (CH) 1337, 1267, 1234 (CO, OH), 
1137, 1104 (COH), 1056, 1010 (CO) 781, 750 (Ph), 727 (CH2), 696 (Ph); δH 
(400 MHz, CDCl3) 7.39-7.27 (5H, m, Ph), 5.09 (2H, s, PhCH2), 4.93 (1H, br s, 
NH), 3.68-3.61 (2H, m, CH2OH), 3.27-3.16 (2H, m, NHCH2), 1.77 (1H, br s, 
OH) and 1.65-1.54 (4H, m, NHCH2CH2CH2); δC (100 MHz, CDCl3) 156.5 (CO), 
136.5 (i-Ph), 128.4 (Ph), 128.2 (p-Ph), 128.0 (Ph), 66.5 (PhCH2), 62.2 (CH2OH), 
40.7 (NHCH2), 29.5 (NHCH2CH2) and 26.4 (CH2CH2OH); m/z 246.1 (M + Na+). 
This data is consistent with that previously reported.352 
 
5-Carbobenzyloxyaminopentan-1-ol (3.83d) 
 
To a solution of 5-aminopentan-1-ol (3.3 mL, 30 mmol) in 3 M NaHCO3 (7.6 g 
in 30 mL H2O, 90 mmol) at 0 oC was added benzyl chloroformate (5.7 mL, 40 
mmol) in THF (30 mL) and stirred vigourously. The reaction mixture was 
allowed to cool to room temperature and stirred over 2 days, whereupon the 
organic layer was separated and the aqueous extracted with ethyl acetate (2 × 35 
mL). The organics were combined, washed with sat, aq. NaCl (100 mL), dried 
over sodium sulfate, filtered, and concentrated in vacuo to give an oil which 
crystallised on standing. The residue was washed with hexane and cold Et2O, 
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refiltered and dried under vacuum to give a clean white crystalline solid (5.0 g, 
21.2 mmol, 71%); m.p.: 46-48 oC; υmax (cm-1) 3387, 3324 (OH, CONH), 2943, 
2863 (CH2), 1682 (CONH), 1528 (NH), 1482, 1462, 1453 (CH) 1356, 1310, 
1258, 1224 (CO, OH), 1139, 1128 (COH), 1056, 1018 (CO) 783, 747 (Ph), 727 
(CH2), 696 (Ph); δH (400 MHz, CDCl3) 7.39-7.28 (5H, m, Ph), 5.09 (2H, s, 
PhCH2), 4.80 (1H, br s, NH), 3.63 (2H, t, J 6.5, CH2OH), 3.24-3.15 (2H, m, 
NHCH2), 1.63-1.48 (5H, m, NHCH2CH2CH2CH2CH2OH) and 1.44-1.34 (2H, m, 
N(CH2)2CH2);  δC (100 MHz, CDCl3) 156.5 (CO), 136.4 (i-Ph), 128.4 (Ph), 
128.3 (p-Ph), 127.9 (p-Ph), 66.4 (PhCH2), 62.2 (CH2OH), 40.8 (NHCH2), 32.0 
(NHCH2CH2), 29.5 (NHCH2CH2CH2) and 22.7 (CH2CH2OH); m/z 239.1 (M + 
H2+) and 260.1 (M + Na+). This data is consistent with that previously 
reported.353 
 
General Method L - Oxidation using DMP 
Alcohol (1 eq) in dichloromethane (1.0 mL per mmol) was stirred at 0 oC and a 
solution of DMP (1.1 eq) in dichloromethane (2.5 mL per mmol) was added to 
the mixture and allowed to stir until the reaction was deemed complete by TLC 
analysis. Work up was completed in one of two ways: 
a) Diethyl ether was added to the reaction mixture and the solution poured 
into a sat. aq. NaHCO3 solution containing 5 eq. of Na2S2O3. The mixture 
was stirred for 5 minutes and the aqueous extracted with more diethyl 
ether. The organics were extracted and washed with sat. aq. NaHCO3, 
H2O, dried over sodium sulfate, filtered and concentrated in vacuo. 
b) Diethyl ether and 1 M NaOH were added to the reaction mixture and the 
organic layer extracted. The organics were combined and washed with 
H2O, dried over sodium sulfate, filtered and concentrated in vacuo. 
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2-Carbobenzyloxyaminoethan-1-al (3.84a) 
 
Oxidation was carried out according to General Method La using 3.83a (0.5 g, 
2.6 mmol). The residue was purified by silica column chromatography (eluent; 
Hexane:EtOAc (1:1) to EtOAc) to give a white crystalline solid (0.2 g, 1.2 mmol, 
45%). m.p.: 54-55 oC; υmax (cm-1) 3335 (CONH), 2953 (CH2), 1686 (CONH), 
1524 (NH), 1425 (CH2) 1325, 1234, 1110 (CO), 734, 695 (Ph); δH (400 MHz, 
CDCl3) 9.55 (1H, s, CHO), 7.37-7.27 (5H, m, Ph), 5.66 (1H, br s, NH), 5.11 (2H, 
s, PhCH2) and 4.05 (2H, d, J 5.0, NHCH2); δC (100 MHz, CDCl3) 197.2 (CHO), 
156.3 (OCO), 135.9 (i-Ph), 128.2 (Ph), 127.9 (Ph), 127.8 (Ph), 66.8 (PhCH2) and 
51.1 (CH2CHO); m/z 102.4 ([M – Bn]+), 216.1 (M + Na+) and 248.1 ([M + Na + 
O2]+). This data is consistent with that previously reported.354 
 
3-Carbobenzyloxyaminopropan-1-al (3.84b) 
 
Oxidation was carried out according to General Method Lb using 3.83b (0.5 g, 
4.5 mmol). The residue was purified by silica column chromatography (eluent; 
Hexane:EtOAc (1:1) to EtOAc) to give a white crystalline solid (50 mg, 0.24 
mmol, 10%);  m.p.: 59-60 oC; υmax (cm-1) 3321 (CONH), 3031, 2924 (CH2), 1681 
(CONH), 1535 (NH), 1439, 1421 (CH2) 1249, 1218, 1026 (CO), 778, 750 (Ph), 
729 (CH2), 696 (Ph); δH (400 MHz, CDCl3) 9.78 (1H, s, CHO), 7.41-7.27 (5H, 
m, Ph), 5.24 (1H, br s, NH), 5.08 (2H, s, PhCH2), 3.53-3.39 (2H, m, NHCH2) and 
2.78-2.62 (2H, m, NHCH2CH2); δC (100 MHz, CDCl3) 199.8 (CHO), 156.3 
(OCO), 136.3 (i-Ph), 128.5 (Ph), 128.2 (Ph), 128.1 (Ph), 66.7 (PhCH2), 44.2 
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(CH2CHO) and 34.7 (NHCH2); m/z 230.1 (M + Na+) and 262.1 ([M + Na + 
O2]+). This data is consistent with that previously reported.355 
 
4-Carbobenzyloxyaminobutan-1-al (3.84c) 
 
Oxidation was carried out according to General Method La using 3.83c (1 g, 
4.5 mmol). The residue was purified by silica column chromatography (eluent; 
Hexane:EtOAc (1:1) to EtOAc) to give a white crystalline solid (0.9 g, 4.2 mmol, 
94%). m.p.: 46-47 oC; υmax (cm-1) 3329 (CONH), 2949 (CH2), 1693 (CONH), 
1528 (NH), 1453, 1406 (CH2) 1252, 1212, 1105 (CO), 749, 697, 667 (Ph); δH 
(400 MHz, CDCl3) 10.00 (1H, s, CHO), 7.38-7.27 (5H, m, Ph), 5.47 (1H, br s, 
NH), 5.08 (2H, s, PhCH2), 3.68-3.58 (2H, m, NHCH2), 3.26-3.07 (2H, m, 
CH2CHO) and 1.62-1.47 (2H, m, NHCH2CH2); δC (100 MHz, CDCl3) 198.1 
(CHO), 153.2 (OCO), 136.4 (i-Ph), 128.4 (Ph), 128.0 (Ph), 127.7 (Ph), 66.7 
(PhCH2), 53.4 (CH2CHO), 45.7 (NHCH2) and 32.6 (NHCH2CH2); m/z 244.1 (M 
+ Na+), 246.1 ([M + H2 + Na]+) and 465.0 ([(2 × M) + Na]+). This data is 
consistent with that previously reported.356 
  
5-Carbobenzyloxyaminopentan-1-al (3.84d) 
 
Oxidation was carried out according to General Method Lb using 3.83d (0.5 g, 
2.1 mmol). The residue was purified by silica column chromatography (eluent; 
Hexane:EtOAc (1:1) to EtOAc) to give a white crystalline solid (0.4 g, 1.6 mmol, 
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78%); m.p.: 52-53 oC; υmax (cm-1) 3334 (CONH), 3032, 2937 (CH2), 1692 
(CONH), 1528 (NH), 1453, 1420 (CH2) 1252, 1133 (CO), 736, 696 (Ph); δH (400 
MHz, CDCl3) 10.00 (1H, s, CHO), 7.41-7.27 (5H, m, Ph), 6.12 (1H, br s, NH), 
5.18 (2H, s, PhCH2), 3.67-3.57 (2H, m, NHCH2), 2.07-1.97 (2H, m, CH2CHO), 
1.87-1.73 (2H, m, CH2CH2CHO) and 1.66-1.36 (2H, m, NHCH2CH2); δC (100 
MHz, CDCl3) 202.1 (CHO), 153.4 (OCO), 136.3 (i-Ph), 128.4 (Ph), 128.2 (Ph), 
128.0 (Ph), 66.8 (PhCH2), 52.1 (CH2CHO), 46.2 (NHCH2), 32.6 (NHCH2CH2) 
and 21.9 (NHCH2CH2CH2); ESI m/z 219.2 ([M – O2]+) 258.1 [M + Na+) and 
260.1 ([M + H2 + Na]+). This compound is known but has previously been 
reported without any characterisation.357 
 
4-Carbobenzyloxyamino-1,1,1-trichlorobutan-2-ol (3.85b) 
 
Trichlorocarbinol was synthesised according to General Method J using 3.84b 
(50 mg, 0.24 mmol) in 1 mL of DMF. The residues were purified by silica 
column chromatography (eluent; Hexane:EtOAc (6:4) to EtOAc) to give a white 
solid (12.4 mg, 0.04 mmol, 16%); m.p.: 142-143 oC; υmax (cm-1) 3478 (CONH), 
3230 (OH), 3098, 2962 (CH2), 1705, 1617 (CONH), 1407, 1389, 1375 (OH), 
1301, 1140 (CO), 872, 800 (CCl), 776, 713 (Ph); δH (400 MHz, CDCl3) 7.39-
7.29 (5H, m, Ph), 5.19-5.02 (3H, m, PhCH2 & NH), 4.12 (1H, d, J 10.0 CHOH), 
3.68-3.52 (2H, m, NHCHHCH2CHOH), 3.37 (1H, dq, J 14.0, 5.5, NHCHH), 
2.30 (1H, dddd, J 14.5, 8.0, 5.5, 2.0 NHCH2CHHCH) and 1.84 (1H, ddd, J 15.0, 
10.0, 5.0, NHCH2CHHCH); δC (100 MHz, CDCl3) 153.6 (OCO), 136.3 (i-Ph), 
128.6, 128.3 (o-Ph & m-Ph), 128.1 (p-Ph), 104.9 (CCl3), 80.8 (CHOH), 67.0 
(PhCH2), 37.9 (NHCH2) and 32.1 (CH2CHOH). This compound has not 
previously been reported. 
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General Method M - Phthalimide protection of aminoalcohol 
A mixture of aminoalcohol (1 eq), phthalic anhydride (1 eq), NEt3 (0.1 eq) and 
toluene (1 mL per mmol) was heated under reflux in a flask fitted with a Dean-
Stark apparatus for 3 hrs. The reaction mixture was allowed to cool and the 
remaining volatiles concentrated in vacuo. The solid residues were taken up in 
ethyl acetate and washed successively with 2M HCl, sat. aq. NaHCO3 and H2O, 
the organics combined and dried over sodium sulfate, filtered and concentrated in 
vacuo. 
 
N-(2-Hydroxyethyl)-phthalimide (3.83e) 
 
Phthalimide protection of ethanolamine (1.0 g, 16 mmol) was carried out 
according to General Method M. The crude solid was recrystallised 
(EtOAc:Hexane (1:1)) to give a white crystalline solid (1.5 g, 7.8 mmol, 48%); 
m.p.: 135-136 oC; υmax (cm-1) 3465, 3068 (OH), 3048, 2954, 2886 (CH2), 1765, 
1686 (CO), 1608 (Ph), 1469 (CH2), 1392 (OH), 1187 (CO), 1055 (COH), 800, 
722, 708 (Ph); δH (400 MHz, CDCl3) 7.82 (2H, dd, J 5.5, 3.0, CCHCHCHCHC), 
7.70 (2H, dd, J 5.5, 3.0, CCHCHCHCHC), 3.93-3.78 (4H, m, CH2CH2OH) and 
2.57 (1H, br s, OH); δC (100 MHz, CDCl3) 168.3 (CO), 133.6 
(CCHCHCHCHC), 131.9 ((CO)CC(CO)), 123.2 (CCHCHCHCHC), 61.2 
(CH2OH), 38.7 (NCH2); m/z 192.1 (M + H+), 214.1 (M + Na+). This data is 
consistent with that previously reported.358 
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N-(3-Hydroxypropyl)-phthalimide (3.83f) 
 
Phthalimide protection of 3-aminopropan-1-ol (2.0 g, 27 mmol) was carried out 
according to General Method M. The crude solid was recrystallised (EtOH) to 
give a white crystalline solid (1.9 g, 9.4 mmol, 35%); m.p.: 107-108 oC; υmax 
(cm-1) 3393 (OH), 2950, 2884 (CH2), 1760, 1702, 1689 (CO), 1608 (Ph), 1446, 
1438 (CH2), 1399, 1374 (OH), 1124 (CO), 1059 (COH), 758, 721, 713 (Ph); δH 
(400 MHz, CDCl3) 7.86 (2H, dd, J 5.5, 3.0, CCHCHCHCHC), 7.73 (2H, dd, J 
5.5, 3.0, CCHCHCHCHC), 3.86 (2H, t, J 6.5, NCH2), 3.66-3.57 (2H, m, 
CH2OH), 2.50 (1H, br t, J 4.5, OH) and 1.88 (2H, quin, J 6.5, CH2CH2OH); δC 
(100 MHz, CDCl3) 168.4 (CO), 133.7 (CCHCHCHCHC), 131.8 ((CO)CC(CO)), 
123.0 (CCHCHCHCHC), 59.2 (CH2OH), 38.7 (NCH2), 31.4 (NCH2CH2); m/z 
206.1 (M + H+), 228.1 (M + Na+). This data is consistent with that previously 
reported.359 
 
N-(5-Hydroxypentyl)-phthalimide (3.83h) 
 
Phthalimide protection of 5-aminopentan-1-ol (4.2 mL, 39 mmol) was carried out 
according to General Method M to give 3.83 as a viscous oil (6.1 g, 26 mmol, 
68%); υmax (cm-1) 3457 (OH), 2936, 2861 (CH2), 1770, 1698 (CO), 1613 (Ph), 
1466, 1437 (CH2), 1395, 1364 (OH), 1126 (CO), 1049 (COH), 751, 717 (Ph); δH 
(400 MHz, CDCl3) 7.76 (2H, dd, J 5.5, 3.0, CCHCHCHCHC), 7.65 (2H, dd, J 
5.5, 3.0, CCHCHCHCHC), 3.67-3.53 (4H, m, NCH2(CH2)3CH2OH), 2.82 (1H, 
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br s, OH), 1.70-1.61 (2H, m, NCH2CH2), 1.60-1.51 (2H, m, CH2CH2OH) and 
1.43-1.31 (2H, m, NCH2CH2CH2); δC (100 MHz, CDCl3) 168.4 (CO), 133.8 
(CCHCHCHCHC), 131.9 ((CO)CC(CO)), 123.0 (CCHCHCHCHC), 62.3 
(CH2OH), 37.7 (NCH2), 32.0 (NCH2CH2), 28.2 (CH2CH2OH), 22.9 
(CH2CH2CH2OH); m/z 234.1 (M + H+), 256.1 (M + Na+). This data is consistent 
with that previously reported.360 
 
General Method N - Oxidation of alcohol with IBX 
Alcohol (1 eq) in ethyl acetate (4.0 mL per mmol) was added IBX (2 eq) and 
stirred under nitrogen at reflux until TLC analysis showed the completion of 
reaction. The reaction mixture was allowed to cool to room temperature and the 
cloudy mixture filtered through a thin pad of celite and the filter cake washed 
with copious amounts of ethyl acetate into a round bottomed flask. The filtrate 
was concentrated in vacuo. 
 
N-(2-Oxoethyl)-phthalimide (3.84e) 
 
Oxidation was carried out according to General Method N using 3.83e (1.5 g, 
7.8 mmol) to give a white solid which required no further purification (97 mg, 
5.1 mmol, 66%); m.p.: 114-115 oC; υmax (cm-1) 3049, 2938 (CH2), 1777, 1705 
(CO), 1614 (Ph), 1406 (CH2), 1191, 1140 (CO), 774, 726, 713 (Ph); δH (400 
MHz, CDCl3) 9.69 (1H, s, CHO), 7.90 (2H, dd, J 5.5, 3.0, CCHCHCHCHC), 
7.76 (2H, dd, J 5.5, 3.0, CCHCHCHCHC) and 4.56 (2H, s, CH2CHO); δC (100 
MHz, CDCl3) 193.7 (CHO), 167.3 (CO), 134.1 (CCHCHCHCHC), 131.6 
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((CO)CC(CO)), 123.4 (CCHCHCHCHC), 47.1 (CH2); m/z 190.1 (M + H+), 
212.1 (M + Na+), 244.0 ([M + MeOH + Na]+) and 276.1 ([M + (2 × MeOH) + 
Na]+). This data is consistent with that previously reported.358 
 
N-(3-Oxopropyl)-phthalimide (3.84f) 
 
Oxidation was carried out according to General Method N using 3.83f (1.5 g, 
7.3 mmol) to give a white solid which required no further purification (97 mg, 
4.8 mmol, 65%); m.p.: 126-127 oC; υmax (cm-1) 3051, 2928 (CH2), 2850 (NCH2), 
1765, 1701 (CO), 1610 (Ph), 1470, 1440 (CH2), 1188, 1135 (CO), 800, 739, 719 
(Ph); δH (400 MHz, CDCl3) 9.82 (1H, s, CHO), 7.85 (2H, dd, J 5.5, 3.0, 
CCHCHCHCHC), 7.73 (2H, dd, J 5.5, 3.0, CCHCHCHCHC), 4.04 (2H, t, J 7.0, 
NCH2) and 2.88 (2H, dt, J 7.0, 1.5, CH2CHO); δC (100 MHz, CDCl3) 199.7 
(CHO), 168.3 (CO), 134.3 (CCHCHCHCHC), 131.9 ((CO)CC(CO)), 122.4 
(CCHCHCHCHC), 42.5 (CH2CHO), 32.0 (NCH2); m/z 204.1 (M + H+), 226.0 
(M + Na+), 258.1 ([M + MeOH + Na]+) and 290.1 ([M + (2 × MeOH) + Na]+). 
This data is consistent with that previously reported.359 
 
N-(5-Oxopentyl)-phthalimide (3.84h) 
 
Oxidation was carried out according to General Method N using 3.83h (1.5 g, 
6.4 mmol) to give a colourless oil which required no further purification (1.1 g, 
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5.0 mmol, 77%); υmax (cm-1) 3045, 2918 (CH2), 2848 (NCH2), 1764, 1703 (CO), 
1609 (Ph), 1465, 1434 (CH2), 1192, 1137 (CO), 742, 718 (Ph); δH (400 MHz, 
CDCl3) 9.66-9.63 (1H, m, CHO), 7.73 (2H, dd, J 5.5, 3.0, CCHCHCHCHC), 
7.60 (2H, dd, CCHCHCHCHC), 3.59 (2H, t, J 7.0, NCH2), 2.40 (2H, t, J 7.0, 
CH2CHO) and 1.70-1.50 (4H, m, NCH2CH2CH2); δC (100 MHz, CDCl3) 202.1 
(CHO), 168.7 (CO), 134.1 (CCHCHCHCHC), 132.2 ((CO)CC(CO)), 123.5 
(CCHCHCHCHC), 43.6 (CH2CHO), 37.9 (NCH2), 28.4 (NCH2CH2), 19.2 
(CH2CH2CHO); m/z 232.1 (M + H+), 254.1 (M + Na+). This data is consistent 
with that previously reported.361 
 
N-(2-Hydroxy-3,3,3-trichloropropyl)-phthalimide (3.85e) 
 
Trichlorocarbinol was synthesised according to General Method J using 3.84e 
(1.0 g, 5.1 mmol) in 5 mL of DMF. The residues were purified by silica column 
chromatography (eluent; Hexane:EtOAc (6:4) to EtOAc) to give a white solid 
(0.7 g, 2.2 mmol, 43%); m.p.: 138-139 oC; υmax (cm-1) 3446 (OH), 2953, 2922 
(CH2), 1780, 1701 (CON), 1618 (Ph) 1466 (CH2), 1399 (OH), 1288, 1194 (CO), 
1143, 1099 (COH), 787 (CCl), 723, 711 (Ph); δH (400 MHz, CDCl3) 7.86 (2H, 
dd, J 5.5, 3.0, CCHCHCHCHC), 7.74 (2H, dd, J 5.5, 3.0, CCHCHCHCHC), 4.46 
(1H, ddd, J 9.5, 7.5, 3.0, CH2CHOH), 4.33 (1H, dd, J 14.5, 3.0, NCHHCH), 4.09 
(1H, dd, J 14.5, 9.5, NCHHCH) and 3.60 (1H, d, J 7.5, CHOH); δC (100 MHz, 
CDCl3) 168.4 (CO), 134.3 (Ph), 131.7 (Ph), 123.6 (Ph), 100.8 (CCl3), 80.0 
(CH2CH) and 39.8 (CH2); m/z (C11H9Cl3NO3 (M + H+) requires 307.9643 and 
309.9613) found 307.9650 and 309.9617. This compound has not previously 
been reported. 
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N-(3-Hydroxy-4,4,4-trichlorobutyl)-phthalimide (3.85f) 
 
Trichlorocarbinol was synthesised according to General Method J using 3.84f 
(1.0 g, 4.8 mmol) in 5 mL of DMF. The residues were purified by dissolving in 
the minimum amount of chloroform and washing with H2O. The organic extract 
was dried again with sodium sulfate, filtered and concentrated in vacuo to give a 
clean white solid (1.2 g, 3.7 mmol, 76%); m.p.: 156-157 oC; υmax (cm-1) 3327 
(OH), 2979, 2946, (CH2), 2855 (NCH2) 1767, 1692 (CON), 1612 (Ph) 1468, 
1439 (CH2), 1397 (OH), 1281, 1227 (CO), 1189, 1091 (COH), 779 (CCl), 716 
(Ph); δH (400 MHz, CDCl3) 7.86 (2H, dd, J 5.5, 3.0, CCHCHCHCHC), 7.73 (2H, 
dd, J 5.5, 3.0, CCHCHCHCHC), 4.11 (1H, m, CH2CHOH), 3.97 (2H, dd, J 7.0, 
5.5, NCH2), 3.59 (1H, br s, CHOH), 2.44 (1H, dtd, J 9.0, 7.0, 2.0, 
NCH2CHHCH) and 2.05 (1H, m, NCH2CHHCH); δC (100 MHz, CDCl3) 168.4 
(CO), 134.2 (Ph), 131.9 (Ph), 123.4 (Ph), 103.1 (CCl3), 80.7 (CH2CHOH), 34.9 
(NCH2) and 30.8 (CH2CH); m/z (C12H10Cl3NO3 (M + H+) requires 321.9799, 
323.9770 and 325.9740) found 321.9803, 323.9773 and 325.9741. This 
compound has not previously been reported. 
 
N-(5-Hydroxy-6,6,6-trichlorohexyl)-phthalimide (3.85h) 
 
Trichlorocarbinol was synthesised according to General Method J using 3.84h 
(1.2 g, 5 mmol) in 5 mL of DMF. The residues were purified by silica column 
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chromatography (eluent; Hexane:EtOAc (8:2) to EtOAc) to give a white solid 
(0.8 g, 2.2 mmol, 44%); m.p.: 131-133 oC; υmax (cm-1) 3425 (OH), 2954, 2933, 
(CH2), 2865 (NCH2) 1765, 1700 (CON), 1608 (Ph) 1460, 1434 (CH2), 1398 
(OH), 1263, 1245 (CO), 1185, 1090 (COH), 792 (CCl), 771, 717 (Ph); δH (400 
MHz, CDCl3) 7.85 (2H, d, J 5.5, 3.0, CCHCHCHCHC), 7.72 (2H, dd, J 5.5, 3.0, 
CCHCHCHCHC), 3.99 (1H, ddd, J 9.5, 6.0, 2.0 CH2CHOH), 3.74 (2H, t, J 7.0, 
NCH2), 2.85 (1H, dd, J 6.0, 1.0, CHOH), 2.16-2.06 (1H, m, NCH2CHH), 1.86-
1.63 (4H, m, NCH2CHHCHHCH2CH) and 1.57-1.47 (1H, m, NCH2CH2CHH); 
δC (100 MHz, CDCl3) 168.5 (CO), 134.0 (m-Ph), 132.1 (i-Ph), 123.2 (o-Ph), 82.7 
(CH2CHOH), 37.5 (NCH2), 30.8 (NCH2CH2), 28.2 (CH2CH) and 23.2 
(N(CH2)2CH2). This compound has not previously been reported. 
 
5.4 Chapter 4 Experimental 
1,1,1-Trichloro-4-phenylbutan-2-ol (4.12) 
 
Trichlorocarbinol was synthesised according to General Method J using 4.11 
(6.6 mL, 50 mmol). The residues were purified by silica column chromatography 
(eluent; EtOAc:Hexane (0.5:9.5) to EtOAc) to give a light yellow oil (8.1 g, 32 
mmol, 63%); υmax (cm-1) 3414, 3062 (OH), 2934, 2862 (CH2, CH), 1602, 1496 
(Ph), 1454 (CH2), 1095, 1075, 1055 (COH), 807, 785 (CCl), 745, 697 (Ph); δH 
(400 MHz, CDCl3) 7.39-7.32 (2H, m, m-Ph), 7.31-7.22 (3H, m, o-Ph & p-Ph), 
4.02 (1H, ddd, J 10.0, 5.0, 1.0, CHOH), 3.04 (1H, ddd, J 14.0, 9.0, 5.0, 
CHHCHOH), 2.90 (1H, br s, OH), 2.81 (1H, dt, J 14.0, 8.5, CHHCH2CH), 2.42 
(1H, dt, J 14.0, 9.0, CHHCH2CH) and 2.03 (1H, dddd, J 14.0, 10.0, 9.0, 5.0, 
CHHCHOH); δC (100 MHz, CDCl3) 140.7 (i-Ph), 128.5 (Ph), 128.4 (Ph), 126.2 
(p-Ph), 104.1 (CCl3), 81.9 (CH), 32.9 (CH2CH2CH) and 31.9 (CH2CH); m/z 
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147.1 ([M – HCCl3 + H]+), 169.1 ([M – HCCl3 + Na]+). This data is consistent 
with that previously reported.259 
 
2-Azido-4-phenylbutanoic acid (4.13) 
 
Azido acid was synthesised according to General Method K using 4.12 (253 
mg, 1 mmol) to give a viscous clear liquid (196 mg, 0.96 mmol, 96%); υmax (cm-
1) 3027 (OH), 2929 (CH2), 2103 (N3), 1713 (CO2H), 1603, 1496 (Ph), 1454 
(CH2), 1225, 1030 (CO), 748, 697 (Ph); δH (400 MHz, CDCl3) 11.15 (1H, br s, 
COOH), 7.36-7.16 (5H, m, Ph), 3.88 (1H, dd, J 9.0, 5.0, CHN3), 2.83 (1H, ddd, J 
9.0, 7.0, 4.0, PhCHHCH2), 2.73 (1H, dd, J 14.0, 9.0, PhCHHCH2), 2.28-2.01 
(2H, m, PhCH2CH2CH); δC (100 MHz, CDCl3) 176.4 (COOH), 139.7 (i-Ph), 
128.6 (Ph), 128.4 (Ph), 126.4 (o-Ph), 60.9 (CHN3), 32.7 (PhCH2), 31.6 
(CH2CH2CH); m/z (C10H12N3O2 (M + H+) requires 206.0924) found 206.0924). 
This compound is known but has previously been reported without any 
characterisation.362 
 
2-Azido-N-benzyl-4-phenylbutanamide (4.14) 
 
Method A 
To a solution of 4.12 (253 mg, 1 mmol) in 1,2-dimethoxyethane (160 µL, 1.5 
mmol) and benzylamine (110 µL, 1 mmol) stirred at 10 oC was added a stirred 10 
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oC solution of NaN3 (130 mg, 2 mmol) and NaOH (160 mg, 4 mmol) in H2O (8 
mL). The mixture was brought to room temperature and left stirring overnight. 
The remaining solution was extracted with EtOAc, dried over sodium sulfate, 
filtered and concentrated in vacuo. The residues were purified by silica column 
chromatography (eluent; Petroleum Ether 40/60 oC to EtOAc) to give a white 
solid (68 mg, 0.23 mmol, 23%). m.p.: 60-61 oC; υmax (cm-1) 3297 (NH), 3027, 
2930 (CH2), 2109, 2090 (N3), 1644 (CONH), 1605 (Ph), 1542 (CONH), 1452 
(CH2), 744, 695 (Ph); δH (400 MHz, CDCl3) 7.39-7.19 (10H, m, Ph), 6.69 (1H, 
br s, CONH), 4.48 (1H, dd, J 13.0, 4.0, CONHCHHPh), 4.44 (1H, dd, J 13.0, 
4.0, CONHCHHPh), 4.01 (1H, dd, J 7.5, 4.5, CHN3), 2.80 (1H, dt, J 14.0, 5.0, 
PhCHHCH2), 2.70-2.78 (1H, m, PhCHHCH2),  2.29 (1H, dddd, J 14.0, 9.5, 7.0, 
5.0, PhCH2CHHCH) and 2.17 (1H, dddd, J 14.0, 9.0, 7.5, 6.0, PhCH2CHHCH); 
δC (100 MHz, CDCl3) 169.0 (CO), 140.2 (CONHCH2(i-Ph)), 137.6 (CH2CH2(i-
Ph)), 128.8 (Ph), 128.5 (Ph), 128.4 (Ph), 127.73 (Ph), 127.68 (CONHCH2(p-Ph)), 
126.3 (CH2CH2(p-Ph)), 63.6 (CHN3), 43.5 (CONHCH2Ph), 33.9 (CH2CHN3) and 
31.4 (PhCH2CH2); m/z (C17H18N4O ([M + H]+) requires 295.1553) found 
295.1550 and (C17H18N4NaO ([M + Na]+) requires 317.1373) found 317.1368. 
This compound has not previously been reported. 
Method B 
To a solution of 4.16 (53 mg, 0.23 mmol) in dihcloromethane (3 mL) was added 
benzylamine (100 µL, 0.9 mmol) and the resulting solution left stirring 
overnight. The remaining residues were taken up in pH 2 buffer and extracted 
with EtOAc, dried over sodium sulfate, filtered and concentrated in vacuo. The 
residues were purified by silica column chromatography (eluent; Hexane:EtOAc 
(4:1)) to give a white solid (4.14,  61 mg, 0.2 mmol,  86%). The spectral data was 
identical to that obtained from Method A.  
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2-Azido-4-phenylbutanoyl chloride (4.16) 
 
Oxalyl chloride (90 µL, 1 mmol) and DMF (20 µL, 0.23 mmol) were added to a 
0.23M solution of 2-azido-4-phenylbutanoic acid (48 mg, 0.23 mmol) in 
hexanes. The reaction mixture was stirred at room temperature until TLC showed 
consumption of the starting material (3 h). The reaction mixture was filtered and 
concentrated in vacuo and the acid chloride (4.16) was used without isolation or 
further purificiation.  
 
General Method O: Heterocycle formation via Jocic/Bargellini type reaction 
3-Phenylethylpiperazin-2-one (4.17) 
 
To a solution of 1,1,1-Trichloro-4-phenylbutan-2-ol (4.12, 0.25 g, 1 mmol) and 
benzyltriethylammoniumchloride (5 mg, 2 mol %) in dichloromethane (10 mL) 
stirred at 0 oC was added ethylenediamine (67 µL, 1 mmol). The mixture was 
allowed to stir for 10 minutes, followed by dropwise addition of 40 % aq. NaOH 
(0.25 mL). Stirring was continued overnight at room temperature. The reaction 
mixture was quenched with H2O until all of the solids were consumed and the 
aqueous was extracted with dichloromethane (3 × 15 mL). The combined organic 
extracts were dried over sodium sulfate, filtered and concentrated in vacuo. The 
residue was purified by silica column chromatography (eluent; EtOAc:Hexane 
(1:1) to EtOAc:MeOH (8:2)) to give a white crystalline solid (113 mg, 0.6 mmol, 
55%); m.p.: 146-147 oC; υmax (cm-1) 3331 (NH), 3252 (CONH), 2962, 2913, 
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2853 (CH2, CH), 1654, 1620 (CONH), 1494 (NH), 1452, 1396 (CH2), 759 (Ph), 
747 (CH2), 702 (Ph); δH (400 MHz, CDCl3) 7.31-7.14 (5H, m, Ph), 6.55 (1H, br 
s, CONH), 3.46-3.36 (2H, m, CHCONHCHH), 3.32-3.34  (1H, m, CONHCHH), 
3.13 (1H, dtd, J 13.0, 4.0, 0.5, CHNHCHH), 2.96 (1H, dddd, J 13.0, 9.5, 4.0, 2.0, 
CHNHCHH), 2.85-2.68 (2H, m, CH2CH2CH), 2.35-2.24 (1H, m, CHHCHNH), 
2.04-1.91 (1H, m, CHHCHNH), and 1.90 (1H, br s, CHNH); δC (100 MHz, 
CDCl3) 172.3 (CO), 141.5 (i-Ph), 128.5, 128.4 (o- & m-Ph), 125.9 (p-Ph), 58.3 
(CH), 43.2 (CONHCH2), 41.4 (CHNHCH2), 33.6 (CH2CHNH) and 32.1 
(CH2CH2CH); m/z (C12H17N2O (M + H+) requires 205.1335) found 205.1335. 
This compound is known but has previously been reported without any 
characterisation.363 
 
2-Phenylethylmorpholin-3-one (4.19) 
 
Heterocycle formation was carried out according to General Method O using 
ethanolamine (61 µL, 1 mmol) in place of ethylenediamine. The residue was 
purified by silica column chromatography (eluent; EtOAc:Hexane (9:1) to 
EtOAc:MeOH (8:2)) to give a viscous oil (91 mg, 0.44 mmol, 44 %); υmax (cm-1) 
3383 (CONH), 2960, 2849 (CH2, CH), 2258 (CON), 1654 (CONH), 1047, 1023 
(CO), 763, 699 (Ph); δH (400 MHz, CDCl3) 7.33-7.27 (2H, m, m-Ph), 7.25-7.18 
(3H, m, o- & p-Ph), 7.00 (1H, br s, CONH), 4.32 (1H, dd, J 9.0, 4.0, CHOCH2), 
3.75 (2H, t, J 5.0, OCH2CH2NH), 3.50-3.42 (2H, m, OCH2CH2NH), 2.92-2.73 
(2H, m, PhCH2), 2.47 (1H, dddd, J 14.5, 9.5, 7.0, 4.0, PhCH2CHHCH) and 2.30-
1.90  (2H, m, PhCH2CHHCHNH); δC (100 MHz, CDCl3) 169.8 (CO), 140.0 (i-
Ph), 128.6, 128.5 (o- & m-Ph), 126.3 (p-Ph), 61.9 (CHOCH2), 60.3 (CH), 42.5 
(CONHCH2), 37.0 (PhCH2CH2CH) and 31.9 (PhCH2CH2CH); m/z (C12H16NO2 
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(M + H+) requires 206.1176) found 206.1178. This compound has not previously 
been reported. 
 
General Method P: Amine alkylation with acid chloride 
4-(Methylsulfonyl)-3-phenylethylpiperazin-2-one (4.20) 
 
To a solution of 4.17 (14 mg, 0.07 mmol) in dry dichloromethane (2 mL) stirred 
at 0 oC was added NEt3 (9 µL, 0.07 mmol) and stirred for 10 minutes, after which 
time methanesulfonyl chloride (10 µL, 0.14 mmol) was added slowly and left 
stirring until the complete consumption of the starting material was observed by 
TLC. The reaction mixture was concentrated in vacuo and pH 2 buffer added to 
the residues. The aqueous mixture was extracted with EtOAc and the combined 
organic extracts dried over sodium sulfate, filtered and concentrated in vacuo. 
The residues were purified by silica column chromatography (eluent; 
EtOAc:Petroleum Ether 40/60 oC (2:8) to EtOAc) to give a white crystalline 
solid (6 mg, 0.02 mmol, 31%); m.p.: 168-169 oC; υmax (cm-1) 3175, 3031 (NH), 
2931 (CH2), 1661 (CONH), 1603, 1494 (Ph), 1454, 1429 (CH2), 1370 (CH3) 
1317, 1141 (SO2N), 773, 702 (Ph); δH (400 MHz, CDCl3) 7.32-7.26 (2H, m, m-
Ph), 7.25-7.16 (3H, m, Ph), 6.46 (1H, br s, CONH), 4.32 (1H, dd, J 9.0, 5.0, 
CHCONH), 3.91 (1H, dd, J 14.0, 4.0, CONHCH2CHH), 3.65 (1H, dt, J 12.0, 4.5, 
CONHCHH), 3.45 (1H, ddd, J 14.0, 11.0, 4.0, CONHCH2CHH), 3.39-3.31 (1H, 
m, CONHCHH), 2.93 (3H, s, CH3), 2.89-2.75 (2H, m, PhCH2CH2), 2.34 (1H, 
dddd, J 11.5, 10.0, 6.5, 5.0, PhCH2CHH) and 2.16-2.06 (1H, m, PhCH2CHH); δC 
(100 MHz, CDCl3) 140.6 (i-Ph), 128.5 (Ph), 128.4 (Ph), 126.2 (p-Ph), 57.8 (CH), 
41.23 (CONHCH2), 40.1 (CH3), 38.5 (CONHCH2CH2), 33.9 (CH2CHCO) and 
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32.3 (CH2CH2CH); m/z (C13H18N2NaO3S (M + Na+) requires 305.0930) found 
205.0931. This compound has not previously been reported. 
 
4-Acetyl-3-phenylethylpiperazin-2-one (4.21) 
 
Amine alkylation was carried out according to General Method P using 4.17 
(10 mg, 0.05 mmol) and acetyl chloride (4 µL, 0.06 mmol). The residue was 
purified by silica column chromatography (eluent; EtOAc to EtOAc:MeOH 
(8:2)) to give a white crystalline solid (11 mg, 0.04 mmol, 88%); m.p.: 147-148 
oC; υmax (cm-1) 3282 (NH), 3030, 2920, 2851 (CH2, CH), 1659 (CON), 1605 
(CONH), 1481 (Ph), 1439, 1426 (CH2), 1338 (CH3), 740 (Ph), 720 (CH2), 702 
(Ph); δH (400 MHz, 1.3:1 rotamer ratio, CDCl3) mj & mi7.34-7.14 (2 × 5H, m, Ph), 
mi6.68 (1H, br s, CONH), mj6.41 (1H, br s, CONH), mi5.19 (1H, dd, J 9.0, 5.0, 
CHCONH), mj4.73-4.65 (1H, m, CHNCHH), mj4.32-4.26 (1H, m, CHCONH), 
mi3.79-3.69 (1H, m, CHNCHH), 3.54-3.40 (3H, m, miCONHCHHCHH & 
mjCONHCHH), mi3.37-3.31 (1H, m, CONHCHH), mj3.30-3.22 (1H, m, 
CONHCHH), mj3.10-2.99 (1H, m, CHNCHH), 2.87-2.73 (3H, m, 
mjPhCH2CH2CH & miPhCHHCH2CH), mi2.71-2.60 (1H, m, PhCHHCH2CH), 
mj2.48-2.37 (1H, m, PhCH2CHHCH), mi2.37-2.27 (1H, m, PhCH2CHHCH), 
mj2.12 (3H, s, CH3CO), 2.09-1.99 (2H, m, mjPhCH2CHHCH & miPhCH2CHHCH) 
and mi1.93 (3H, s, CH3CO); δC (100 MHz, CDCl3) mj140.1 (i-Ph), mi135.1 (i-Ph), 
mj128.6 (Ph), mj128.4 (Ph), mi128.30 (Ph), mi128.25 (Ph), mj126.4 (p-Ph), mi125.9 
(p-Ph), mj58.5 (CH), mi55.0 (CH), 41.6, 41.0, 40.2 , 34.6 (CONHCH2CH2), 34.1, 
33.2, 32.4, 32.1 (PhCH2CH2), mj30.9 (CH3) and mi21.0 (CH3); m/z 
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(C14H18N2NaO2 (M + Na+) requires 269.1260) found 269.1260. This compound 
has not previously been reported. 
 
3-Phenylethyl-4-propionylpiperazin-2-one (4.22) 
 
Amine alkylation was carried out according to General Method P using 4.17 
(10 mg, 0.05 mmol) and propionyl chloride (5 µL, 0.06 mmol). The residue was 
purified by silica column chromatography (eluent; EtOAc to EtOAc:MeOH 
(9:1)) to give a white crystalline solid (10 mg, 0.04 mmol, 82%); m.p.: 184-186 
oC; υmax (cm-1) 3229 (NH), 3026, 2918 (CH2, CH), 1638 (CON), 1490 (Ph), 1422 
(CH2), 1326 (CH3) 750, 700 (Ph); δH (400 MHz, 1.1:1 rotamer ratio, CDCl3) mj & 
mi7.34-7.13 (2 × 5H, m, Ph), mi6.45 (1H, br s, CONH), mj6.21 (1H, br s, CONH), 
mi5.25-5.19 (1H, m, CHCONH), mj4.75-4.67 (1H, m, CHNCHH), mj4.34 (1H, t, J 
7.0, CHCONH), mi3.85-3.75 (1H, m, CHNCHH), 3.52-3.39 (3H, m, 
miCONHCHHCHH & mjCONHCHH), mi3.36-3.31 (1H, m, CONHCHH), mj3.30-
3.22 (1H, m, CONHCHH), mj3.11-3.00 (1H, m, CHNCHH), 2.88-2.72 (3H, m, 
mjPhCH2CH2CH & miPhCHHCH2CH), mi2.70-2.59 (1H, m, PhCHHCH2CH), 
mj2.48-2.38 (1H, m, PhCH2CHHCH), mi2.38-2.26 (3H, m, PhCH2CHHCH & 
CH3CH2), 2.24-1.97 (4H, m, mjPhCH2CHHCH,  miPhCH2CHHCH & mjCH3CH2), 
mi1.18 (3H, t, J 7.5 CH3CH2) and mj1.08 (3H, t, J 7.5 CH3CH2); δC (100 MHz, 
CDCl3) mj128.6 (Ph), mj128.4 (Ph), mi128.29 (Ph), mi128.26 (Ph), mj126.4 (p-Ph), 
mi125.9 (p-Ph), mj57.6 (CH), mi55.2 (CH), 41.7, 41.1, 39.2, 34.7 (CONHCH2CH2), 
34.2, 33.3, 32.4, 32.1 (PhCH2CH2), mi26.6 (CH3CH2), mj25.9 (CH3CH2), mj9.30 
(CH3CH2) and mi9.27 (CH3CH2); m/z (C15H20N2NaO2 (M + Na+) requires 
283.1417) found 283.1419. This compound has not previously been reported. 
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4-Isobutyryl-3-phenylethylpiperazin-2-one (4.23) 
 
Amine alkylation was carried out according to General Method P using 4.17 
(10 mg, 0.05 mmol) and isobutyryl chloride (6 µL, 0.06 mmol). The residue was 
purified by silica column chromatography (eluent; EtOAc to EtOAc:MeOH 
(9:2)) to give a white crystalline solid (1.2 mg, 0.004 mmol, 9%); m.p.: 171-172 
oC; υmax (cm-1) 3259 (NH), 3026, 2919, 2850 (CH2, CH), 1633 (CON), 1545 
(NH), 1494 (Ph), 1427 (CH2), 1332 (CH3) 746, 699 (Ph); δH (400 MHz, rotamer 
ratio 2:1, CDCl3) mj & mi7.36-7.15 (2 × 5H, m, Ph), mj5.24 (1H, t, J 7.0, CH2CH), 
mi4.44 (1H, t, J 7.0, CH2CH), mi4.30-4.19 (1H, m, CHNCHH), 3.98-3.56 (7H, m, 
mjNCH2CH2NH, mjN(CO)CH, miNHCH2), mi3.37-3.25 (1H, m, CHNCHH), 2.85-
2.73 (3H, m, miN(CO)CH, mjPhCH2), 2.72-2.61 (2H, m, miPhCH2), 2.45-2.17 (2H, 
m, mjCH2CH), 2.17-1.97 (2H, m, miCH2CH), 1.21-1.18 (6H, m, mjCH3CHCH3) 
and 1.17-1.12 (6H, m, miCH3CHCH3); δC (100 MHz, CDCl3) mi128.7 (Ph), 
mi128.6 (Ph), mj128.4 (Ph), mj128.3 (Ph), mi126.6 (p-Ph), mj126.1 (p-Ph), 57.3 
(CH2CH), 42.7, 40.8 (CONHCH2CH2), mj36.0 (CHCH3), 34.6, 32.4 (PhCH2CH2), 
mi30.5 (CHCH3) and 19.5, 19.2 (CH3CHCH3); m/z (C16H22N2NaO2 (M + Na+) 
requires 297.1573) found 297.1575. This compound has not previously been 
reported. 
 
3-Phenylethyl-4-pivaloylpiperazin-2-one (4.24) 
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Amine alkylation was carried out according to General Method P using 4.17 
(10 mg, 0.05 mmol) and trimethylacetyl chloride (7 µL, 0.06 mmol). The residue 
was purified by silica column chromatography (eluent; Hexane:EtOAc (1:1) to 
EtOAc:MeOH (9:1)) to give a white crystalline solid (13 mg, 0.04 mmol, 89%); 
m.p.: 177-178 oC; υmax (cm-1) 3180 (NH), 3053, 2971, 2927 (CH2, CH), 1662 
(CON), 1621 (CONH), 1494 (Ph), 1456 (CH2), 1348 (CH3) 754, 702 (Ph); δH 
(400 MHz, CDCl3) 7.31-7.26 (3H, m, CONH & m-Ph), 7.22-7.16 (3H, m, Ph), 
5.16 (1H, t, J 6.5 CHCONH), 4.38-4.28 (1H, m, CONHCH2CHH), 3.72-3.58 
(2H, m, CONHCH2CH2), 3.51 (1H, ddd, J 14.5, 11.0, 4.0, CONHCH2CHH), 
2.84 (1H, ddd, J 13.5, 12.0, 5.0, PhCHHCH2), 2.68 (1H, ddd, J 13.5, 11.5, 5.5, 
PhCHHCH2), 2.37-2.25 (1H, m, PhCH2CHH), 2.09-1.97 (1H, m, PhCH2CHH) 
and 1.32 (9H, s, COC(CH3)3); δC (100 MHz, CDCl3) 176.1 (CON), 170.8 
(CONH), 141.0 (i-Ph), 128.5 (Ph), 128.4 (Ph), 126.2 (p-Ph), 58.0 (CH), 45.9 
(CONHCH2CH2), 43.8 (C(CH3)3), 39.0 (CONHCH2CH2), 34.1 (PhCH2CH2), 
32.4 (PhCH2CH2) and 28.2 (C(CH3)3); m/z (C17H24N2NaO2 (M + Na+) requires 
311.1730) found 311.1733. This compound has not previously been reported. 
 
1,1,1-Trichloro-4-phenylbutan-2-one (4.30) 
 
Oxidation was carried out according to General Method N using 4.12 (1.8 g, 7 
mmol). The residues were purified by silica column chromatography (eluent; 
EtOAc:Hexane (1:9) to EtOAc) to give a colourless oil (1.4 g, 5.4 mmol, 54%); 
υmax (cm-1) 3028, 2927 (CH2), 1749 (COCCl3), 1604, 1496 (Ph), 1454 (CH2), 
806, 782 (CCl3), 741, 697 (Ph); δH (400 MHz, CDCl3) 7.35-7.30 (2H, m, m-Ph), 
7.27-7.21 (3H, m, Ph), 3.32  (2H, t, J 7.5, CH2CH2CO) and 3.07  (2H, t, J 7.5, 
CH2CH2CO); δC (100 MHz, CDCl3) 189.5 (CO), 139.5 (i-Ph), 128.6 (Ph), 128.3 
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(Ph), 126.5 (p-Ph), 96.2 (CCl3), 35.7 (CH2CH2CO) and 30.7 (CH2CH2CO). This 
compound is known but has previously only been reported with 1H NMR data 
and IR data, which is consistent with that reported here.237 
 
General Method Q: Asymmetric transfer hydrogenation reaction 
(S)-1,1,1-Trichloro-4-phenylbutan-2-ol ((S)-4.12) 
 
To 0.5 mL of a stock solution of (p-cymene)ruthenium(II) chloride dimer (3.1 
mg, 0.005 mmol), ligand (1S,2S)-(+)-N-p-Tosyl-1,2-diphenylethylenediamine 
(3.7 mg, 0.01 mmol) and HCO2H:NEt3 complex (1 mL) was added 4.30 (252 mg, 
1 mmol) and the resulting solution stirred under nitrogen at room temperature for 
18 h. The reaction mixture was filtered through a plug of silica and washed with 
EtOAc:Petroleum Ether 40/60 oC (1:9). The organics were concentrated in vacuo 
to give a colourless oil (232 mg, 0.9 mmol, 91%); [ߙ]஽ଶ଻ (c = 1, MeOH) -36.1; 
υmax (cm-1) 3416, 3058 (OH), 2935, 2862 (CH2, CH), 1600, 1494 (Ph), 1454 
(CH2), 1080, 1056 (COH), 801, 797 (CCl), 745, 699 (Ph); δH (400 MHz, CDCl3) 
7.27-7.20 (2H, m, m-Ph), 7.19-7.11 (3H, m, Ph), 3.94-3.86 (1H, m, CHOH), 2.93 
(1H, ddd, J 14.0, 9.0, 5.0, CHHCH2CH), 2.77 (1H, br s, OH), 2.70 (1H, dt, J 
14.0, 8.5, CHHCH2CH), 2.37-2.26 (1H, m, CHHCH) and 1.92 (1H, dddd, J 14.5, 
10.0, 5.0, 1.0, CHHCH); δC (100 MHz, CDCl3) 140.6 (i-Ph), 128.5 (Ph), 128.4 
(Ph), 126.2 (p-Ph), 104.1 (CCl3), 81.9 (CHOH), 32.9 (CH2CH2CH) and 31.9 
(CH2CH2CH). This data is consistent with that previously reported.364 
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(R)-3-Phenethylpiperazin-2-one ((R)-4.17) 
 
Asymmetric heterocycle formation via the Jocic/Bargellini type reaction was 
carried out according to General Method O using (S)-4.12 (91 mg, 0.36 mmol). 
The residue was purified by silica column chromatography (eluent; EtOAc to 
EtOAc:MeOH (8:2)) to give a white crystalline solid (14 mg, 0.07 mmol, 19%); 
m.p.: 145-146 oC; [ߙ]஽ଶହ (c = 0.7, MeOH) +18.1; υmax (cm-1) 3222 (NH), 3025 
(CONH), 2926, 2860 (CH2, CH), 1652 (CONH), 1492 (NH), 1452 (CH2), 748, 
699 (Ph); δH (400 MHz, CDCl3) 7.35-7.28 (2H, m, m-Ph), 7.27-7.26 (2H, m, o-
Ph), 7.24-7.18 (1H, m, p-Ph), 6.65 (1H, br s, CONH), 3.50-3.39 (2H, m CHNH 
& CONHCHH), 3.32  (1H, qd, J 7.0, 3.5 CONHCHH), 3.17 (1H, dt, J 13.0, 4.0, 
CHNHCHH), 2.99 (1H, ddd, J 13.0, 9.5, 4.0, CHNHCHH), 2.89-2.73 (2H, m, 
PhCH2), 2.33 (1H, dddd, J 14.0, 10.5, 7.0, 4.0, PhCH2CHH), 2.17-1.95 (2H, m, 
PhCH2CHH & CHNH); δC (100 MHz, CDCl3) 172.4 (CO), 141.5 (i-Ph), 128.4 
(Ph), 128.3 (Ph), 125.9 (p-Ph), 58.3 (CH), 43.2 (CONHCH2), 41.3 (CHNHCH2), 
33.5 (CH2CHNH) and 32.1 (CH2CH2CH); m/z (C12H17N2O (M + H+) requires 
205.1335) found 205.1335. This compound has not previously been reported. 
 
(R)-1,1,1-Trichloro-4-phenylbutan-2-ol ((R)-4.12) 
 
Asymmetric transfer hydrogenation was carried out according to General 
Method Q using 4.30 (252 mg, 1 mmol) and (1R,2R)-(−)-N-p-Tosyl-1,2-
diphenylethylenediamine in place of (1S,2S)-(+)-N-p-Tosyl-1,2-
diphenylethylenediamine to give a colourless oil (244 mg, 0.96 mmol, 96%); 
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[ߙ]஽ଶ଻ (c = 1, MeOH) +38.7; υmax (cm-1) 3321 (OH), 2941, 2888 (CH2, CH), 
1602, 1499 (Ph), 1454 (CH2), 1078, 1056 (COH), 800, 795 (CCl), 747, 700 (Ph); 
δH (400 MHz, CDCl3) 7.28-7.21 (2H, m, m-Ph), 7.19-7.12 (3H, m, Ph), 3.91 (1H, 
ddd, J 10.0, 5.5, 2.0 CHOH), 2.93 (1H, ddd, J 14.0, 9.0, 5.0, CHHCH2CH), 2.76-
2.65 (2H, m, CHHCH2CHOH), 2.37-2.26 (1H, m, CHHCH) and 1.97-1.86 (1H, 
m, CHHCH); δC (100 MHz, CDCl3) 140.7 (i-Ph), 128.6 (Ph), 128.5 (Ph), 126.3 
(p-Ph), 104.1 (CCl3), 82.0 (CHOH), 32.9 (CH2CH2CH) and 31.9 (CH2CH2CH); 
This data is consistent with that previously reported.237,365 
 
(S)-3-Phenethylpiperazin-2-one ((S)-4.17) 
 
Asymmetric heterocycle formation via the Jocic/Bargellini type reaction was 
carried out according to General Method O using (R)-4.12 (50 mg, 0.2 mmol). 
The residue was purified by silica column chromatography (eluent; 
EtOAc:Hexane (1:1) to EtOAc:MeOH (8:2)) to give a white crystalline solid (12 
mg, 0.06 mmol, 30%); m.p.: 133-134 oC; [ߙ]஽ଶହ (c = 0.24, MeOH) -30.8; υmax 
(cm-1) 3201 (NH), 3025 (CONH), 2922, 2857 (CH2, CH), 1653 (CONH), 1493 
(NH), 1453 (CH2), 749, 699 (Ph); δH (400 MHz, CDCl3) 7.30-7.25 (2H, m, m-
Ph), 7.24-7.20 (2H, m, o-Ph), 7.18 (1H, m, p-Ph), 6.73 (1H, br s, CONH), 3.43 
(1H, dd, J 8.5, 3.5, CHNH), 3.40 (1H, ddd, J 9.5, 4.5, 1.0, CONHCHH), 3.31-
3.24  (1H, m, CONHCHH), 3.13 (1H, dtd, J 13.5, 4.0, 0.5, CHNHCHH), 2.95 
(1H, ddd, J 13.5, 9.5, 4.0, CHNHCHH), 2.85-2.69 (2H, m, CH2CH2CH), 2.29 
(1H, dddd, J 14.0, 10.5, 7.0, 4.0, CHHCHNH), 2.05-1.86 (2H, m, CHHCHNH & 
CHNH); δC (100 MHz, CDCl3) 172.4 (CO), 141.5 (i-Ph), 128.4 (Ph), 128.3 (Ph), 
125.9 (p-Ph), 58.3 (CH), 43.2 (CONHCH2), 41.3 (CHNHCH2), 33.6 
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(CH2CHNH) and 32.1 (CH2CH2CH); m/z (C12H17N2O (M + H+) requires 
205.1335) found 205.1335. This compound has not previously been reported. 
 
(3R,5R,6R)-3-Phenylethyl-5,6-diphenylpiperazin-2-one (4.41) 
 
Asymmetric heterocycle formation was carried out according to General 
Method O using (S)-4.12 (52 mg, 0.2 mmol) and (1R,2R)-1,2-diphenylethane-
1,2-diamine (42 mg, 0.2 mmol). The residue was purified by silica column 
chromatography (eluent; Hexane:EtOAc (1:1) to EtOAc) to give a white 
crystalline solid (72 mg, 0.2 mmol, 98%); m.p.: 138-139 oC; [ߙ]஽ଶ଻ (c = 0.6, 
MeOH) +109.2; υmax (cm-1) 3167, 3060, 3030 (NH, CONH), 2923, 2880 (CH2), 
1670 (CONH), 1603 (Ph), 1491 (NH), 1453, 1402 (CH2), 768, 751, 695 (Ph); δH 
(400 MHz, CDCl3) 7.39-7.24 (11H, m, Ph), 7.22-7.17 (2H, m, Ph), 7.11-7.06 
(2H, m, Ph), 6.21 (1H, br s, CONH), 4.69 (1H, d, J 8.5, CONHCHPh), 4.11 (1H, 
d, J 8.5, CHNHCHPh), 3.80 (1H, dd, J 9.5, 4.5, CH2CH),  2.96-2.82 (2H, m, 
CH2CH2CH), 2.49 (1H, dddd, J 14.0, 9.5, 7.0, 4.5, CH2CHHCH), 2.31 (1H, dtd, 
J 14.0, 9.5, 6.0, CH2CHHCH) and 2.24 (1H, br s, CH2CHNH); δC (100 MHz, 
CDCl3) 172.6 (CO), 141.0 (CONHCH(i-Ph)), 138.8 (CH2(i-Ph)), 138.7 
(CHNHCH(i-Ph)), 128.5 (Ph), 128.42 (Ph), 128.40 (Ph), 128.34 (Ph), 128.26 
(Ph), 128.1 (Ph), 127.7 (Ph), 127.1 (Ph), 126.0 (CH2(p-Ph)), 64.3 (CHNHCHPh), 
60.0 (CONHCHPh), 57.2 (CH2CH), 33.6 (CH2CHNH) and 32.6 (CH2CH2CH); 
m/z (C24H25N2O (M + H+) requires 357.1961) found 357.1964. This compound 
has not previously been reported. 
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(3R,5S,6S)-3-Phenylethyl-5,6-diphenylpiperazin-2-one (4.42) 
 
Asymmetric heterocycle formation was carried out according to General 
Method O using (S)-1,1,1-trichloro-4-phenylbutan-2-ol (58 mg, 0.2 mmol) and 
(1S,2S)-1,2-diphenylethane-1,2-diamine (42 mg, 0.2 mmol). The residue was 
purified by silica column chromatography (eluent; Hexane:EtOAc (1:1) to 
EtOAc) to give a white crystalline solid (78 mg, 0.2 mmol, 96%); m.p.: 127-128 
oC; [ߙ]஽ଶ଺ (c = 0.44, MeOH) -67.8; υmax (cm-1) 3169, 3060, 3028 (NH, CONH), 
2923, 2878 (CH2), 1670 (CONH), 1605 (Ph), 1490 (NH), 1453, 1408 (CH2), 769, 
751, 696 (Ph); δH (400 MHz, CDCl3) 7.33-7.16 (11H, m, Ph), 7.11-7.05 (2H, m, 
Ph), 7.00-6.95 (2H, m, Ph), 5.97 (1H, br s, CONH), 4.54 (1H, d, J 9.5, 
CONHCHPh), 3.86 (1H, d, J 9.5, CHNHCHPh), 3.81 (1H, dd, J 7.0, 4.0, 
CH2CH),  2.93-2.78 (2H, m, CH2CH2CH), 2.37 (1H, dddd, J 14.0, 10.5, 7.0, 4.0, 
CH2CHHCH), 2.26-2.15 (1H, m, CH2CHHCH) and 2.06 (1H, br s, CH2CHNH); 
δC (100 MHz, CDCl3) 171.6 (CO), 141.6 (CONHCH(i-Ph)), 138.8 (CH2(i-Ph)), 
138.3 (CHNHCH(i-Ph)), 128.5 (Ph), 128.4 (Ph), 128.34 (Ph), 128.31 (Ph), 
128.24 (Ph), 128.19 (Ph), 127.8 (Ph), 127.4 (Ph), 125.9 (CH2(p-Ph)), 66.3 
(CHNHCHPh), 65.1 (CONHCHPh), 59.1 (CH2CH), 33.9 (CH2CHNH) and 31.8 
(CH2CH2CH); m/z (C24H25N2O (M + H+) requires 357.1961) found 357.1964. 
This compound has not previously been reported. 
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APPENDIX I - Representative 1H and 13C NMR Traces 
Index 
 Compound Page 
5-[(tert-Butyloxycarbonyl)amino]-ethane-2-Benzyloxycarbonylamino-3-
mercapto-propionic acid tert-butyl ester 2.96 219 
(R)-6-(Carboxybenzylamino)-[1,4]-thiazepan-5-one 2.97 220 
(R)-6-(2',2'-Dimethylpropionylamino)-[1,4]-thiazepan-5-one 2.104 221 
(R)-6-(1'-Adamantanecarbonylamino)-[1,4]-thiazepan-5-one 2.105 222 
(R)-6-(2’,2’-Dimethyldodecanoylamino)-[1,4]-thiazepan-5-one 2.106 223 
2-Benzyloxycarbonylamino-3-(2-tert-butoxycarbonylamino-3-phenyl-
propylsulfanyl)-propionic acid tert-butyl ester 
(2R,2’S)-
2.113 224 
(3S,6R)-6-(Carboxybenzylamino)-3-benzyl-[1,4]-thiazepan-5-one (3S,6R)-2.114 225 
(3S,6R)-6-(ammonium bromide)-3-benzyl-[1,4]-thiazepan-5-one (3S,6R)-2.115 226 
(3S,6R)-6-(2',2'-Dimethylpropionylamino)-3-benzyl-[1,4]-thiazepan-5-one (3S,6R)-2.116 227 
(3S,6R)-6-(1'-Adamantanecarbonylamino)-3-benzyl-[1,4]-thiazepan-5-one (3S,6R)-2.117 228 
(3S,6R)-6-(1'-dimethylpropionylamino)-3-benzyl-[1,4]-thiazepan-5-one (3S,6R)-2.111 229 
(3R,6R)-6-(1'-dimethylpropionylamino)-3-benzyl-[1,4]-thiazepan-5-one (3R,6R)-2.111 230 
(3R,6R)-6-(Carboxybenzylamino)-3-benzyl-[1,4]-thiazepan-5-one (3R,6R)-2.114 231 
(3R,6R)-6-(2',2'-Dimethylpropionylamino)-3-benzyl-[1,4]-thiazepan-5-one (3R,6R)-2.116 232 
(3S, 6R)-6-(2’,2’-Dimethyldodecanoylamino)-3-benzyl-[1,4]-thiazepan-5-one (3S,6R)-2.118 233 
(S)-3-(Dimethylundecanoylamino)tetrahydropyridin-2-one 2.163 234 
1,1,1-Trichloro-5-methyl-5-nitrohexan-2-ol 3.52 235 
2-azido-5-methyl-5-nitrohexanoic acid 3.53 236 
5-carbobenzyloxyamino-5-methyl-1,1,1-trichlorohexan-2-ol 3.70 237 
N-(2-Hydroxy-3,3,3-trichloropropyl)-phthalimide 3.85e 238 
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N-(3-Hydroxy-4,4,4-trichlorobutyl)-phthalimide 3.85f 239 
N-(5-Hydroxy-6,6,6-trichlorohexyl)-phthalimide 3.85h 240 
1,1,1-Trichloro-4-phenylbutan-2-ol 4.12 241 
2-Azido-4-phenylbutanoic acid 4.13 242 
2-Azido-N-benzyl-4-phenylbutanamide 4.14 243 
3-Phenylethylpiperazin-2-one 4.17 244 
2-Phenylethylmorpholin-3-one 4.18 245 
4-(Methylsulfonyl)-3-phenylethylpiperazin-2-one 4.20 246 
1,1,1-Trichloro-4-phenylbutan-2-one 4.30 247 
(S)-1,1,1-Trichloro-4-phenylbutan-2-ol (S)-4.12 248 
(R)-3-Phenethylpiperazin-2-one (R)-4.17 249 
(S)-3-Phenethylpiperazin-2-one (S)-4.17 250 
(3R,5R,6R)-3-Phenylethyl-5,6-diphenylpiperazin-2-one 4.41 251 
(3R,5S,6S)-3-Phenylethyl-5,6-diphenylpiperazin-2-one 4.42 252 
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APPENDIX II - Representative High Resolution Mass 
Spectrum 
 
Representative high resolution mass spectrum taken on a Bruker micro-TOF ESI attached to 
a time of flight (TOF) analyser. 
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APPENDIX III - ATH HPLC trace  
 
Representative HPLC trace of the asymmetric transfer hydrogenation reaction, taken from 
compound (S)-4.12. 
 
 
 
